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ABSTRACT 
JEANNIE M. PADOWSKI 
A MULTI-FACTORIAL APPROACH TO UNDERSTANDING AND PREDICTING 
BRAIN EXPOSURE TO PHARMACOLOGIC AGENTS 
(Under the direction of Gary M. Pollack, PhD) 
 
Development of effective neurotherapeutics is limited by an inability to deliver 
sufficient drug mass to sites of action within the brain, due to specialized structural 
and functional characteristics of the interface between the CNS and the systemic 
circulation (the blood-brain barrier; BBB).  A potential solution to this critical 
challenge involves chemical inhibition of P-glycoprotein (P-gp), an important barrier 
transporter expressed at the blood-brain interface that attenuates brain uptake of 
numerous CNS-targeted agents.   
To determine how modulation of brain exposure to a model P-gp substrate could 
impact pharmacologic response, the relationship between response of a human 
brain tumor cell line and exposure to the antineoplastic paclitaxel was explored in 
vitro.  Mathematical modeling of these data demonstrated that substantial inhibition 
of BBB P-gp could significantly reduce the paclitaxel dose required to elicit a 
meaningful antitumor effect.   
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As P-gp is expressed in many tissues, selective inhibition of BBB P-gp is desirable 
for increasing brain partitioning of P-gp substrates.  A brain-targeted approach for P-
gp inhibitors via nasal delivery therefore was explored.  The nasal route conferred 
compound-specific brain exposure advantages among three model inhibitors.  
However, the ability of this route to deliver a mass of drug required to confer the 
desired pharmacologic effect was insufficient; the profound inhibition of BBB P-gp 
needed for meaningful increases in brain exposure after systemic administration of 
paclitaxel could not be achieved.   
A fundamental limitation of the model system was slow paclitaxel equilibration 
between blood and brain.  Mathematical simulations explored relationships between 
accuracy of assessment of brain partitioning, including the influence of P-gp on 
partitioning, and sampling time.  These simulations identified a previously 
undescribed effect of peripheral distribution on the kinetics of brain partitioning.  
Using data-mining and targeted prospective experimentation, distribution into a 
peripheral pharmacokinetic compartment was identified as a novel mechanistic 
explanation for previously unexplained time-dependent decreases, rather than 
increases, in brain partitioning of the antiepileptic, valproate. Taken together, these 
studies identify an important cause of erroneous assessment of P-gp impact on 
brain exposure, elucidate fundamental kinetic processes underlying the distribution 
of drugs into brain, and establish a framework for metrics that can provide 
appropriate descriptions of CNS exposure.   
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CHAPTER 1.1 
 
 
 
 
 
PHARMACOKINETIC AND PHARMACODYNAMIC 
IMPLICATIONS OF P-GLYCOPROTEIN MODULATION 
 
 
 
 
 
 
 
 
This chapter is constructed as an invited review for the book Multi-Drug Resistance 
in Cancer, to appear in the series, Methods in Molecular Biology, which is to be 
published by The Humana Press Inc 
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 Transport proteins that operate in the efflux direction (against substrate 
uptake into a particular organ or tissue) have garnered significant attention in recent 
years within the pharmaceutical sciences community, and have been the subject of 
numerous comprehensive reviews (Gradhand and Kim, 2008; Miller et al., 2008; 
Zhou et al., 2008). These proteins can act at one or more steps in the cascade of 
pharmacokinetic and pharmacodynamic events that ultimately lead to the biologic 
response, either beneficial or untoward, to a pharmacologic agent. Transport 
proteins operating in the efflux direction in the gastrointestinal tract can impede 
absorption (Glaeser and Fromm, 2008), decreasing the rate and, potentially, the 
extent of presentation of the substrate to the systemic circulation. Outwardly-directed 
transport in organs of elimination, primarily the liver (Shitara et al., 2006) and kidney 
(Launay-Vacher et al., 2006), can facilitate the irreversible removal of substrate 
molecules from the systemic circulation. Finally, and perhaps most importantly from 
a biologic response standpoint, efflux proteins can serve as barriers to substrate 
distribution into organs (Liu et al., 2008), tissues (Lum and Gosland, 1995), or 
cellular spaces (Fojo and Coley, 2007) that represent important pharmacologic 
targets. Such barrier functions may appear at the interface between the organ and 
the vasculature, or may be present on the cell surface. In either case, the net result 
of efflux transport is to diminish the amount of substrate available at the site of action 
to interact with the biologic receptor. 
 Although a variety of efflux transport proteins are expressed in mammalian 
tissues, the most well-characterized, and perhaps the globally most important, of 
these systems is P-glycoprotein (P-gp). P-gp is a 170-kDa protein that is a member 
of the ABC superfamily of energy-dependent transport systems (Teodori et al., 
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2006). It is localized to cellular membranes, and originally was identified by its ability 
to confer multi-drug resistance to mammalian cells (Juliano and Ling, 1976).  
Although P-gp often is viewed in terms of its ability to transport bulky hydrophobic 
cations, it is in actuality a relatively indiscriminate system that can interact with 
compounds from a wide range of chemical classes and with a large degree of 
structural and physicochemical dissimilarity (Ha et al., 2007). Indeed, attempts to 
develop structure-transport relationships for P-gp have yielded mixed, generally 
negative, results due the lack of well-defined structural specificity. This lack of 
specificity may be due, in part, to the presence of multiple substrate recognition sites 
on the protein (Ma and Lu, 2008). 
 In addition to complexities associated with substrate recognition, the location 
of the binding sites on P-gp relative to the cellular membrane has been debated. 
Although this is a biologically subtle point, it is of critical importance to the kinetics of 
substrate transport, as it will determine the apparent driving-force concentration for 
the efflux process. Although both extracellular and intracellular locations have been 
suggested, the most widely-accepted model for P-gp-mediated transport is with the 
substrate binding site localized within the cellular membrane (Siarheyeva et al., 
2006). From a pharmacokinetic standpoint, the proximate driving-force concentration 
for substrate flux may be the extracellular concentration (e.g., if binding to 
extracellular proteins is low and if the extracellular concentration is in rapid 
equilibrium with substrate concentration in the cell membrane) or the intracellular 
concentration (if sequestration within cellular organelles is minimal and if the 
cytosolic substrate concentration is in rapid equilibrium with substrate concentration 
in the cell membrane). It also is conceivable that neither the extracellular nor the 
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intracellular concentration will appear to be the driving force for P-gp-mediated flux if 
neither locale serves as an adequate surrogate for concentrations in the cellular 
membrane. 
 Given these brief introductory comments, the purpose of this review is to 
focus on the pharmacokinetic and pharmacodynamic implications of modulation of 
P-gp-mediated transport. Approaches or mechanisms through which P-gp activity 
may be changed will be considered first; the impact of those changes on drug 
disposition then will be reviewed. Finally, the outcome of altered substrate flux in 
terms of biologic response will be discussed with respect to several different types of 
drug response. 
 
Modulation of P-gp Activity 
Changes in substrate flux by P-gp may be the result of chemical modulation 
(inhibition or induction of transport activity) or due to genetic polymorphisms. The 
most common and well-studied chemical modulation of P-gp is inhibition of 
transport. P-gp inhibition has received significant attention within the pharmaceutical 
industry as a means to enhance pharmacologic response to existing drugs or new 
chemical entities that may be significant substrates for this transport protein (Shukla 
et al., 2008). The initial impetus for identifying or developing compounds that would 
effectively inhibit P-gp was to reverse multidrug resistance in cancer cells, thereby 
enhancing antitumor effects (Wigler and Patterson, 1993). Several existing 
therapeutic agents (e.g., quinidine, verapamil, and cyclosporine) were identified as 
P-gp inhibitors. Subsequently, several new compounds (e.g., PSC833 and 
GF120918) were developed for the express purpose of limiting P-gp-mediated flux. 
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Despite significant efforts to develop a P-gp inhibitor with clinical efficacy, to date no 
such compound has become part of the therapeutic armamentarium for cancer or 
any other disorder. The inability to translate this fundamental idea into a clinically 
useful approach is due to a large extent to difficulties associated with targeted 
delivery of potential inhibitors to the appropriate site of P-gp transport. 
Because P-gp is an inhibitable transporter, because it can affect substrate 
disposition at a variety of pharmacokinetic steps, and because it interacts with such 
a wide variety of substrates, drug-drug interactions at the level of P-gp-mediated 
transport are a likely phenomenon (Aszalos, 2007b; Aszalos, 2007a). The high 
likelihood of unintended inhibition of P-gp has led the pharmaceutical industry to 
screen new compounds for their P-gp transport and inhibition properties, in much the 
same way that compounds are routinely screened for lability in the presence of 
various isoforms of cytochrome P450 (Sun et al., 2008). Specific examples of drug-
drug interactions in P-gp transport will be considered in subsequent sections of this 
review. 
Although the focus of much less attention than inhibition, the potential 
induction of P-gp by drugs or other xenobiotics also represents a potential form of 
drug-drug interaction that could have pharmacokinetic or pharmacodynamic 
consequences (Matheny et al., 2004; Bauer et al., 2006). The first suggestion that P-
gp might evidence biologically significant induction resulting in overt pharmacokinetic 
changes was a report that expression of P-gp in rat brain tissue was increased 
following sub-chronic exposure to morphine (Aquilante et al., 2000). Morphine and 
many other opioids are substrates for P-gp, albeit to varying degrees (Dagenais et 
al., 2004; Kalvass et al., 2007); one hypothesis was that induction of P-gp by 
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morphine at the blood-brain barrier would decrease concentrations of morphine in 
brain tissue, leading to the appearance of functional tolerance to the antinociceptive 
effects of the drug.  It is currently unclear as to what extent P-gp is generally 
inducible and, if so, in what organ systems such induction might occur. This topic will 
be touched upon briefly in the section on pharmacodynamics later in this review.  
Significant recent attention has been paid to genetic polymorphisms of P-gp, 
and how those polymorphisms may influence drug disposition or action in vivo. This 
complicated line of investigation has yielded contradictory results. To date, there is 
little consensus on whether genetic polymorphisms in humans result in a consistent 
and clinically-relevant change in P-gp-mediated transport (Macdonald and Gledhill, 
2007). This issue also will be discussed in more detail in the following sections of 
this review. 
 
Pharmacokinetic Consequences of P-gp Modulation 
 Gastrointestinal absorption. P-gp is expressed on the apical membrane of 
intestinal epithelial cells, oriented in a manner to secrete substrates from the 
epithelial cell into the intestinal lumen.  As such, P-gp serves as a functional barrier 
to absorption of a variety of substrates from the intestinal lumen, including the 
cardiovascular agents digoxin, quinidine, verapamil, and talinolol, and the opioid 
loperamide (Adachi et al., 2003). 
 The expression of P-gp appears to vary along the length of the human 
intestine in a manner somewhat inverse to that of the primary intestinal isoform of 
cytochrome P450, CYP3A4 (Badhan et al., 2008). P-gp and CYP3A4 have common 
substrates and inhibitors, and there is evidence that the two proteins may act in a 
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concerted fashion to limit systemic absorption of some compounds (Kivisto et al., 
2004).  Drugs that are substrates of both P-gp and CYP3A4 have three possible 
fates upon entering the enterocyte: they may cross the enterocyte and reach the 
systemic circulation, they may be biotransformed in the gut wall, or they may be 
effluxed back into the intestinal lumen.  Of course, molecules that reappear in the 
lumen of the intestine may be reabsorbed distally, with subsequent opportunities to 
be absorbed, metabolized or effluxed.  The possibility that a compound may enter 
and exit the intestinal epithelium multiple times prior to either absorption into the 
systemic circulation or metabolism in the gut wall results in lumen-to-enterocyte 
recycling (Badhan et al., 2008) with an increased luminal mean residence time and a 
decrease in the overall rate of intestinal absorption. In general, intestinal P-gp 
appears to influence the peak concentration of an orally-administered substrate in 
the systemic circulation (Cmax) more significantly than overall systemic exposure 
(area under the concentration-time curve or AUC) (Kitamura et al., 2008). P-gp-
mediated efflux will decrease the extent of systemic absorption if the substrate also 
is metabolized in the intestinal epithelium (by CYP3A4 or another enzyme) or if 
absorption of the substrate occurs only at a specific site in the intestine. 
 There is limited but compelling evidence that intestinal P-gp can serve an 
excretory rather than absorptive barrier function, and can actually facilitate flux of 
substrates from the systemic circulation into the intestinal lumen (Gramatte and 
Oertel, 1999; Ballent et al., 2006). Thus, P-glycoprotein in the intestine will play a 
dual role for some substrates, by limiting flux from the intestinal lumen into blood and 
by stimulating flux from the blood into the intestinal lumen. 
Several lines of evidence suggest that drug-drug interactions at the level of P-
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gp in the gut may be biologically significant.  For example, the calcium channel 
blocker verapamil, one of the first compounds shown to inhibit P-gp-mediated flux, 
increased systemic exposure in rats to orally-administered talinolol, a model P-gp 
substrate (Spahn-Langguth et al., 1998).  Because talinolol is not metabolized 
extensively, it was suggested that this interaction occurred at the level of efflux 
transport.  A similar interaction between digoxin and quinidine (increased systemic 
exposure to digoxin in the presence of quinidine) in humans has been known for 
many years, but only recently was attributed to P-gp (Igel et al., 2007). 
In addition to drug-drug interactions based on inhibition of P-gp, the potential for 
drug-associated induction of intestinal P-gp also has been examined. For example, 
subchronic oral administration of rifampin decreased the ability of oral verapamil to 
permeate the rat small intestine (Sandstrom and Lennernas, 1999). This interaction 
was interpreted as induction of intestinal P-gp, resulting in increased secretion of 
verapamil from the enterocyte into the intestinal lumen.  In a classic clinical study, 
the single-dose (oral or intravenous) pharmacokinetics of digoxin were compared 
before and after administration of rifampin in healthy volunteers (Drescher et al., 
2003).  The systemic exposure to oral digoxin, expressed as the AUC in blood, was 
reduced during rifampin treatment; the rifampin-dependent reduction in AUC was 
lower for intravenous digoxin.  Rifampin increased intestinal P-gp (protein content); 
among individual subjects, the rifampin-associated decrease in AUC correlated with 
intestinal P-gp content after oral, but not intravenous, digoxin.  A similar study design 
was used to examine the pharmacokinetics of talinolol in the presence or absence of 
rifampin administration (Westphal et al., 2000). Rifampin decreased systemic 
exposure to oral talinolol by approximately 33%, and increased the systemic 
9 
 
clearance of intravenous talinolol by nearly 30%.  These observations suggest that 
P-gp-mediated drug-drug interactions at the level of intestinal absorption may be 
relatively common. 
Biliary excretion. P-gp is one of several transport proteins located on the 
canalicular membrane of hepatocytes that serve to mediate substrate flux from 
hepatocytes into bile (Chandra and Brouwer, 2004). Several compounds of clinical 
importance undergo P-gp-mediated biliary excretion, including anticancer agents 
such as doxorubicin and paclitaxel (Advani et al., 2001), cardiac agents such as 
digoxin and quinidine (Fromm et al., 1999), the immunosuppressive agent 
cyclosporine (Marie et al., 1992), and antivirals such as ritonavir and saquinavir (Kim 
et al., 1998).  
Drug-drug interactions at the level of P-gp-mediated biliary excretion are also of 
potential clinical importance.  For example, quinidine has been shown to decrease 
the biliary excretion of digoxin in humans by nearly 50% (Angelin et al., 1987) and 
the P-gp inhibitor GF120918 significantly reduced the biliary clearance of 
doxorubicin in an isolated perfused rat liver model (Booth et al., 1998). Any change 
in the excretory transport of a compound undergoing substantial biliary clearance 
would, by definition, alter the systemic exposure to this compound.  In addition, 
modulation of excretion into bile would change substrate accumulation in the 
hepatocellular compartment, a site of potential toxicity or, in a limited number of 
cases, the site of the intended pharmacologic response. Finally, altered biliary 
clearance would change substrate presentation to the intestinal lumen, another site 
of potential drug toxicity, via the common bile duct. If the compound undergoes 
enterohepatic recycling, the change in luminal exposure may be substantial.  
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Most drugs are metabolized in the liver. In some cases, metabolism produces 
toxic species that may be eliminated into bile.  If the metabolite was a substrate for 
P-gp, inhibition of this protein would decrease metabolite excretion, potentially 
resulting in hepatotoxicity.  Due largely to difficulties in obtaining bile from humans, 
clinical studies evaluating the role of P-gp in biliary excretion have been limited.  
Numerous in vitro and preclinical in vivo studies have been conducted, and have led 
to an increased understanding of the possible mechanisms underlying some 
clinically-important drug-drug interactions.   
Induction of P-gp on the canalicular membrane of hepatocytes may increase 
the rate of biliary clearance for some drugs.  For example, treatment of rats with 
phenothiazine to induce hepatic P-gp expression stimulated the rate of biliary 
excretion of the peptide octreotide and the antineoplastic vincristine (Yamada et al., 
1998). Tamoxifen and its biotransformation products are excreted into bile; 
tamoxifen pretreatment increased biliary excretion of tamoxifen and its metabolites 
approximately 6-fold, and increased the expression of mRNA which encodes P-gp in 
the rat (mdr1b), suggesting that tamoxifen displays autoinduction of P-gp-mediated 
biliary excretion (Riley et al., 2000). 
 Urinary excretion. A significant body of evidence suggests that P-gp can 
mediate substrate secretion into urine, and therefore can be a determinant of renal 
clearance for some drugs such as digoxin (Tanigawara, 2000).  P-gp is expressed 
on the luminal surface of cells lining the proximal tubule of the kidney, the region of 
the nephron in which most active secretion in the blood-to-urine direction occurs.  
Evidence for P-gp-mediated secretory clearance in the kidney has been 
generated with the P-gp substrate digoxin in combination with known modulators of 
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P-gp. Quinidine decreased the renal secretion of digoxin in isolated dog (De Lannoy 
et al., 1992) and rat (Hori et al., 1993) models of renal excretion. Consistent with 
these observations in preclinical species, co-administration of quinidine with digoxin 
in humans increased digoxin serum concentrations and correspondingly decreased 
digoxin renal clearance (Schenck-Gustafsson and Dahlqvist, 1981; Schenck-
Gustafsson et al., 1981). A similar interaction between quinidine and digoxin was 
observed in vitro (Fromm et al., 1999). Ritonavir, an inhibitor of P-gp in vitro, 
markedly decreased renal, as well as non-renal, clearance of digoxin in human 
subjects (Ding et al., 2004). The P-gp inhibitor cyclosporine also decreased renal 
secretion of digoxin in isolated perfused rat kidneys (Okamura et al., 1993).  The role 
of P-gp in this interaction was confirmed using P-gp over-expressing LLC-PK1 renal 
epithelial cells (Ito et al., 1993).  Clarithromycin (Hirata et al., 2005) and itraconazole 
(Ito et al., 1993) have also been shown to inhibit P-gp-mediated renal excretion of 
digoxin.   
Clinical studies also have demonstrated drug-drug interactions with digoxin at the 
level of P-gp-mediated renal secretion. For example, coadministration of PSC 833 
(valspodar), a P-gp inhibitor, to healthy volunteers decreased the renal clearance of 
digoxin by approximately 75% (Kovarik et al., 1999).  
While it is clear, based upon the aggregate results of studies of digoxin renal 
clearance, that P-gp is involved in the renal excretion of this cardiac glycoside, these 
efforts also suggest an important and clinically-relevant conclusion. Digoxin has a 
narrow therapeutic window, and even modest changes in bioavailability or systemic 
clearance can lead to untoward side effects. A multitude of drug-drug interactions 
with digoxin had been cataloged, yet the proximal mechanism(s) underlying these 
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interactions remained elusive. It is now clear that modulation of P-gp-mediated 
transport in the kidney is one explanation for previously uncharacterized drug-drug 
interactions involving alterations in the renal clearance of digoxin. Because P-gp 
expressed in the intestine (which limits the rate and extent of digoxin absorption) and 
the liver (which mediates biliary excretion of digoxin) also determine systemic 
exposure to digoxin, it is obvious that global modulation of P-gp function can have 
significant effects on the disposition and action of this important cardiac agent.  
 Extravascular distribution. P-gp serves as a barrier transporter to the flux of 
substrates from the systemic circulation into protected organs or tissues. These so-
called “sanctuary sites” include the placenta (Ceckova-Novotna et al., 2006), testes 
(Fromm, 2004), and brain (Golden and Pollack, 2003). The protective role of P-gp 
relative to tissue exposure has been most well-studied in the central nervous 
system. Arguably, the most significant biologic role of P-gp, at least relative to 
protecting mammalian systems from chemical insult, is as a functional component of 
the blood-brain barrier. 
The structural and biochemical features of the blood-brain interface, 
particularly with respect to drug delivery to central nervous system (CNS) targets, 
have been the subject of numerous reviews (Pardridge, 1998; Ohtsuki and Terasaki, 
2007; Sun et al., 2008). The blood-brain barrier is composed of a single layer of 
endothelial cells with intimate cell-to-cell communication afforded by complex tight 
junctions. These tight junctions limit paracellular permeability of hydrophilic 
molecules and bulky compounds.  Substrate penetration of the blood-brain barrier 
therefore requires flux through the luminal membrane of capillary endothelia, the 
endothelial cytoplasm, and the abluminal membrane prior to entry into the 
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extracellular fluid compartment of the brain. The close association of pericytes and 
astrocytic foot processes with the abluminal endothelial membrane presents an 
additional barrier to xenobiotic flux. 
The endothelial cells lining the brain microvasculature also contain systems 
that serve as functional, rather than structural, impediments to substrate 
translocation into the central nervous system (Miller et al., 2008). Cellular 
components of the blood-brain barrier also express metabolic enzymes that 
biotransform drugs, limiting brain exposure to the intact parent (Meyer et al., 2007). 
However, enzyme expression (at the BBB or in the brain as a whole) does not 
provide a significant route of drug elimination or a general barrier to substrate influx 
into brain for most substrates.  
More importantly, the blood-brain barrier endothelial cells express numerous 
membrane transport proteins that mediate substrate influx into and/or efflux from the 
brain. These various transport systems have been reviewed previously (Graff and 
Pollack, 2004). From the standpoint of drug delivery to the brain, transport proteins 
mediating influx could be used to facilitate uptake of hydrophilic compounds across 
the blood-brain barrier. These systems mediate nutrient (glucose, for example) 
uptake into brain; attempts to engineer drug delivery modalities to make use of these 
systems are ongoing (Pardridge, 2008). Protein-mediated efflux, on the other hand, 
serves to limit brain exposure primarily to lipophilic substrates that otherwise would 
permeate the blood-brain barrier readily. 
P-gp, the primary barrier transporter at the blood-brain interface, is expressed 
on the luminal surface of brain capillary endothelial cells (Golden and Pollack, 2003).  
However, other structural models of P-gp localization have been suggested. For 
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example, Golden and Pardridge demonstrated that P-gp is expressed on foot 
processes of astrocytes in close proximity to capillary endothelium (i.e., on the 
abluminal side of endothelial cells) (Golden and Pardridge, 2000). As discussed 
previously in this review, although the difference in anatomical location is minor, the 
driving forces responsible for P-gp-mediated transport will be markedly different 
between these two sites, resulting in differences in substrate transport kinetics 
between brain tissue and the systemic circulation.  
Experiments performed in mice lacking P-gp expression, including genetic 
knockouts and naturally-occurring P-gp-deficient animals have provided voluminous 
evidence that P-gp can significantly impede drug translocation across the blood-
brain interface (Chen et al., 2003b; Miller et al., 2008). Pharmacokinetic experiments 
in transport-deficient mice form the foundation of the current understanding of 
attenuated blood-brain barrier translocation by P-gp. This experimental model will be 
highlighted in the subsequent section on pharmacodynamics. 
 The fact that P-gp can mediate efflux lipophilic molecules of varying 
pharmacologic classes and chemical structures complicates the design of effective 
CNS-targeted drugs. The ability of numerous lipophilic molecules to diffuse through 
the blood-brain barrier is counterbalanced by P-gp, resulting in low brain penetration 
despite otherwise favorable physicochemical characteristics. 
 Several studies have demonstrated the role of P-gp in the exposure of brain 
tissue to pharmacologically-relevant compounds.  One of the earliest examples 
focused on the opioid peptide [D-penicillamine2,5]enkephalin (DPDPE).  Although 
DPDPE enters the brain rapidly (Chen and Pollack, 1997), only a limited fraction of 
the administered dose (<0.1%) reaches brain tissue, and brain-to-serum partitioning 
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is thus low.  These characteristics (rapid uptake; low partitioning at apparent 
distribution equilibrium) suggest that DPDPE may undergo active efflux in the brain-
to-blood direction.  Subsequent dose-ranging studies revealed that DPDPE is a 
substrate for a saturable efflux process at the blood-brain interface (Chen and 
Pollack, 1997). The identity of the efflux transport system as P-gp was confirmed by 
experiments in mdr1a(-/-) mice (Chen and Pollack, 1998), which evidenced 
enhanced brain uptake of DPDPE compared to P-gp-competent controls. 
Pretreatment of mdr1a(+/+) mice with the P-gp inhibitor GF120918 produced similar 
results (Chen and Pollack, 1999).  These studies illustrate the usual experimental 
paradigm to document the influence of P-gp on brain uptake, and demonstrate 
clearly that P-gp plays a pivotal role in determining brain exposure to this opioid 
pentapeptide. 
 The list of drugs for which P-gp serves as a barrier transporter at the blood-
brain interface has grown considerably over the past decade. The most important of 
these are CNS-targeted agents, which include, but are not limited to, 
antidepressants (amitriptylline, doxepine, nortriptylline, venlafaxine), antipsychotics 
(chlorpromazine, questiapine, risperidone), antiemetics (ondansetron), analgesics 
(morphine), and anticonvulsants (phenytoin) (Thuerauf and Fromm, 2006). Of 
course, a variety of other agents are used to treat systemic disorders that may 
express some CNS involvement. Brain exposure is limited by blood-brain barrier P-
gp to many of these agents, including anticancer drugs (e.g., doxorubicin, 
paclitaxel), antivirals (indinavir, nelfinavir and saquinavir), antibiotics (erythromycin, 
levofloxacin, rifampin), and steroids (dexamethasone) (Thuerauf and Fromm, 2006). 
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 Limited brain exposure to therapeutic agents often is viewed as a negative 
characteristic. However, limited brain exposure can be a positive attribute when 
peripheral response is desired but the agent can elicit undesirable effects in the 
CNS. To the extent that P-gp expressed in the blood-brain barrier may abate or limit 
such responses, the classic example is the opioid loperamide. Loperamide is used 
therapeutically in the treatment of diarrhea; despite reasonable receptor potency, 
loperamide is devoid of central opioid effects because it is excluded by P-gp from 
permeating the blood-brain barrier. When P-gp-mediated transport is abolished, 
loperamide elicits significant central opioid effects (Schinkel et al., 1996). A more 
recent example involves non-sedating antihistamines. The lack of central 
antihistaminic effects, which include drowsiness, is conferred by P-gp-mediated 
efflux at the blood-brain interface (Chen et al., 2003a). Thus, mitigation of brain 
uptake of P-gp substrates can be a beneficial result in many therapeutic instances. 
 
Pharmacodynamic Consequences of P-gp Modulation 
 Pharmacodynamics, or the magnitude and time course of pharmacologic 
effect, clearly can be impacted by P-gp modulation. In considering the 
pharmacodynamic implication of changes in P-gp function, it is useful to keep in 
mind that the unbound substrate concentration at the site of action will, in most 
cases, drive pharmacologic response. Modulation of P-gp function, which generally 
means a decrease in intrinsic transport activity, can increase substrate concentration 
at the receptor site in one of three ways. First, a decrease in P-gp-mediated 
transport can increase systemic concentrations of a P-gp substrate, either by 
increasing systemic bioavailability (for a substrate administered orally) or by 
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decreasing systemic clearance (for a substrate eliminated significantly by biliary 
and/or renal clearance). Next, substrate concentrations at the site of action could be 
increased secondary to a decrease in P-gp-mediated flux if the receptor is located in 
a “sanctuary” organ, such as the brain, for which P-gp has an important role as a 
barrier transporter. In this case, systemic concentrations might not be affected by P-
gp modulation, but the end-organ-to-blood concentration ratio (i.e., tissue-to-blood 
partition coefficient) would be increased. Finally, if P-gp is located on the target cell 
membrane (cancer cells, for example), substrate concentration in the target 
intracellular space might be increased following P-gp inhibition even though 
systemic substrates concentrations and substrate concentrations in the bulk tissue 
containing the cellular target were not increased. It should be noted that two, or 
perhaps all three, of these mechanisms may be in play for a given substrate. Thus, 
concentrations at the target site might be elevated more than would be predicted by 
a simple change in the systemic concentration to dose relationship, the target organ 
to blood concentration ratio, or the cellular target to end-organ extracellular fluid 
concentration relationship. 
 Changes in systemic concentration leading to altered pharmacologic 
response. In general, inhibition of P-gp-mediated transport changes systemic 
concentrations of P-gp substrates relatively modestly compared to changes 
associated with inhibition of metabolic enzymes (Lin, 2007). Thus, one would expect 
only a modest influence of altered P-gp function on biologic response when the 
locus of the P-gp-mediated interaction is at the level of systemic bioavailability or 
clearance. Nevertheless, there are several examples in the clinical literature of drug-
drug interactions, likely at the level of P-gp-mediated transport, that enhance biologic 
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effect (usually toxicity). The cause of this enhanced activity in the presence of P-gp 
modulation is an increase in systemic exposure (peak concentration, AUC, or mean 
residence time) at a fixed dose of the pharmacologic agent. For example, the 
antiviral drug ritonavir, which can inhibit P-gp-mediated transport, increases the AUC 
for digoxin, prolongs its residence time, and increases its toxicity (Phillips et al., 
2003; Ding et al., 2004). Diltiazem, another P-gp inhibitor, increases the systemic 
concentrations and associated toxicity of the immunosuppressive agent tacrolimus 
(Hebert and Lam, 1999). 
 Changes in target organ concentration leading to altered pharmacologic 
response. The most significant pharmacodynamic impact of P-gp modulation 
appears to occur when inhibition of P-gp-mediated flux increases target-organ drug 
concentrations compared to drug concentrations in the systemic circulation. In these 
cases, systemic drug concentrations no longer are predictive of concentrations in the 
target organ. Although this situation can occur for any target organ that represents a 
“sanctuary site” protected by P-gp, the most common examples involve the CNS. 
 With respect to perturbations of CNS pharmacodynamics secondary to P-gp 
modulation, opioids have served as a useful pharmacologic class. Many opioids are 
excluded from the brain to some extent by blood-brain barrier P-gp. The fact that the 
P-gp effect, i.e., the ratio of brain uptake in the absence versus absence of 
functional P-gp, varies significantly among this compound class (from approximately 
1.2 for morphine to more than 10 for DPDPE and loperamide) (Dagenais et al., 
2004), coupled with the ability to measure a clear pharmacologic endpoint 
(antinociception or respiratory depression), makes this an ideal compound set with 
which to probe the pharmacodynamic implications of P-gp modulation. 
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 A relatively early report in humans suggested that inhibition of P-gp-mediated 
transport by quinidine could unmask central opioid effects for loperamide, an opioid 
normally devoid of antinociceptive and respiratory depressant effects (Sadeque et 
al., 2000). In this experiment, co-administration of quinidine with loperamide led to 
measurable respiratory depression compared with the administration of loperamide 
alone. Because loperamide does not enter the brain under normal circumstances, 
one interpretation of these results was that quinidine inhibited P-gp-mediated efflux 
at the blood-brain interface, allowing sufficient accumulation of loperamide in brain to 
elicit a central pharmacologic response. 
 Although clinical data on opioid responsivity secondary to P-gp modulation 
are limited, animal experimentation has provided a wealth of information. Early 
studies in this area showed that the dose-response relationship for DPDPE-
associated antinociception was shifted approximately 30-fold to the left (i.e., 
demonstrating enhanced sensitivity) in P-gp-deficient [mdr1a(-/-) mice] compared 
with their P-gp-competent counterparts, and that the leftward shift remained even 
when effect was related to blood concentration as opposed to dose (Chen and 
Pollack, 1998). This latter result confirmed that the primary pharmacodynamic 
influence of P-gp was on distribution of DPDPE between blood and brain as 
opposed to systemic elimination of the opioid. Similar results were obtained with 
chemical inhibition, as opposed to genetic disruption, of the transporter (Chen and 
Pollack, 1999), indicating that the pharmacodynamic outcome was specific to loss of 
P-gp function as opposed to a non-specific change in the gene-deficient animals. 
 Because DPDPE had a very high P-gp effect (>10-fold), loss of P-gp function 
had a substantial impact on the magnitude and duration of antinociception. In 
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contrast, the P-gp effect for morphine was modest (<1.5-fold) (Letrent et al., 1999; 
Zong and Pollack, 2000), and the corresponding influence of P-gp disruption on 
morphine-associated antinociception was measurable but limited. This large 
difference in P-gp-related modulation of opioid pharmacology suggested that this 
class of compounds presents unique advantages in dissecting the role of P-gp in the 
blood-brain barrier. 
 Subsequent experimentation in this area was directed at several different 
goals. The first was to determine the degree of variability in P-gp effect among a 
wide range of opioid compounds. This goal can be accomplished using a variety of 
experimental paradigms, including in situ brain perfusion in P-gp-competent vs. P-
gp-deficient mice, in vivo brain-to-blood partitioning studies (either pre- or post-
establishment of distribution equilibrium) in P-gp-competent vs. P-gp-deficient mice, 
and through use of chemical modulators of P-gp function in any animal species 
(typically mice or rats, but also moving up in species complexity all the way to 
humans, as in the loperamide-quinidine example cited above). 
 Based on the results of in situ brain perfusion experiments, opioids were 
classified as having no P-gp effect (meperidine), low P-gp effect (morphine, 
fentanyl), intermediate P-gp effect (methadone, naltrindole), or high P-gp effect 
(SNC 121, DPDPE, and loperamide) . These designations were borne out by in vivo 
experiments (Kalvass et al., 2007), although the absolute magnitude of the P-gp 
effect differed to some extent between the two experimental approaches. This 
observation leads to an important question that is not completely resolved: does 
determination of the P-gp effect prior to the attainment of distribution equilibrium 
predict the P-gp at substrate equilibration across the blood-brain barrier? Across a 
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compound set, it is possible to develop such categorical predictions, although there 
are distinct quantitative differences in estimating the P-gp effect pre- and post-
distribution equilibrium. A related but separate issue concerns the precision with 
which such measurements may be made. Intuitively, one may expect that 
measurements made at distribution equilibrium would be more reproducible than 
measurements made prior to distribution equilibrium, simply because in the former 
case the system is under a stable, time-independent condition, whereas in the latter 
the system is still in dynamic flux. These experimental issues require further 
investigation. 
 Having categorized the influence of P-gp on brain uptake of opioids as a 
class, the next step was to determine the degree to which the pharmacodynamics of 
opioids could be altered by P-gp modulation. This goal was also addressed 
predominantly with mouse models (genetic or chemical disruption of P-gp) and 
measurement of opioid-associated antinociception (response to a thermal stimulus). 
In general, disruption of P-gp-mediated transport shifted the dose-response and 
blood concentration-response data to the left (Chen and Pollack, 1998; Zong and 
Pollack, 2000; Kalvass et al., 2007), consistent with an increase in opioid partitioning 
into brain. The degree of leftward shift in these relationships was, in general, 
consistent with the P-gp effect characterization of the opioids. At a fixed 
administered opioid dose, P-gp disruption increased the magnitude of 
antinociceptive effect, the duration of antinociception, and the area under the effect 
vs. time curve. Finally, in general, P-gp disruption did not alter the relationship 
between antinociceptive effect and bulk brain tissue concentration. This latter 
observation is important in that it suggests that the only influence of P-gp with 
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respect to central opioid pharmacology is its influence on opioid distribution into 
brain. Once the opioid molecule penetrates the blood-brain barrier, P-gp no longer 
has an influence on the ability of that molecule to access the opioid receptor. 
 DPDPE is an exception to these general observations (Chen and Pollack, 
1998). Ablation of P-gp-mediated flux (in P-gp-deficient animals) caused an 
approximate 30-fold leftward shift in the DPDPE dose-response relationship. When 
antinociceptive response was related to brain tissue concentration, as opposed to 
dose or blood concentration, an approximate 10-fold leftward shift remained, 
suggesting that P-gp-deficient mice were more sensitive to DPDPE than their P-gp-
competent counterparts, even at a fixed concentration of the opioid peptide in bulk 
brain tissue. 
 There currently is no adequate explanation for the apparently anomalous 
behavior of DPDPE. Initial speculation focused on the possible expression of P-gp at 
parenchymal locales in brain, consistent with observations in human brain tissue 
(Golden and Pardridge, 2000). Modeling the DPDPE pharmacodynamics in this 
manner indeed rectified the difference between P-gp-deficient and P-gp-competent 
animals (Chen and Pollack, 1998). Other explanations, however, also must be 
considered. One reasonable aspect to consider is the fact that P-gp function 
appears heterogeneous throughout the brain (Graff et al., 2005). If P-gp function is 
regional, and if regionality of substrate transport corresponds with regionality of 
receptor expression, then use of bulk brain tissue concentration as a surrogate for 
concentration at the receptor site may be misleading. Continued experimentation is 
required to address this point, and once again use of opioids as a pharmacologic 
class may provide fruitful results. 
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 Changes in intracellular concentration leading to altered pharmacologic 
response. P-gp originally was identified based upon its ability to confer cellular 
resistance to the effects of several drugs (Juliano and Ling, 1976), leading to its 
designation as a multi-drug resistance transport protein. In this capacity, P-gp 
regulates the distribution of pharmacologic agents not between the systemic 
circulation and the extracellular fluid space of an organ or tissue, as it does at the 
blood-brain interface, but rather between the extracellular and intracellular fluid 
spaces. If the relevant pharmacologic target is expressed intracellularly, P-gp has 
the potential to provide very close regulation of the amount of substrate that can 
reach that target at a fixed extracellular concentration of the substrate. 
 The most obvious and well-studied influence of P-gp on intracellular 
accumulation and/or the pharmacologic response to P-gp substrates at the cellular 
level is with respect to anticancer drugs. This topic has been the subject of 
numerous and ongoing comprehensive reviews (e.g., Pallis et al., 2002; Takara et 
al., 2004; Lee and Swain, 2005; Coley, 2008).  
The ability to inhibit P-gp (or other efflux transport proteins that confer cellular 
resistance to anti-cancer agents) substantially would represent a significant 
therapeutic gain. From the standpoint of cellular pharmacodynamics, the system is 
relatively simple: inhibition of a barrier transporter leads to enhanced cellular 
accumulation of the pharmacologic agent, which in turn causes a more significant or 
prolonged pharmacologic effect. In the case of tumor cells in vivo, this effect would 
translate, in theory, to an enhanced anti-tumor response. 
Despite the simplicity of the cellular pharmacodynamic system, translation of 
P-gp inhibition into a meaningful therapeutic approach for the treatment of cancer is 
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fraught with difficulties. One way in which tumor cell accumulation of an anticancer 
agent can be increased is simply by increasing the administered dose of the agent. 
Dose escalation would increase circulating concentrations of the drug, ultimately 
resulting in increased drug accumulating in the tumor cells. This simplistic approach 
is unworkable due to the systemic toxicity associated with anticancer agents. The 
advantage associated with a P-gp inhibition strategy is thus the potential to achieve 
enhanced tumor cell accumulation of an anticancer agent in the absence of 
increased systemic toxicity. 
Unfortunately, the relatively ubiquitous expression of functional P-gp 
throughout the body has effectively limited this strategy. Because P-gp is an 
important determinant of systemic exposure at multiple pharmacokinetic steps 
(absorption, biliary clearance, renal clearance), inhibition of P-gp may lead to 
increased systemic concentrations of P-gp substrates, the same outcome 
associated with a simple increase in dose of a P-gp substrate. Moreover, because 
P-gp plays a protective role for several important organs and tissues, indiscriminate 
inhibition of the transporter may lead to enhanced accumulation, and toxicity, in 
those organs. 
 Although results to date have been generally disappointing, it is premature to 
abandon the P-gp (or other barrier transporter) inhibition strategy. Undoubtedly, this 
will represent a fruitful area of research in the future. Experimental goals, however, 
must shift from identifying increasingly potent or specific P-gp inhibitors to 
developing strategies for targeting those inhibitors to specific sites of action. In the 
case of cancer chemotherapy, strategies for targeting P-gp inhibitors specifically, or 
at least preferentially, to the tumor would limit the degree of systemic drug-drug 
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interaction, increasing the potential utility of the transport-inhibition strategy. 
 A less specific, but possibly feasible, drug delivery strategy for P-gp inhibitors 
would be to preferentially (or selectively) target the inhibitor to the end-organ of 
interest. In the case of cancer chemotherapy, this might increase exposure of the 
anticancer agent to an entire organ or tissue space (the brain, for example, in 
treating CNS tumors) while sparing exposure throughout the rest of the body. One 
recently-explored approach for targeting P-gp inhibitors to the blood-brain barrier is 
delivery of the inhibitory compounds via the nasal route (Graff et al., 2005). While 
this approach appears to result in selective delivery to the brain, at least in rodents, it 
also is associated with numerous challenges, such as appropriate formulation of 
these generally lipophilic agents to allow mass delivery sufficient to exert a 
meaningful degree of inhibition. 
 
Summary 
 Modulation of P-gp-mediated transport has significant pharmacokinetic 
implications for P-gp substrates. Pharmacokinetic alterations may be at the systemic 
(blood concentrations), regional (organ or tissue concentrations), or local 
(intracellular concentrations) level. Regardless of the particular location of P-gp 
modulation, changes in substrate pharmacokinetics will have the potential to alter 
the magnitude and duration of pharmacologic effect (pharmacodynamics). It is 
important to understand each of the aspects of P-gp modulation for a given P-gp 
substrate in order to predict the degree to which P-gp modulation may affect that 
substrate, to minimize untoward effects associated with that modulation, or to exploit 
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that modulation for specific therapeutic advantage. 
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PROJECT RATIONALE AND SCOPE 
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It is widely accepted that the primary limitation hindering development of new 
neurotherapeutic agents is not the ability to identify new active chemical entities, but 
rather the ability to identify compounds with appropriate pharmacokinetic 
characteristics (Neuwelt et al., 2008).  As with all pharmaceuticals, CNS-targeted 
compounds must possess a constellation of “drug-like” properties in order to be 
therapeutically effective.  Various rules have been articulated to describe the 
physicochemical properties requisite for a drug-like compound, based upon meta-
analyses of combinatorial and medicinal chemistry libraries (Ghose et al., 1999).  
These requisite properties ideally convey appropriate ADME characteristics, for 
example, a reasonable rate and extent of absorption, if the compound is to be 
administered extravascularly.  Drugs also must not be overly metabolically labile, 
and not metabolized significantly by enzymes that display large inter-subject 
variability (e.g., CYP2D6) (Parkinson et al., 2004).  In addition, compounds must not 
be subject to a high degree of first-pass loss in the liver, and must possess a 
reasonable systemic half-life (Roberts, 2001; Singh, 2006).   
 
In addition to these generalized ADME requirements, potential 
neurotherapeutic agents also must possess properties which will allow effective 
permeability across the blood-brain barrier (BBB).  Although generalized factors 
which aid brain penetrability have been identified (e.g., lipophilicity, low molecular 
weight), the complexity of the BBB precludes any effective strategy to identify BBB-
permeable compounds based upon structural properties alone (Pardridge, 2007).  
Consequently, the ability to measure or predict permeation characteristics or brain 
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exposure vs. dose relationship is important in identifying potential therapeutic 
agents.   
 
The stringency of ADME and BBB-permeability requirements, in addition to 
CNS target specificity, renders the development of CNS therapeutics a difficult task. 
Consequently, the vast majority of CNS disorders remain poorly-treated with 
pharmacotherapeutics; only four types of CNS disorders (affective disorders, chronic 
pain, epilepsy, and migraine) are cited as being reasonably effectively treated with 
existing pharmaceuticals (Pardridge, 2005).  In cases for which a particular 
pharmacologic class (e.g., antineoplastics) evidences consistently suboptimal 
permeation of the BBB, the ability to enhance brain exposure would represent a key 
therapeutic advantage.   
 
 Given the significant role of BBB-expressed P-gp in exclusion of therapeutic 
compounds from the brain, chemical P-gp inhibition represents a potentially efficient 
strategy for enhancing the BBB penetrability of a substantial number of P-gp 
substrate compounds.  The clinical success of this approach, however, has been 
compromised by the inability to achieve sufficient unbound concentrations of these 
inhibitors without encountering significant systemic toxicity and unintended drug-
drug interactions (Kemper et al., 2003).  Previous studies conducted in this 
laboratory generated evidence that delivery of compounds via the nasal route 
afforded a degree of selectivity in exposure of the compound to the brain (Graff and 
Pollack, 2005).  It was reasoned that targeting chemical inhibitors to P-gp expressed 
at the BBB via nasal delivery could improve the therapeutic ratio of these 
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compounds and afford a means to augment brain exposure relative to systemic 
exposure of a P-gp substrate.  A P-gp substrate representative of one entire class of 
drugs virtually excluded from the brain by the BBB, antineoplastics, was selected as 
a model compound for evaluation of this approach.  As a proof of concept of the 
therapeutic advantage of this approach, it was anticipated that a successful P-gp 
inhibition approach could be evaluated using a mouse brain tumor model.  The 
overall goal of the current dissertation project was thus to evaluate the efficacy of a 
targeted approach to deliver a chemical inhibitor of P-gp expressed at the BBB in 
order to augment brain exposure to a model P-gp substrate. As part of this goal, a 
framework for appropriately understanding the pharmacokinetic factors that govern 
brain exposure also was needed. 
 
 As a therapeutic proof-of-concept study (using a mouse brain tumor model) 
was anticipated, one sub-goal of the project was to establish the relationship 
between cellular response to the model compound paclitaxel, and the kinetics of 
drug exposure.  The main objective of this research project was to modulate the 
kinetics of brain exposure to paclitaxel.  In order to evaluate the effect of this 
strategy on tumor cellular response, it was necessary to first understand the kinetic-
dynamic linkage at the cellular target.  Tumor cells, like bacteria, may respond 
preferentially to a compound when administered with certain exposure kinetics 
(Gardner, 2002; Nicolau, 2003).  Thus, despite the overall efficacy of the 
experimental strategy to enhance brain exposure to paclitaxel, a lack of 
understanding of the kinetic-dynamic linkage at the level of cellular response could 
obscure the relationship between the efficacy of the P-pg inhibition strategy and the 
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magnitude of the pharmacodynamic response.  The utility of mathematical modeling 
approaches for this purpose of linking substrate exposure kinetics to tumor cellular 
response has been documented (Jusko, 1973).   
 
 Regardless of the level of understanding of the kinetic-dynamic linkage at the 
cellular target, inability to deliver a sufficient mass of drug to the target site precludes 
any chance of observing therapeutic efficacy.  The second sub-goal of this project 
was to demonstrate a therapeutically relevant increase in brain exposure to the 
model substrate, paclitaxel, via the proposed targeted P-gp inhibition approach.  As 
discussed above, some attention has been directed toward the nasal delivery route 
as a means to target drugs to the brain via a potentially weak spot in the BBB at the 
site of penetration of olfactory neurons through the nasal epithelium (Illum, 2000).  
While this approach may be theoretically attractive due to the potential for 
augmenting brain exposure while minimizing potentially toxic systemic exposure, the 
ability to deliver sufficient mass by this route is limited.  This limitation precludes the 
delivery of a therapeutic volume of antineoplastic agents to the brain by this route; 
however, it may be possible to deliver a sufficient quantity of a potent chemical P-gp 
inhibitor by nasal administration to target P-gp expressed at the BBB.  As paclitaxel 
brain uptake is substantially limited by P-gp at the BBB (Kemper et al., 2003), this 
strategy could allow a sufficient mass of systemically-administered antineoplastic to 
enter the brain.  It is noted that an additional layer of complexity, related to the 
unique properties of the tumor environment, will impact the ability of the proposed 
therapeutic approach to elicit an antineoplastic response (Li et al., 2000).  Thus, the 
current work was primarily intended to serve as a proof of concept that brain 
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exposure to neurotherapeutics can be enhanced by a nasal P-gp inhibitor 
administration strategy. 
 
 It was recognized that in order to assess the outcome of the proposed 
therapeutic strategy, or any strategy to enhance brain exposure, an appropriate 
method for expressing brain exposure, and the impact of the therapeutic strategy 
upon brain exposure, relative to systemic exposure, is required.  A common, and 
generally-accepted metric of brain exposure is the brain-to-blood tissue partition 
coefficient, Kp, brain (Liu et al., 2005).  This metric is calculated as the ratio of 
concentrations or areas under the concentration-time curves in brain tissue vs. the 
systemic circulation.  By comparing Kp, brain in the presence and the absence of P-gp 
inhibition (either with chemical inhibition or in a genetic model of transporter 
deficiency), the net influence of the inhibition strategy can be expressed as the ratio 
of Kp, brain values in the presence vs. the absence of P-gp modulation (termed the P-
gp effect).  Because Kp, brain, which is zero at the time of systemic administration, 
changes as substrate concentrations equilibrate between the two tissues, this metric 
is necessarily time-dependent, and thus most appropriately calculated at steady-
state or following establishment of brain-to-blood distribution equilibrium (DE).  The 
P-gp effect, however, often is calculated under a variety of experimental conditions 
which may inherently limit the ability to sample post-steady-state or post-DE (e.g., in 
situ brain perfusion) (Dagenais et al., 2000).   Because Kp, brain, and thus P-gp effect, 
are time-dependent metrics, the final sub-goal of this project was to determine how 
these metrics behave, temporally, under a variety of kinetic conditions, and to 
understand the extent to which early (relative to attainment of DE) determination of 
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these values will be predictive of the same measures taken at steady-state.  These 
experimental questions were addressed by utilizing the principles of the emerging 
field of quantitative systems pharmacology (Zhang et al., 2006).  This approach 
combined simulation experiments and data mining efforts to inform the design of 
highly targeted, prospective experimentation.   
 
 The goals outlined above were addressed, and are described within the 
seven experimental chapters of this dissertation as summarized below. 
 
Chapter 2 of this dissertation communicates experiments designed to 
investigate the kinetic-dynamic linkage between exposure to the anticancer agent 
paclitaxel and cellular response of brain tumor cells in vitro.  An in vivo-in vitro 
pharmacodynamic model is developed to predict the range of potential tumor 
responses, based upon preliminary determination of the CNS pharmacokinetics of 
paclitaxel in mice. 
 
In Chapter 3, the selective brain vs. systemic exposure advantage conferred 
by nasal delivery is evaluated for three model P-gp inhibitors, quinidine, rifampin, 
and GF120918, by comparing brain partitioning under conditions of nasal vs. 
systemic administration.   
 
Rifampin has been used as an important experimental tool to probe the 
induction and inhibition of P-gp and CYP enzymes.  Surprisingly, the systemic 
kinetics and the exposure at various organs of experimental interest had not been 
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defined in preclinical species.  To enable the development of rational administration 
strategies to probe these important functions of rifampin, the systemic 
pharmacokinetics, as well as tissue-to-blood partition ratios in various organs were 
evaluated and mathematically modeled, as described in Chapter 4.  
 
Due to the various anatomical and experimental limitations posed by the 
physiology of the murine nares, the delivery of sufficient mass of even a potent P-gp 
inhibitor to selectively target P-gp at the BBB is challenging.  Chapter 5 
communicates the exploration of a variety of strategies to evaluate the impact of 
nasal administration of P-gp inhibitors on the brain exposure to paclitaxel.  The 
incorporation of a range of experimental paradigms necessitated evaluation of brain 
exposure, and the effect of the therapeutic strategy on brain exposure, at a variety of 
sampling times, some prior to the attainment of paclitaxel brain-to-blood DE.   
 
Observations outlined in the previous chapter raised questions about the 
importance of sampling time on the ability to determine a P-gp inhibitor effect, or a 
simple tissue partition ratio.  Chapter 6 reports the results of a series of 
mathematical simulation experiments, based upon the behavior of paclitaxel in the 
mouse CNS, which were undertaken to address these questions.  An unexpected 
result was an unusual relationship between the apparent volume of distribution of a 
peripheral pharmacokinetic compartment and substrate brain-to-blood equilibration, 
leading to an initial peak (overshoot) followed by a time-dependent decrease in brain 
partitioning.   
 
42 
 
The studies described in Chapter 7 were designed to further probe the 
unexpected observations reported in the preceding chapter.  These simulation 
experiments comprehensively explored the relationship between brain partitioning 
and peripheral distribution volume.  As part of this effort, a literature search identified 
valproic acid (VPA) as a compound that evidences overshoot behavior in brain 
partitioning under several circumstances.  Due to the tendency of VPA to undergo 
enterohepatic recycling (ER), this compound behaves in accordance with distribution 
into a large peripheral pharmacokinetic compartment.  Published VPA data were 
evaluated in the context of model predictions in order to evaluate the degree to 
which these simulated observations were consistent with VPA behavior.   
 
Chapter 8 communicates a series of experiments which were designed to 
prospectively evaluate the model predictions generated in the preceding chapter.  
These studies capitalized on the unique opportunity, afforded by VPA ER, to 
modulate the apparent peripheral volume of distribution by experimental interruption 
of the recycling process.  These studies evaluated strategies for attenuating VPA 
recycling, and tested the hypothesis that interruption of ER would alter overshoot 
behavior in the kinetics of brain-to-blood partitioning.   
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CHAPTER 2 
 
 
 
 
ROLE OF ADMINISTRATION KINETICS ON PACLITAXEL-INDUCED TUMOR 
CELL DEATH IN VITRO AND RELATION TO PREDICTION OF IN VIVO TUMOR 
RESPONSE 
 
 
 
 
 
 
 
This chapter is constructed as a research article to be submitted to Biochemical 
Pharmacology, and is written in the style of that journal. 
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ABSTRACT 
 
Purpose.  The goals of this study were to develop a mathematical model to 
elucidate the role of exposure kinetics on drug-induced tumor cell death in vitro, and 
to extend model predictions to cellular response in vivo.   
Methods.  Human glioma cells were exposed to paclitaxel in medium under four 
exposure scenarios differing in exposure magnitude, duration and frequency.  Cell 
death was assessed periodically by tetrazolium assay, and cellular response was 
described by pharmacodynamic and compartmental pharmacokinetic models.  In 
vivo brain pharmacokinetics were characterized following intravenous bolus 
administration of paclitaxel to mice.  Mice were sacrificed serially and brain 
concentrations of paclitaxel were determined by LCMS/MS.  Brain pharmacokinetics 
were incorporated into in vitro models to predict in vivo tumor cell response. 
Results.  A sigmoidal Emax model estimated the greatest cell death response (Emax) 
in cells exposed to a single concentrated dose, while the lowest 50% effective 
exposure level (EAUC50) was associated with frequent fractionated exposure.  
Based on models of time course of cellular response, no consistent relationship 
between administration kinetics and response parameters was detected. Predictions 
of in vivo tumor cell response depended on model specification of exposure as total 
exposure versus a time-dependent concentration profile, where use of total 
exposure predicted lower response.  
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Conclusions.  Drug exposure kinetics can influence cellular response, however 
models of time course of cellular response did not describe a consistent relationship, 
or consistently predict in vivo response.  
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INTRODUCTION 
Optimal characterization and prediction of the effects of any 
pharmacotherapeutic agent may depend on understanding the influences of several 
interacting drug exposure variables, including exposure frequency, magnitude, and 
duration.  Although limited research has been directed towards addressing the 
intersection of these exposure kinetic parameters, significant evidence supports their 
individual importance in determining cellular response to drugs (1-3).    
These factors are particularly important in cancer chemotherapeutics.  This 
area, similarly to that of antimicrobial chemotherapeutics, deals with populations of 
drug targets which are subject to rapid proliferation as well as degradation.  Not only 
does this phenomenon affect determination of the exposure of the target population 
to drug, but the change in target numbers due to irreversible reaction with the drug 
(cell death) often constitutes the drug effect.  The kinetics of target turnover 
(cytokinetics) therefore represent a factor somewhat unique to these areas of 
pharmacology, and dictate the development of models specific to irreversible effect 
agents (4).  In order to make accurate predictions of the effects of cancer 
chemotherapeutics, it is necessary to account for the baseline rates of change of the 
target population, as well as to determine the influence of a given drug on baseline 
cytokinetics (5).  
The concept that the kinetics of drug exposure and the kinetics of cell 
turnover can interact to determine the response of tumor cells to a given drug is not 
new.  Over the past forty years there has accumulated a substantial body of 
literature dedicated to the development of mathematical models describing the 
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intersection of these factors.  In many cases, these models have directly contributed 
to the successful development and administration of drugs (6).  
Anticancer compounds are increasingly being developed rapidly by high 
throughput in vitro screens such as those currently used by the National Cancer 
Institute’s Developmental Therapeutics Program (7).  Like the protocol utilized by the 
Developmental Therapeutics Program, many researchers employ screens involving 
application of several concentrations of a test compound to multiple cell lines (8).  
Resulting cytotoxicity is assayed based on cellular response to a single exposure of 
a fixed duration.  While the need for efficiency in some cases precludes more 
extensive testing, a range of parameters including exposure duration, concentration, 
and frequency, may impact the outcome of such evaluations.  
Although the effects of the exposure kinetic parameters mentioned above are 
straightforward to test experimentally, evaluation of tumor cytokinetics can be more 
complex, and is less frequently conducted in the context of cancer chemotherapy 
studies.  Accordingly, the present studies evaluated models which can be applied to 
standard cytotoxicity assays, which do not identify cell cycle phase.  These models 
attempt to take into account different types and percentages of subpopulations of 
cells that are capable of dividing or may have become resistant to the drug.  The 
models also consider the impact of cell death affecting cells in these various phases.   
The utility of developing pharmacokinetic models obviously lies in the ability of 
those models to predict effects under a variety of conditions.  The ability to correlate 
in vivo and in vitro predictions of cancer chemotherapy effects provides a potential 
means for improving clinical outcomes as well as informing the design of cancer 
drug efficacy screens.  This chapter presents an evaluation of an extensive range of 
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drug exposure conditions in a human glioma cell line model, using paclitaxel as a 
model chemotherapeutic drug.  Along with this in vitro model, a basic description of 
paclitaxel pharmacokinetics in the murine brain is provided to facilitate mathematical 
predictions of in vivo response. 
Paclitaxel has been used successfully for nearly two decades to treat cancers 
of the ovary, lung, neck, and breast (9-11).  It is known to promote cell cycle arrest 
and apoptosis by binding to and stabilizing microtubules (12).  Using paclitaxel as an 
example, the intersecting effects of the various categories of kinetics could be 
deduced based on standard measures of chemotherapeutic efficacy by developing 
semi-mechanistic mathematical models. The goals of the current study were to 
examine the impact of cell turnover and drug exposure kinetics on cell-kill effect in 
an in vitro model of paclitaxel-induced cytotoxicity in human glioma cells, and to link 
these predictions developed in vitro to an in vivo mouse model of paclitaxel brain 
pharmacokinetics.   
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MATERIALS AND METHODS 
 
Chemicals 
Semisynthetic paclitaxel and thiazolyl blue tetrazolium bromide (MTT) were 
purchased from Sigma Aldrich.  The clinical formulation of paclitaxel, (Taxol injection 
solution, 6 mg/mL) was purchased from Bristol Myers Squibb.  All other chemicals 
were of the highest grade available from commercial sources.  
 
Cell Culture 
U251MG cells were purchased from the National Cancer Institute.  Cells were 
thawed and grown to confluency at 37°C in a humidified incubator with 5% CO2 and 
95% air. Cell culture medium consisted of RPMI 1640 (Gibco) supplemented with 
5% fetal bovine serum (HyClone) and 0.1% penicillin and streptomycin.   
 
Paclitaxel Exposure 
Following at least one subculture, 5,000 cells were inoculated into each well 
of 96 well microtiter plates in 100 µL medium.  After 24 hr to allow for cell 
attachment, medium was gently aspirated using a multichannel micropipettor, and 
was replaced with 100 µL fresh medium containing 0.2 µL DMSO vehicle or 
paclitaxel dissolved in DMSO to achieve final drug concentrations ranging from 0.2 
to 50 nM in medium.   
Under all drug exposure conditions, the relationship between cytotoxicity and 
overall paclitaxel exposure (calculated as area under the paclitaxel medium 
concentration-time profile; AUC) was determined throughout 4.5 doubling times (72 
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hr).  Four types of exposure scenarios were evaluated at 7 exposure levels each: 0, 
15, 90, 120, 270, 900 and 2,700 nM * hr.  Effect of exposure duration was evaluated 
by exposing cells to 50 nM paclitaxel in culture medium, followed by replacement 
with drug-free medium at various intervals to achieve the specified exposure.  
Magnitude of exposure was evaluated by exposing cells for the entire duration of the 
experiment to paclitaxel in medium at concentrations appropriate to achieve the 
specified exposure levels.  Fractionated exposure was achieved by removing and 
replacing medium containing 50 nM paclitaxel at regular intervals to achieve the 
desired exposure levels. 
 
MTT Cell Density Assay 
Cell density was assayed twice per doubling time by MTT assay (26) using 
one 96 well plate per assay.  Medium was replaced with 100 µL fresh medium 
containing 11 µL MTT solution (5 mg/mL in PBS).  After 2 hours of incubation, cells 
were lysed with 111 µL 0.04 N HCl in isopropanol and absorbance was evaluated at 
590 nm using an FL600 microplate reader (BioTek Instruments, Inc., Winooski VT).  
The relationship between cell number and absorbance was determined to be linear 
across the range of relevant cell densities.  
 
Modeling Cellular Response Kinetics 
A sigmoidal Emax model was employed to characterize exposure paradigm 
effects in terms of intrinsic parameters of cytotoxic response.  Input data consisted of 
MTT absorbance values at the completion of the exposure period (72 hr).  Data were 
plotted as effect (percent cytotoxicity; [(control absorbance – treated absorbance) / 
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control absorbance] * 100) vs. exposure.  For each treatment group, the following 
equation was used. 
AUCEAUC
AUCEE
+
=
50
max*
 
 
Control MTT absorbance value versus time data were analyzed by compartmental 
methods, using WinNonlin (v. 4.1) (Pharsight, Mountain View, CA).  In order to 
account for effects related to cell loss during medium removal or differential baseline 
growth rates as a function of frequency of the number of medium changes, individual 
control groups were included for each exposure paradigm.  Control cell growth was 
characterized with a one-compartment model incorporating a single recirculating 
first-order rate constant, kng, representing net growth (natural rate of cell growth + 
natural rate of cell death) of dividing cells (Cd).  Growth lag time, (tau), absorbance 
at time 0 (abs0), and post-lag cell growth rates were modeled as parameters. For all 
models, 1/Y weighting was employed.   
 
Cdkng
dt
dCd
*=  
 
Several compartmental models were tested for their ability to describe 
paclitaxel-induced cytotoxicity.  Based on the model described above, all models 
included as fixed parameters kng and tau specific to each treatment group, and a 
single fixed abs0 value for all groups.  Data from all treatment groups at all exposure 
levels were fitted simultaneously.  In order to account for the different exposure 
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levels, each model included at least one cell death rate term dependent on 
concentration (term applied only during specified time intervals representing periods 
of drug application), or on AUC.   
Model discrimination was accomplished using standard goodness-of-fit 
criteria including model convergence, Akaike’s information criterion (AIC), 
examination for bias in residuals, parameter covariance, and %CV for the final 
parameter estimates.  The best three models were identified and absorbance versus 
time data from each treatment group was fitted individually in order to evaluate 
exposure paradigm effects across groups. 
 
Paclitaxel Administration in Vivo 
Male BALB/c athymic nude mice between 4-6 weeks of age were purchased 
from NxGen Biosciences (San Diego, CA).  Mice were housed separately in 
microisolator cages in a temperature- and humidity-controlled room with a 12 hr light 
/ dark cycle, with free access to irradiated food and water.  The experimental 
protocol was approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill.  Study design and all experimentation 
adhered to the Principles of Laboratory Animal Care (NIH publication #85-23, 
revised 1985). 
Four mice per time point were briefly restrained and administered 10 mg/kg of 
paclitaxel as the clinical formulation, Taxol, via tail vein injection, then returned to 
their cages.  At 5, 10, 20, 30, 60, 120, 240, 360, 480, 720, 1,080 and 1,440 minutes 
post administration, brain and plasma were collected and stored at –80°C until 
analysis by LC-MS/MS.   
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Analytical method for determination of paclitaxel in mouse tissue. 
The analytical system consisted of an Applied Biosystems API 4000 triple 
quadrupole mass spectrometer with Turbo-IonSpray interface (MDS Sciex, Foster 
City, CA), a Shimadzu LC-10ADvp micro-plunger pump and a thermostatic CTC PAL 
Leap autosampler (Hamilton Co., Reno, NV).  Upon injection of 20 µL of sample 
supernatant, paclitaxel was eluted through a Phenomenex Gemini, 30 x 2 mm 5 µm 
analytical column, using a mobile phase gradient (solvent A, 0.1% formic acid in 
HPLC grade water; solvent B, 0.1% formic acid in HPLC grade methanol) and a flow 
rate of 0.75 mL/min at room temperature.  Initial gradient conditions of 90% solvent 
A were held for 50 s.  The percentage of solvent A was decreased linearly over 2 
min to 5%.  This composition was maintained at 5% for 10 s, then increased linearly 
over 30 s back to 90%, where it was maintained for 30 s.  Paclitaxel and 
fexofenadine (internal standard) were detected in positive ion mode using multiple 
reaction monitoring: paclitaxel (854.4  286.1, 870.5  509.3, 870.5  525.2), 
fexofenadine (502.3  466.3).  Raw values for brain samples were corrected for 
contamination with cerebral blood, based upon a calculated mouse brain vascular 
space of 1.3 mL * 100g-1 (27). 
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Mathematical modeling of paclitaxel pharmacokinetics. 
For the purposes of correlating in vivo paclitaxel brain pharmacokinetics with 
tumor cell kill based on in vivo predictions, brain concentration data only were 
analyzed by compartmental methods using WinNonlin software.  AUC∞ was 
calculated by the log-linear trapezoidal method.   
 
In Vivo Response Prediction 
Based on the pharmacokinetic modeling of in vivo paclitaxel brain 
pharmacokinetics described above, calculated AUC values or differential equations 
describing predicted concentration-time profiles were incorporated into four in vitro 
cell death models.  Model input consisted of final estimated parameters obtained by 
modeling the continuously-exposed groups of cells.  Absorbance versus time profiles 
were simulated at the seven experimental exposure levels as well as at the 
predicted in vivo brain exposure level (expressed as AUC or a differential equation 
describing concentration-time profile as appropriate for the model).   
57 
 
RESULTS 
  
Effect vs. Exposure Modeling 
 Cytotoxic response at seven exposure levels was compared using a 
sigmoidal Emax model.  The effects of exposure magnitude versus exposure duration 
are contrasted in Fig. 1 and Table 1.  Cells exposed to paclitaxel in medium for a 
fixed period of time but at varied drug concentrations had the lowest maximal 
cytotoxic effect level (Emax).  In contrast, cells exposed to a constant drug 
concentration for variable duration evidenced the highest Emax and a slightly 
elevated EAUC50 value (Fig. 1a).  As the number of exposures increased from 1 
(single exposure) to 9 (9x fractionated), both Emax and EAUC50 decreased (Fig. 1b). 
 
Control Cell Growth 
The time course for control cell growth is shown in Fig. 2.  For all control 
groups, there was an inverse relationship between number of fractionations and rate 
of control cell growth.  After an initial period of approximately 20 hr in which control 
growth rate was slow for all groups, growth rates began to diverge, with cells from 
the single exposure and continuous exposure groups growing faster than cells in the 
3x or 9x fractionated groups.  Post-lag-time growth was exponential in all groups 
throughout the entire experimental period.  Growth vs. time data were fit with a one 
compartment model (Fig. 3) with a single rate constant (kng) reflecting net cell 
growth of dividing cells (Cd).  Iteration for lag time (tau), absorbance at time 0 
(abs0), and the net growth rate constant (kng) showed that the lag time increased 
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with increasing dose fractionation (Table 2). The rate constant kng, calculated during 
the time following tau until the end of the experiment, increased with decreasing 
fractionation.   
 
Paclitaxel Cell Kill Models 
 Schematics representing three models best capable of describing the 
experimental data are presented in Fig. 3.  As specified in the methods section, all 
models included fixed kng and tau values specific to treatment group.  The initial 
condition at time zero was specified as an abs0 value general to all treatment 
groups.  All models included at least one cell death rate term dependent on drug 
concentration or AUC.  
Model 1 consisted of a single compartment representing dividing cells (Cd), 
and a single cell death rate constant with Michaelis-Menten kinetics, 
 
Cd
AUCEAUC
AUCKCdkng
dt
dCd
*)
50
max*(*
+
−=  
 
where AUC values specify the drug exposure level, Kmax represents the maximum 
rate constant for cell death, and EAUC50 specifies the drug exposure capable of 
producing a half-maximal rate of cell death.  Model descriptions based on individual 
fit to data from all treatment groups are shown in Fig. 4a-d.  Despite a modest 
amount of bias at late time points, the fit of the model to the observed data was 
reasonable. Model 1 was associated with the lowest AIC value (-160) among all the 
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models tested, and therefore was statistically superior in describing the present set 
of data.   
Final estimates for Kmax and EAUC50 based on analyzing the data from 
individual treatment groups with Model 1 are presented in Table 3.  There was little 
difference between estimated Kmax values for the fractionated and single initial 
exposure groups, relative to the continuous exposure group;  Kmax was ~ 3-fold 
higher in the continuous exposure group.  Estimated EAUC50 values were roughly 
3-fold greater in the 9x fractionated and the single initial exposure group versus the 
3x fractionated group.  EAUC50 was markedly larger in the continuous exposure 
group as compared to all other treatments.  
Model 2 also consisted of a single compartment representing dividing cells, 
and one cell death rate, which increases as a function of time: 
 
kdk
dt
dkd
CdAUC
dt
dkdCdkng
dt
dCd
*
*)*(*
=
−=
 
The initial condition for the second equation was determined by iteration as a 
parameter.  This model was capable of capturing the shape of the plateau and 
subsequent net decrease in absorbance observed at high exposure levels (Fig. 5a-
d).  There was, however, some bias in the fit of this model to the observed data as 
well, particularly at later time points.  The model generally overpredicted absorbance 
in the fractionated and single exposure groups, while it slightly underpredicted 
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absorbance in the continuous exposure group.  The second lowest AIC value (-16) 
was calculated for Model 2.   
Final estimates of kd and k based on modeling of individual data sets are 
presented in Table 4.  Kd was highest in the 3x fractionated group, ~ 2-fold higher 
than the 9x fractionated and single initial dose groups, and 3-fold higher than the 
continuous exposed group.  The baseline rate estimates (k) were similar among all 
groups except the 3x fractionated group, in which k was an order of magnitude 
lower. 
Model 3 incorporated two compartments, one representing cells capable of 
mitotic division (Cd) and the other representing sterilized cells (Cs).  Drug-induced 
cell death was assumed to directly affect only the sterile population of cells, by a 
first-order rate constant dependent on drug concentration: 
 
)*)*(()*)*((
)*)*((*
CsCkdCdCks
dt
dCs
CdCksCdkng
dt
dCd
−=
−=
 
In order to represent total drug exposure levels between groups, the concentration-
dependent cell death and cell sterilization rates were specified to apply only during 
intervals of time when drug was present in medium.  Model 3 tended to overpredict 
absorbance at most exposure levels, but underpredicted absorbance at the highest 
exposure level (Fig. 6a-d).  Bias was least apparent in the fit to the continuous 
exposed treatment group.   
61 
 
 The estimates for the rate constant for sterilization, ks, did not differ 
significantly between treatment groups (Table 5).  The rate constant for cell death, 
kd, was estimated to be highest in the single initial exposure group.  In both 
fractionated exposure groups, kd was 5-fold lower, while in the continuous exposure 
group, the rate was more than 10-fold lower.   
 
Paclitaxel Pharmacokinetic Model 
  The paclitaxel brain concentration versus time profile appeared to decline 
monoexponentially (Fig. 7).  Optimal description of the data was achieved with a 
standard one-compartment model with a first-order elimination rate constant.  The 
value representing the initial concentration in the brain was determined by iteration, 
along with a first-order rate constant describing the decrease in paclitaxel brain 
concentrations over time.   AUC∞, calculated by the log-linear trapezoidal method, 
was 919 nM * hr, which was within the range of exposure levels tested in vitro.   
 
In Vivo Response Prediction 
 For in vitro cell death models 1 and 2, prediction of in vivo paclitaxel -induced 
tumor cell death was based on calculated brain AUC∞ (919 nM * hr).  Simulated in 
vivo absorbance values were consistent with simulations of in vitro cell death in the 
continuous exposure group, falling between 900 and 2,700 nM * hr exposure levels 
(Fig. 8a and b).  In Model 3, in vivo tumor cell death was simulated by substitution of 
the differential equation describing the in vivo brain kinetics for the concentration 
term in Model 3.  Simulation of in vivo cell death was not consistent with in vitro cell 
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death, with the predicted values falling below the 2,700 nM*hr in vitro simulations 
(Fig. 8c).   
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DISCUSSION 
The results of this study demonstrate that in this in vitro model of paclitaxel-
dependent cytotoxicity, kinetic parameters of drug exposure can influence cellular 
response.  These results are consistent with existing evidence for the importance of 
drug exposure kinetics, rather than simply the magnitude or duration of exposure 
alone, on drug response (1-3).   
In the current study, analysis of response data with the sigmoidal Emax model, 
regardless of the specific modeling aspects of cell death, revealed that the maximum 
cytotoxic effect was highest under conditions of brief initial exposure to high 
concentrations of drug. Essentially 100% of maximum response could be elicited 
with a single application of the drug, if initial concentrations were sufficiently high. In 
contrast, all other administration modalities resulted in incomplete response, a least 
over the exposure conditions evaluated in this experiment. 
In contrast to Emax (a measure of maximal efficacy), EAUC50 (a surrogate for 
apparent potency) was lowest for the 9x fractionated dosing approach. Apparent 
potency decreased approximately 3-fold (i.e., 3-fold higher EAUC50) with 3x 
fractionation, and was highest (5-6-fold higher than 9x fractionation) with the single- 
and continuous-exposure modes. 
Estimation of EAUC50 indicated that, although the maximum cytotoxic effect 
was reduced with increased frequency of drug exposure, cell kill may be more 
efficient, per total exposure.  This interpretation may have some support in 
resonance theory of cytotoxicity, which postulates that for cell-cycle-specific drugs 
such as paclitaxel, frequent drug exposure relative to doubling time can lead to 
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synchronization of cell division cycles and more effective tumor cell kill per exposure 
(13).  Other hypotheses centered on the positive effects of increased drug exposure 
frequency are related to factors such as drug half-life and concentration-dependent 
activity (14). 
The models which incorporated an AUC term were generally better able to 
describe the absorbance-time profile than identical models incorporating a 
concentration dependent term, applied only during intervals during which drug was 
present.  This was true for the fractionated exposure groups as well as the treatment 
groups where drug was applied once.  In general, the effects of cytotoxic cancer 
chemotherapeutics are thought to be primarily AUC-dependent (16), although it has 
been suggested that the effects of paclitaxel are time-dependent (17).  It is 
interesting to consider the possibility that a scaling factor may be utilized to improve 
the ability to describe effect based on specification of exposure by time-dependent 
concentration terms in models such as Model 3. 
The parameters generated by Emax model fit are consistent with a 
concentration- (or more generally exposure)-related rapid response. In essence, the 
higher concentrations required with a single application to produce an exposure 
equivalent to continuous administration, whether that is represented as unchanging 
concentrations with time or fractionated dosing, are sufficient to drive effect to its 
maximum. The explanation for the administration modality-related differences in 
EAUC50, on the other hand, is more speculative. It is possible, for example, that 
some metabolism of paclitaxel occurred in these cells in culture. By fractionating the 
dose, cells were exposed to parent paclitaxel on a regular basis. The more closely-
spaced the fraction, the more net exposure to unchanged parent drug. 
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Comprehensive in vitro pharmacokinetic experiments would be required to address 
this particular point. However, the in vitro kinetics of paclitaxel, while providing 
context for the modest differences in cellular pharmacodynamics observed in this 
study, would not inform future in vivo dynamic experiments, in which case exposure 
of tumor cells to the drug would be dictated almost entirely by in vivo 
pharmacokinetics.  
It is possible, even with the relatively short time scale examined, that the 
tumor cells developed resistance to paclitaxel during the course of this experiment 
(e.g., due to stimulation of P-glycoprotein expression, for example). The 
development of such resistance would be expressed as a time-dependent increase 
in the EAUC50. This possibility was not included in the current modeling effort. 
However, if unchanged parent was responsible for induction of a resistance 
mechanism, and if the parent drug was chemically or metabolically unstable in cell 
culture, it is likely that the 9x fractionated dosing scheme would result in the highest 
degree of resistance (and therefore the highest EAUC50). Because this dosing 
approach resulted in the lowest, not the highest, EAUC50, other explanations likely 
are responsible. Regardless of the underlying cause, the relatively modest 
differences in pharmacodynamic parameters among the different drug administration 
schedules examined likely would not result in discernible differences in in vivo 
response, as other factors (e.g., pharmacokinetic variability, tumor location in the 
CNS, or tumor cell growth) likely would be the dominant source of variability in the 
kinetic-dynamic system. 
If drug administration schedule were to be exploited for therapeutic gain (e.g., 
to optimize cell kill, to maximize potency, or to minimize cellular resistance), the 
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kinetics of drug administration must be the rate-determining step in the drug 
exposure vs. time profile at the site of action. Based on pacltaxel disposition in 
murine brain tissue, modulation of CNS drug exposure by altering the kinetics of 
drug administration may be feasible. The apparent half-life of Taxol in brain was 
approximately 5 hours (Fig. 7). Thus, once-daily administration would likely result in 
a markedly different concentration vs. time profile (an approximate 50-fold fluctuation 
in peak-to-trough concentrations) than, for example, drug administration 4 times per 
day (which would result in an approximate 2-fold fluctuation in concentrations). 
However, the overall concentration-time profile in brain tissue will be affected by the 
route of pacltaxel administration, as well as by accumulation from the first 
administered dose to steady-state. As will be shown in subsequent chapters in this 
dissertation, the time to achieve distribution equilibrium between brain tissue and 
blood for pacltaxel is extremely long. Ultimately, the slow approach to distribution 
equilibrium may be the rate-determining factor in the entire system, and might mask 
any treatment schedule-related modulation of the concentration-time profile. 
In addition to differences in drug distribution in tumors in situ, the kinetics of cell 
growth are likely to differ as well due to a host of biochemical and physical factors 
which differ from the in vitro environment.  This topic has been addressed in the 
literature, and mathematical models which have been developed to characterize 
these phenomena (22-24).  These models could potentially be incorporated into the 
current model, to improve characterization of cell growth kinetics.   
Recognizing that the dynamic system may behave differently after a single 
application of drug in vivo than under steady-state conditions, the results of the in 
vitro effect modeling were combined with the in vivo brain tissue exposure in mice to 
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generate a simulated response vs. time profile for short-term (<3 days) pacltaxel 
administration (Fig. 8). The rationale for this simulation study was to determine 
whether discernible drug response could be expected in vivo, assuming that the in 
vitro cellular response data would translate to the in vivo condition. The results of 
this simulation effort suggested that in vivo efficacy of paclitaxel would indeed be 
measurable. Moreover, differences in the simulated response vs. time profiles 
among the three different pharmacodynamic models employed suggest that in vivo 
data may allow further discrimination and model identification for this dynamic 
system.  This observation was supported by the results of simulated in vivo 
cytotoxicity. Incorporation of a concentration term in Model 3 allowed the 
specification of a high initial concentration with exponential decline throughout the 
exposure period.   
Although a clear anti-tumor response would be expected in vivo, the response 
likely would be incomplete and continued cell growth, albeit at a slower rate, would 
be expected. Because the in vitro experiments indicated that a high initial 
concentration is required for complete cell kill, maximal therapeutic benefit from 
paclitaxel in the treatment of brain tumors might be expected only in the presence of 
high brain concentrations of the drug. Because paclitaxel is excluded from the brain 
by the blood-brain barrier (to a large extent by P-glycoprotein-mediated efflux), one 
approach to enhancing brain exposure to the drug would be to inhibit P-glycoprotein. 
Due to the somewhat ubiquitous expression of this transporter in various tissues, 
and the likelihood of systemic drug-drug interactions in the presence of a P-
glycoprotein inhibitor, selective modulation of the transporter at the blood-brain 
interface would represent the best opportunity for achieving a positive therapeutic 
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outcome. Experiments are ongoing to evaluate the use of the nasal route for delivery 
of P-glycoprotein inhibitors preferentially to the blood-brain barrier. 
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Fig. 1a. 
Data from continuous exposure and single initial exposure treatment groups were fit 
with a sigmoidal Emax model.  Seven exposure levels from each treatment were 
plotted to obtain estimates of Emax and EAUC50.  Data are plotted as % cytotoxicity, 
calculated as [(control absorbance – treated absorbance) / control absorbance] * 
100). 
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Fig. 1b. 
Data from treatment groups reflecting three levels of dose fractionation (single initial 
exposure, 3x fractionated exposure, and 9x fractionated exposure) were fit with a 
sigmoidal Emax model.  Seven exposure levels from each treatment group were 
plotted to obtain estimates of Emax and EAUC50.  Data are plotted as % cytotoxicity, 
calculated as [(control absorbance – treated absorbance) / control absorbance] * 
100). 
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Fig. 2. 
Observed control cell growth in each treatment group.  A single treatment group with 
one medium change was used as a control for both continuous exposure and single 
initial exposure groups.  Data are plotted as corrected absorbance values (reported 
absorbance– blank absorbance at 590 nm).   
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Fig. 3. 
Structural representations of three models of paclitaxel-induced death in U251MG 
cells are presented along with AIC values calculated based on simultaneous fit of 
each model to all four exposure groups.   
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Fig.  4 a-d.  
Model 1 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance – blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 1-generated estimates of fit based on input 
of each treatment group individually. 
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Fig. 4 a-d.  
Model 1 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance – blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 1-generated estimates of fit based on input 
of each treatment group individually. 
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Fig. 5 a-d. 
Model 2 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance – blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 2-generated estimates of fit based on input 
of each treatment group individually. 
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Fig. 5 a-d. 
Model 2 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance– blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 2-generated estimates of fit based on input 
of each treatment group individually. 
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Fig.5 a-d. 
Model 2 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance – blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 2-generated estimates of fit based on input 
of each treatment group individually. 
84 
 
 
 
 
 
 
 
Fig. 6 a-d.  
Model 3 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance – blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 3-generated estimates of fit based on input 
of each treatment group individually. 
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Model 3 observed and predicted values.  Plots of corrected absorbance values 
(reported absorbance – blank absorbance at 590 nm) versus time are presented.  
Seven exposure levels from 0 to 2,700 nM * hr are given for each treatment group:  
continuous exposure (a), single initial exposure (b) 3x fractionation (c), and 9x 
fractionation (d).  Lines represent model 3-generated estimates of fit based on input 
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Fig. 7. 
 
Observed values and associated model fit to paclitaxel concentrations in mouse 
brain tissue at 12 time points post-intravenous bolus dose.  Model fit is based on 
application of a one-compartment model. 
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Fig. 8 
Simulated values for model 1 (a), model 2 (b) and model 3 (c) predictions of MTT 
absorbance versus time at 7 exposure levels.  Dashed lines represent simulation of 
cellular response based on incorporation of in vivo paclitaxel brain concentrations 
following a 10-mg/kg intravenous dose.  
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 Emax 
(absorbance) 
CV 
(%) 
EAUC50 
(nM*hr) 
CV 
(%) 
Gamma CV 
(%) 
Continuous  71.8 8.39 456 16.5 1.78 21.3 
Single Initial 99.9 47.8 575 202 0.516 44.8 
3x Fractionated 80.7 6.85 300 20.2 0.943 13.4 
9x Fractionated 73.6 11.8 92.1 28.8 0.867 43.6 
 
 
 
 
 
 
 
 
Table 1.   
Parameter estimates generated by fit of sigmoidal Emax model to cellular response 
data from four treatment groups. 
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 kng 
(hr-1) 
CV 
(%) 
abs0 
(abs.) 
CV 
(%) 
tau CV 
(%) 
Continuous  0.0261 5.39 0.152 6.80 5.35 0.00 
Single Initial 0.0261 5.39 0.152 6.80 5.35 0.00 
3x Fractionated 0.0239 4.43 0.139 4.94 6.39 0.00 
9x Fractionated 0.0210 4.84 0.147 4.48 7.92 0.00 
 
 
 
 
 
 
 
 
 
Table 2. 
Parameter estimates and corresponding CV values generated by fit of control cell 
growth model to cellular response data. 
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 Kmax 
(hr-1) 
CV 
(%) 
EAUC50 
(nM*hr) 
CV 
(%) 
Continuous  0.0431 34.2 3700 49.2 
Single Initial 0.0171 2.86 205 4.25 
3x Fractionated 0.0139 5.02 62.6 19.4 
9x Fractionated 0.0151 7.24 196 20.1 
 
 
 
 
 
 
 
 
 
Table 3. 
Parameter estimates and associated CV values generated by Model 1 fit to cellular 
response vs. time data. 
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 kd 
(hr-1) 
CV 
(%) 
k
 
(nM*hr) 
CV 
(%) 
Continuous  0.0310 5.82 2.56 0.0600 
Single Initial 0.0628 19.6 1.31 60.3 
3x Fractionated 0.0971 14.0 3.75 73.2 
9x Fractionated 0.0511 21.5 1.83 49.6 
 
 
 
 
 
 
 
 
Table 4. 
Parameter estimates and associated CV values generated by Model 2 fit to cellular 
response vs. time data. 
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 ks 
(hr-1) 
CV 
(%) 
kd 
(hr-1) 
CV 
(%) 
Continuous  0.000547 8.49 0.0953 0.150 
Single Initial 0.000541 12.3 0.00852 37.5 
3x Fractionated 0.000648 16.9 0.0179 30.1 
9x Fractionated 0.000596 12.4 0.0229 0.630 
 
 
 
 
 
 
 
Table 5. 
Parameter estimates and associated CV values generated by Model 3 fit to cellular 
response vs. time data. 
 
CHAPTER 3 
 
 
 
 
 
EXAMINATION OF THE ABILITY OF THE NASAL ADMINISTRATION ROUTE TO 
CONFER A BRAIN EXPOSURE ADVANTAGE FOR THREE CHEMICAL 
INHIBITORS OF P-GLYCOPROTEIN 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to the Journal of Pharmaceutical Sciences as a Short 
Communication, and is presented in the style of this journal. 
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ABSTRACT: 
 
The central nervous system (CNS), which is efficiently isolated from the 
systemic circulation by the blood-brain barrier (BBB), represents a particularly 
challenging target site for therapeutic agents.  For CNS-targeted agents, achieving 
sufficient brain exposure by increasing systemic concentrations is generally not 
feasible due to the potential for systemic toxicity.  Therefore, a means for selectively 
increasing brain exposure, while minimizing systemic exposure, would be desirable.  
Limited evidence has indicated that nasally-administered compounds can penetrate 
into brain tissue, although the selectivity of this approach is unclear.  The current 
study demonstrates a distinct, but compound-specific, advantage of the nasal 
delivery route relative to systemic administration, in terms of ability to confer 
selective CNS delivery (a brain exposure advantage; BEA).  Brain and systemic 
concentrations of three P-glycoprotein inhibiting agents were evaluated after a single 
nasal or systemic dose to mice, and the influence of the nasal route on brain 
exposure (absolute BEA) and on partitioning into brain vs. the systemic circulation 
(relative BEA) were calculated.  Both absolute and relative BEA differed markedly 
among rifampin, quinidine, and GF120918, with absolute BEA ranging between 0.1- 
and 9-fold, and relative BEA between 1.6- and 794-fold.  Although substantial 
increases in brain exposure and partitioning in conjunction with the nasal 
administration route were demonstrated, the utility of this approach may be limited 
by the inability to deliver a therapeutically-relevant mass of drug to the brain, as well 
as by technical issues associated with this delivery route.  
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INTRODUCTION 
The blood-brain barrier (BBB), a network of physical (e.g., tight junctions, 
reduced fenestrations and pinocytotic vesicles) and biochemical (e.g., enzymes, 
efflux transporters) adaptations at the interface between the systemic circulation and 
brain parenchyma, effectively attenuates and regulates the flux of chemicals 
between these two environments.  This protective barrier poses a formidable 
obstacle to delivery of many drugs to the CNS, limiting the range of 
pharmacotherapeutic options available for the majority of brain diseases (Pardridge, 
2005).   
Several approaches to overcoming difficulties in CNS drug delivery have 
been tested, including modifications of the physicochemical properties of drugs (e.g., 
to increase lipophilicity or avoid efflux transporter interactions) and modulation of the 
BBB itself (e.g., osmotic disruption, chemical inhibition of efflux transporters, and 
physical penetration of the barrier such as intra-cerebral delivery). Issues unique to 
each of these approaches continue to prohibit generally-effective brain delivery for 
most compounds (Mayer, 1998; Kemper et al., 2003). 
Nasal administration has been investigated as a means to target drug delivery 
to the CNS by exploiting potential vulnerabilities in the barrier between the nasal 
cavity and the brain.  Through the cribiform plate, olfactory neurons penetrate 
directly into the olfactory epithelium lining the nasal cavity. However, evidence 
suggests that at least some barrier properties (e.g., drug-degrading enzymes, efflux 
transporters) remain intact at the interface between nose and brain (Graff and 
Pollack, 2005).  Nevertheless, in certain instances, the nasal delivery route has 
appeared to allow preferential access to the brain, as suggested by rates of brain 
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uptake more rapid than possible via systemic delivery (Chow et al., 1999), altered 
patterns of within-brain distribution upon physical transection of the nose-brain 
pathway (Perlman et al., 1990), or unilateral brain exposure to substrates delivered 
via the ipsilateral nostril (Brenneman et al., 2000).  Another line of evidence for a 
nose-brain connection is the increased magnitude of brain partitioning for 
compounds delivered by nasal vs. systemic routes (Graff and Pollack, 2005).  This 
type of evidence is perhaps the most therapeutically-relevant, as preferential 
delivery to the CNS vs. the systemic circulation (as opposed to increasing brain 
exposure by overwhelming systemic concentrations, risking toxic side-effects) is the 
fundamental goal for most CNS-targeted compounds. 
This work compares the effect of administration route (nasal vs. systemic) on 
brain and plasma exposure to three physicochemically diverse compounds (Fig. 1, 
Table 1) of potential utility in the CNS as inhibitors of the efflux transporter P-
glycoprotein (P-gp), an important constituent of the BBB.  The focus of this effort 
was to define the ability of the nasal administration route to confer either an absolute 
BEA (increased brain concentration following nasal vs. systemic administration) or a 
relative BEA (increased brain-to-blood partition ratio following nasal vs. systemic 
administration) for each compound.  In light of the intrinsic differences between the 
mass of drug deliverable by the nasal vs. systemic routes, doses were selected to 
be representative of the magnitude of this difference under single-dose conditions.   
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METHODS AND MATERIALS 
Rifampin and quinidine sulfate salt dihydrate were obtained from Sigma 
Aldrich.  GF120918 was a gift from GlaxoSmithKline.  All other reagents were 
obtained from commercial sources and were of the highest grade available. 
Adult (35-45 g) CF-1 mice (Charles River Laboratories, Wilmington, MA, 
USA) were anesthetized with ketamine and xylazine (100 and 10 mg/kg, 
respectively) and placed in a supine position on a 37°C heating pad. Quinidine, 
rifampin, or GF210918 were administered via the nasal route to 5 mice per group 
using the following technique. Drugs were tamped into 2-cm lengths of PE-10 
polyethylene tubing (0.024" OD x 0.011" ID), and tared for calculation of mass 
delivered.  Drug-loaded tubes were inserted into one nostril at a time, and drug was 
expelled into the nasal cavity via an air-filled 1-mL syringe attached to the tubing by 
a blunted 27-gauge needle.  Alternating between the left and right nares, drug 
contents of 6 tubes (average capacity per tube of 0.033 mg) were delivered to the 
nasal cavity of each animal in order to provide a total dose of approximately 0.2 mg 
(average 4.05 mg/kg) over the course of 1 min.  Timing was initiated at the 
completion of drug administration.   
For comparative purposes, systemic delivery was achieved in similarly 
anesthetized mice by intraperitoneal injection of quinidine (5 mg/mL in saline; 50 
mg/kg), rifampin (5 mg/mL in 5% methanol in saline; 50 mg/kg) or GF120918 (1 
mg/mL in 1:3 propylene glycol:saline; 10 mg/kg).   
After either nasal or systemic administration of a single test compound, blood 
and brain tissue were collected by decapitation at 5, 15, 30, 45 and 60 min post-
dose.  The brain, including olfactory bulbs, was carefully removed, homogenized 1:2 
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w/v in water by ultrasonication and stored at -20°C until analysis. Plasma was 
harvested from heparinized (20 U/mL) blood and stored at -20°C pending analysis. 
All experimental procedures were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina.   
Drug concentrations in serum and brain homogenate were determined by LC-
MS/MS.  Data are presented as mean ± SD.  Areas under the concentration-time 
curve (AUC0-60 min) were calculated by the trapezoidal method, with variance 
surrounding the area estimate determined as described by Bailer (1988).  Brain-to-
plasma partition coefficients (Kp, brain) were calculated as a ratio of AUCs (AUC0-60 
min,brain / AUC0-60 min, plasma). The relative increase in brain exposure conveyed by the 
nasal administration route (relative BEA) was calculated as Kp,brain, nasal delivery / Kp,brain, 
systemic delivery for each compound.  Absolute BEA values were calculated as AUC0-60 
min,brain  following nasal vs. systemic delivery.   
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RESULTS 
 As shown in Fig. 2, drug concentrations were detectable in brain by 5 min 
following systemic administration. Brain concentrations were maximal at 30 and 45 
min for rifampin and GF120198, respectively, and increased through 60 min for 
quinidine.  Plasma concentrations, which peaked within 5-15 min, were consistently 
higher than brain concentrations for all three systemically-administered compounds. 
The degree of brain partitioning varied considerably among the test compounds 
(Table 2).  Kp, brain for rifampin (0.00011) was lowest; nearly three orders of 
magnitude lower than quinidine (0.068) or GF120198 (0.079).  Brain exposure 
(AUC0-60min, brain) was also lowest for rifampin, at 8- and 138-fold lower than 
GF120918 and quinidine, respectively.   
 Following nasal administration (Fig. 2), drug penetration into brain and 
plasma was rapid, with detectable concentrations of each compound achieved within 
5 min. Concentrations in both matrices changed roughly in parallel over 60 min.  As 
with systemic administration, concentrations of quinidine and rifampin were 
consistently higher in plasma than in brain. The reverse was true for GF120918.  
With a Kp, brain of 2.6, the extent of GF120918 brain partitioning was 25-fold and 30-
fold higher than that for quinidine or rifampin (0.107 and 0.086, respectively) 
following equivalent (mg/kg) intranasal doses of each compound (Table 2).  
Although brain partitioning was highest for GF120918, brain exposure (AUC0-60min, 
brain) to this compound was lowest; 4.9- and 8.9-fold lower than for rifampin and 
quinidine, respectively.  The relatively high brain partitioning of GF120198 reflects 
substantially lower plasma concentrations of this compound following intranasal 
administration; 150- and 218-fold lower than for rifampin or quinidine, respectively.   
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 Advantages in relative brain exposure associated with nasal as compared to 
systemic administration (relative BEA) were observed for all three compounds. 
However, the magnitude of this advantage ranged over three orders of magnitude: 
1.58-fold (quinidine), 33.1-fold (GF120918), and 794-fold (rifampin).  Although Kp, 
brain for rifampin was the lowest of the three nasally-administered compounds, the 
nasal route conferred an extremely large advantage in brain exposure, due to the 
virtual exclusion of this compound from brain (Kp, brain 0.00011) following systemic 
administration.   
 In terms of the ability of a nasal delivery route to confer an advantage in 
absolute brain exposure, limitations on the mass deliverable by a nasal route were 
considered.  Table 2 lists differences between AUC0-60 min,brain following nasal 
administration of 4 mg/kg vs. systemic administration of 50 (quinidine, rifampin) or 
10 (GF120918) mg/kg. The AUC0-60 min,brain  for nasally-delivered quinidine was 
approximately one-tenth of that associated with systemic delivery, although the 
mass delivered by the nasal route was 8% of that delivered systemically.  While the 
total mass of GF120918 delivered by the nasal route was 40% of that delivered by 
the systemic route, the AUC0-60 min,brain  was nearly equivalent (1.2-fold absolute 
BEA).  The AUC0-60 min,brain  for rifampin was nearly an order of magnitude higher after 
nasal vs. systemic delivery, despite the administration of only 8% of the systemic 
dose (a 9-fold absolute BEA).   
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DISCUSSION 
 Advantages in terms of systemic or brain exposure associated with nasal 
administration (by avoidance of first pass metabolism, or by a “direct” nose-brain 
pathway, respectively) have been reported for several compounds (Illum, 2000).  
This communication documents nasal-dosing-associated brain exposure advantages 
that vary over 500-fold among three physicochemically-diverse compounds 
evaluated under identical conditions.   
The difference in BEA between compounds observed in this study is likely 
attributable to differences in physicochemical properties (Table 1), including 
molecular mass, lipophilicity/water solubility, pKa, and plasma unbound fraction.  In 
general, more lipophilic compounds are associated with higher brain permeability 
(Mahar Doan et al., 2002). However, all three compounds tested have P-gp-
inhibiting properties, and are thus (to varying degrees) substrates for this efflux 
transporter themselves (Matheny et al., 2001).  The specific mechanisms leading to 
a BEA for these compounds are unknown.  Although a direct pathway from nose to 
brain has been posited for some substances (Illum, 2004), it is unclear what the 
common physicochemical characteristics may be that lead to this pathway being 
favorable for net brain uptake.   
As summarized in Table 3, the relative BEA identified in these studies 
(GF120918 and rifampin) indicates that the nasal delivery route may be useful in 
some cases for minimizing systemic concentrations while, at minimum, retaining 
brain exposure levels associated with systemic delivery.  The potential utility of this 
route lies in whether this level of brain exposure is sufficient to confer the desired 
pharmacologic activity.   
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Dose-normalized differences in AUC0-60 min,brain  conferred by the nasal vs. 
systemic route were 1.5-, 3-, and 113-fold for quinidine, GF120918 and rifampin, 
respectively.  However, as it is not currently possible to deliver equally large 
amounts of substrate by each route, the absolute BEA was instead calculated to 
reflect the differences in mass delivered by the each route.  Although the dose 
selection in these studies was specific to the techniques and compounds utilized 
herein, the doses are generally representative of the magnitude of the difference in 
mass deliverable by each route.  Rifampin exemplified a case in which delivery of a 
small mass of drug nasally was associated with higher brain exposure than a much 
larger dose administered systemically.  In cases such as this, net pharmacologic 
efficiency could be increased by delivering the compound nasally.  For GF120918, 
brain exposure was similar by both routes, while for quinidine, exposure was lower 
by the nasal route due to a combination of lower mass administered and a lack of 
CNS selectivity of the nasal route for this compound.   
Although both absolute and relative BEA were observed in association with 
nasal delivery, several caveats temper the potential utility of the nasal route for 
maximizing brain exposure while minimizing systemic exposure.  First, the technique 
is associated with variable mass delivery, particularly in small animal species such 
as the mouse, for which few standardized nasal delivery devices exist.  Variability in 
both the dose (i.e., difficulty in delivering a precise mass of dry drug) and the 
delivery site (i.e., difficulty confining either dry drug or drug solutions to the nasal 
cavity vs. deeper into the airway or into the esophagus) are currently problematic.  
Although the mass of drug delivered by the nasal route in this study was reasonably 
reproducible (4.01 mg/kg, ± 0.76 SD; 19% CV), the resulting exposure in brain and 
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plasma was much more variable by this route (77% average CV) than for systemic 
delivery (35% CV). The consistent initial early peak in brain and plasma 
concentration-time profiles (prior to 15 min), followed by a second peak, may reflect 
delivery of a portion of the dose to the lung, where it may be absorbed more rapidly. 
Further evaluation of the model would be required to evaluate this point. 
Second, factors unique to the nasal cavity as a drug administration site 
(relatively small size, difficulty in accessing) preclude delivery of more than a few mg 
of drug at a time.  Although various formulations, including chitosans and 
nanoparticles, may increase mass delivery (Illum, 2007; Di Colo et al., 2008), the net 
amount of drug that can be administered by this route is necessarily substantially 
smaller than for systemic delivery.  These factors effectively limit the utility of this 
approach to compounds that are very potent and/or are particularly toxic to non-CNS 
organs.   
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Fig. 1.   
Chemical structures of the three compounds compared in this study; quinidine (as 
quinidine sulfate salt dihydrate), rifampin, and GF120918 (as GF120918 HCl). 
Quinidine               Rifampin             Elacridar 
                         (GF120918) 
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Fig. 2.  
Concentration-time profiles for quinidine, rifampin, and GF1201918 in brain (filled 
circles) and plasma (open circles) following intranasal (a-c) or systemic (d-f) 
administration.  Data represent mean ± SD (n = 3-4).   
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  MW LogP pKa fu Ki* 
(µM) 
H2O Solubility 
Quinidine 324.4 2.5 8.6 0.22 26 140 mg/L 
Rifampin 822.9 3.7 1.7, 7.9 0.11 2.4 1.3 mg/mL 
Elacridar 563.6 5.9 n.r. <0.001 0.011 (negligible) 
 
Table 1.   
Comparison of physicochemical properties of quinidine, rifampin and GF120918.   
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 Intranasal  Intraperitoneal  IN / IP ratio  
Quinidine     
      AUC0-60min, brain (nM*min)  2,820  23,800  0.12  
      AUC0-60min, plasma (nM*min)  26,400  352,000   
      Kp, brain  0.107  0.0680  1.58  
GF120918     
      AUC0-60min, brain (nM*min)  316  263  1.20  
      AUC0-60min, plasma (nM*min)  121  3,330   
      Kp, brain  2.62  0.0790  33.1  
Rifampin     
      AUC0-60min, brain (nM*min)  1,560  173  9.02  
      AUC0-60min, plasma (nM*min)  18,200  1,590,000   
      Kp, brain  0.0860  0.000110  794  
 
Table 2.   
Brain and plasma drug exposure (expressed as AUC), Kp, brain, and effect of nasal 
administration route (as IN:IP ratio) values, calculated for each of the three 
compounds tested. 
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Compound  Quinidine  GF120918  Rifampin  
Relative BEA due to  
nasal administration route  
↔ K
p,brain 
 ↑ K
p,brain
  ↑ K
p,brain
  
Absolute BEA due to 
nasal administration route  
↓ X
,brain
  ↔ X
,brain 
 ↑ X
,brain
  
Potential clinical utility  Not useful  
Could minimize 
systemic toxicity, 
if X
,brain is 
pharmacologically 
effective  
Could minimize 
systemic toxicity 
and increase net 
pharmacologic 
efficiency  
 
 
Table 3.   
Summary of compound-specific differences in absolute and relative BEA associated 
with the nasal delivery route and relation to potential clinical utility. 
CHAPTER 4 
 
PHARMACOKINETICS OF RIFAMPIN AFTER SINGLE AND MULTIPLE  
ORAL DOSES IN MICE 
 
 
 
 
 
 
 
 
This chapter will be submitted to Drug Metabolism and Disposition, and is written in 
the style of that journal. 
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ABSTRACT 
 Rifampin has gained significant use as a tool to probe aspects of enzyme and 
transport protein inducibility. In addition to inducing P-glycoprotein (P-gp) after sub-
chronic exposure in humans, rifampin inhibits P-gp in intestine and the blood-brain 
barrier of mice. Despite its use as a probe, little pharmacokinetic information is 
available to design dosage regimens to achieve selected rifampin concentrations in 
blood or target organs. These studies were conducted to provide such information. 
Mice received a single 250-mg/kg oral dose of rifampin, and were sacrificed at 
selected intervals over 48 hours for collection of blood and target tissues (liver, 
kidney, lung, intestine, and brain). Rifampin concentrations, determined in plasma 
and tissue homogenates by LC-MS/MS, varied widely among tissues. At 24 hours 
post-dose, the order of rifampin concentrations (from high to low) was 
liver>kidney>intestine>lung>plasma>brain. Tissue-to-plasma concentration ratios at 
24 hours exceeded 1.0 for all tissues except brain, consistent with exclusion of CNS 
rifampin uptake by the blood-brain barrier. A compartmental model was constructed, 
fit to the single-dose data, and used to predict the concentration-time profile during 
once-daily oral dosing (250 mg/kg/day, 5 days); mice were evaluated with this 
regimen on day 5 to test model predictions. With the exception of liver, the model 
provided reasonable predictions of rifampin concentrations on day 5. The model 
significantly over-predicted liver concentrations, consistent with induction of a 
removal mechanism (excretion or metabolism) from the liver. These data will be 
useful in the design of experiments using rifampin as a potential inducer or inhibitor 
of P-gp in mice.  
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INTRODUCTION 
 
 Rifampin, an antibiotic which has long been in clinical use for treatment of 
tuberculosis, has garnered significant attention in recent years as a modulator of 
protein function. The ability of rifampin to induce cytochrome 3A (CYP3A4 in 
humans) is well established. This induction is achieved by activation of the pregnane 
X receptor (PXR) (LeCluyse, 2001). A significant body of evidence also has shown 
that rifampin can enhance P-glycoprotein (P-gp) function. Administration of oral 
rifampin to humans (600 mg per day for 10 days), for example, induced P-gp 
expression in the small intestine (Greiner et al., 1999; Westphal et al., 2000). This 
induction of expression appears to have a functional correlate. Circulating 
concentrations of orally-administered P-gp substrates (e.g., digoxin, fexofenadine, 
and talinolol) were reduced following rifampin pretreatment (Greiner et al., 1999; 
Westphal et al., 2000; Hamman et al., 2001).  Because these P-gp substrates tend 
to be excreted mainly as unchanged parent drug, it is likely that rifampin reduced the 
fraction of the dose absorbed; this decrease in bioavailability would be consistent 
with induction of intestinal P-gp expression. More recent evidence has indicated that 
rifampin can induce P-gp in the blood-brain barrier of mice that express human PXR, 
as evidenced by limitation of brain uptake and pharmacologic activity of methadone, 
an opioid analgesic and P-gp substrate (Bauer et al., 2006). 
 
In contrast to CYP 3A and P-gp induction, the ability of rifampin to inhibit 
protein function is less well appreciated.  For example, at the end of a course of 
rifampin administered to induce CYP3A4 metabolism, residual rifampin appeared to 
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attenuate the inductive effect (Lam et al., 2006). Whether this attenuation was due to 
inhibition of metabolic enzymes or uptake transporters required for substrate 
presentation to those enzymes (or a combination of the two effects) is not known. In 
tumor cells over-expressing P-gp, rifampin increased the uptake of P-gp substrates 
in a concentration-dependent manner, consistent with competitive P-gp inhibition 
(Fardel et al., 1995; Furusawa et al., 1997).  Moreover, acute (single-dose) rifampin 
administration increased the uptake into mouse brain of the P-gp substrates 
verapamil and quinidine; enhancement of uptake was dependent on dose (or 
systemic concentration) of rifampin (Zong and Pollack, 2003). Similarly, nasal 
administration of rifampin in mice enhanced the brain uptake of nasally-administered 
P-gp substrates (Graff and Pollack, 2005). In aggregate, these results clearly 
establish rifampin as an effective inhibitor of P-gp and, as such, a useful probe of P-
gp-mediated transport. 
 
Given the growing importance of rifampin as a modulator of enzyme and 
transporter function, the ability to design rifampin administration strategies in order to 
achieve predetermined rifampin concentrations in blood or target tissues, either after 
a single dose or during repeated administration, would represent a distinct 
experimental advantage. Rational design of drug administration schedules to 
achieve a specified target concentration or concentration range requires a complete 
understanding of the pharmacokinetics of the agent in question. If a target 
concentration must be achieved in a particular tissue, vs. in blood, data describing 
partitioning into the tissue must be available. Such information may be obtained by 
determining a tissue to blood partition coefficient under steady-state conditions or 
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after distribution equilibrium has been achieved, by assessing a tissue to blood area 
under the concentration-time curve (AUC) ratio, or through construction of a 
pharmacokinetic model that incorporates all relevant tissues of interest. To date, 
however, pharmacokinetic information for rifampin in key preclinical species such as 
the mouse has not been available. 
 
The purpose of the present study was to evaluate the disposition kinetics of 
rifampin in mice. Both single-dose (the typical approach for inhibition studies) and 
multiple-dose (the requisite paradigm for induction experiments) administration 
schedules were used, and rifampin concentration-time data were obtained in blood 
and several relevant target tissues. Because of its importance in intestinal P-gp 
induction, the oral route of rifampin administration was selected. 
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METHODS 
 
Chemicals and reagents.  Rifampin was purchased from Sigma-Aldrich (St. 
Louis, MO).  All other chemicals and reagents used in this study were of the highest 
grade available from commercial sources.   
 
Animals.  Male FVB mice (25-35 g), purchased from Taconic (Germantown, 
NY) were housed in temperature and humidity-controlled facilities with a 12-hour 
light-dark cycle and access to food and water ad libitum throughout the experiment.   
All procedures were approved by the Institutional Animal Care and Use Committee 
of The University of North Carolina at Chapel Hill.   
 
 Rifampin single and multiple dose pharmacokinetics. Mice received 250-
mg/kg rifampin by oral gavage (25 mg/mL in 1:1 water:DMSO).  At 2, 6, 12, 16, 24 
and 48 hr, animals (n = 4 per time point) were euthanized by decapitation for 
collection of trunk blood, liver, brain, kidney, lung, and three sections of intestine: 
duodenum, jejunum, and illeum.  Additional blood samples were collected from the 
same animals by tail nick into heparinized capillary tubes, at 0.25, 0.5, 1, 1.5, 3, 4 
and 9 hr post-dose.  Blood and tissue samples were placed into cryotubes, snap-
frozen in liquid nitrogen, and stored at -80°C until analysis by a sensitive and specific 
HPLC-MS assay, described below.  Multiple dose pharmacokinetics were evaluated 
by administering rifampin (250 mg/kg, as described above) every 24 hr for 5 days.  
At 2 and 24 hr following the final dose, blood and tissue samples were collected and 
analyzed identically to single-dose samples.   
119 
 
 
 Quantitation of rifampin by LC/MS/MS. Rifampin concentrations in plasma 
and tissue homogenates were determined by capillary HPLC with a single-quadruple 
mass spectrometer and electrospray ionization [ESI] source (1100 Series, Agilent 
Technologies; Wilmington, DE).  Briefly, tissues were homogenized in 5 volumes of 
saline containing ascorbic acid (200 µg/ml).  The internal standard (flunitrizepam [5 
µl, 10 µg/ml]) was added to plasma (20 µl) or tissue homogenate (40 µl) and 
analytes were extracted into chloroform (500 µl).  The organic phase was removed 
and evaporated under a nitrogen stream; the residue was reconstituted with 
acetonitrile (100 µl) and centrifuged (14,000 g for 5 min).  Supernatant (1 µl) was 
injected onto the column.  Mass detection was performed in positive ion mode using 
mass scanning (to detect potential rifampin metabolites) or selected ion monitoring 
(SIM) for rifampin (m/z 823.1) and flunitrizepam (m/z 314.2).  The mobile phase 
consisted of acetonitrile:ammonium acetate (32:68 v:v; 30 mM, pH 4.0) delivered at 
a flow rate of 300 µl/min, and chromatographic separation was achieved on a Luna® 
(Phenomenex; Torrance, CA) C8 column (100 mm x 2 mm, 4 µm particle size) at 
30ºC.  Retention times for rifampin and flunitrizepam were 5.3 min and 7.4 min, 
respectively.  Chemstate software (version A.09.03, Agilent Technologies) was used 
for data acquisition and processing.  
 
Calibration curves were linear in the range of 0.3 to 50 µg/ml (or µg/g tissue; 
r2 > 0.999).  Samples with rifampin concentrations exceeding this range were diluted 
as necessary.  The limit of quantitation was ≤ 0.2 µg/ml (or µg/g for intestinal tissue).  
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Precisions in the range of 3.2 – 8.7% (CV) and 3.5 – 7.5% and accuracies in the 
range of -4.6 – 1.3% and -5.2 – 0.8%, were obtained in intra- and inter-day validation 
studies, respectively, for blood and tissues. 
   
 Protein binding.  Protein binding was determined by ultrafiltration in plasma 
samples containing 2, 20, or 200 µg/mL rifampin.  Unbound drug was separated 
from plasma protein-bound drug using a Centri-free YMT membrane ultrafiltration 
device.  Centrifugation conditions were optimized to recover approximately 100 µL of 
ultrafiltrate from a 1 mL plasma sample.  Rifampin in ultrafiltrate and plasma was 
determined by LC/MS/MS. 
 
Pharmacokinetic modeling.  Pharmacokinetic parameters were determined 
by compartmental modeling using WinNonlin software (Pharsight, Mountain View, 
CA).  Rifampin concentration vs. time data was fit with a seven-compartment model 
representing administration into an absorption site, with first-order absorption (ka) 
into a central compartment (plasma) and clearance from the central compartment 
(CL).  Intestine, liver, and brain were represented as separate compartments, with 
bidirectional clearances between the tissues and plasma (CLin,intestine, and 
CLout,intestine, CLin,liver, and CLout,liver, and CLin,brain, and CLout,brain, respectively).  
Clearance was unidirectional from plasma into lung and kidney (CLin,lung, and 
CLin,kidney), and unidirectional from each compartment (CLout,lung, and CLout,kidney).  
Organ compartmental volumes were fixed at physiological values (Vintestine, 0.0025 
mg/kg; Vliver, 0.00015 mg/kg; Vbrain, 0.0003 mg/kg; Vkidney 0.0003 mg/kg; Vlung, 
0.00012 mg/kg).  Model fit was evaluated using standard goodness of fit criteria.   
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 Data analysis.  Data are presented as mean ± SD.  Accumulation ratios (RA) 
are calculated as the ratio of concentrations after multiple / single doses.   
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RESULTS 
  
 Single-dose rifampin.  Rifampin concentrations were detectable in all 
tissues through 24 hr following a single 250-mg/kg oral dose (Fig. 1).  Plasma 
concentrations peaked at 2 hr post-dose, and declined mono-exponentially 
throughout the remainder of the experiment.  Concentrations in organs were at or 
near maximum by the first sampled time point (2 hr) and decreased slowly 
thereafter.  Tissue-to-blood partition coefficients increased consistently through all 
sampled time points (Fig. 2).  Tissue partitioning differed by two orders of magnitude 
among the various tissues examined, with the greatest degree of tissue partitioning 
observed in liver and the lowest partitioning in brain.   
 
The pharmacokinetic model, simultaneously fit to concentration vs. time data 
from plasma and all organs, was able to predict concentrations with reasonable 
accuracy, with slight underprediction of lung concentrations at early points, and 
some regions of bias in the fit to brain concentration data (Fig. 3).  Parameter 
estimates obtained from this modeling are compiled in Table 1.  Rifampin plasma 
protein binding was linear from 2 through 200 ng/L, averaging 95.6 ± 0.02% bound.   
 
 Multiple-dose rifampin.  Following 5 days of once-daily rifampin 
administration (250 mg/kg), concentrations in blood and organ samples collected at 
2 and 24 hr following the final dose were compared to concentrations obtained at 2 
and 24 hr following a single dose of rifampin (Table 2).  Accumulation ratios 
calculated based upon 2-hour samples indicated approximately 2- to 7-fold 
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accumulation resulting from multiple dosing.  Interestingly, RA values calculated 
based upon 24-hour samples indicated an apparent reduction, rather than an 
accumulation of drug over the course of multiple dosing.  These RA values were 
uniformly below unity, ranging from 0.3 in liver to 0.8 in duodenum.   
 
 Based upon the parameter estimates derived from the single-dose data, 
multiple dose concentration-time profiles for rifampin were simulated.  The simulated 
profiles are presented in Figure 4.  Model predictions of multiple-dose behavior 
based on single-dose disposition corresponded to the actual multiple-dose data 
reasonably well. The largest deviation between model predictions and observed data 
were concentrations in the liver, which were markedly over-predicted. 
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DISCUSSION 
 
Previous experiments in mice have been directed at defining the ability of 
rifampin to induce P-gp expression in the intestinal wall (Matheny et al., 2004). The 
magnitude of induction, based on protein expression, of P-gp following 100 to 250 
mg/kg/day of rifampin (~3-fold) was similar to that observed in human duodenum 
following chronic rifampin administration (600 mg/day orally) (Greiner et al., 1999). 
Furthermore, mouse intestinal and hepatic CYP3A was induced ~3.5-fold by rifampin 
at 250 mg/kg/day (Matheny et al., 2004), consistent with the effects of rifampin on 
CYP3A4 expression in human intestine and liver (Paine et al., 2002).  These results 
suggest that the mouse may be a suitable preclinical species in which to evaluate 
interactions with rifampin at the level of intestinal P-gp or P-gp and CYP3A in 
combination. The similar induction responses in mice to those in humans suggest 
that the dose selected in the present study (250 mg/kg) has relevance for probing P-
gp-related functions in mice and extrapolating those results to humans. 
 
There was a remarkable difference in rifampin tissue concentrations after 
single-dose administration, with peak concentrations ranging over 2 orders of 
magnitude among the tissues examined (Fig. 1). Peak concentrations were achieved 
at 6 hours for all tissues. In contrast, plasma concentrations were maximal at 2 
hours post-dose. The highest tissue concentrations were observed in the liver, 
followed by the kidneys and the intestinal tract. Each of these organs expresses P-
gp (Lin, 2007), which has the capacity to operate as an excretory transporter 
(mediating biliary excretion, renal excretion, and intestinal exsorption, respectively). 
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Tissue concentrations were lowest in brain, an organ in which P-gp is expressed as 
a barrier transporter that impedes the uptake of P-gp substrates (Golden and 
Pollack, 2003). 
 
Tissue-to-blood concentration ratios (the tissue partition coefficient) were also 
widely variable among tissues. The partition coefficient increased with time for all 
tissues throughout the entire course of the experiment. Several tissues (liver, 
duodenum, jejunum, and kidney) had measurable concentrations 48 hours post-
dose. These four tissues had slightly higher partition coefficients at 48 hours than at 
24 hours (Fig. 2). At the 48-hour time point, the partition coefficient approached 10. 
For the remaining tissues examined, the ability to detect rifampin was lost after the 
24-hour sampling point. At 24 hours, brain was the only tissue examined that had a 
partition coefficient less than 1. 
 
The extremely slow equilibration of tissue rifampin with rifampin in the 
systemic circulation was somewhat surprising. The specific mechanism underlying 
slow accumulation in tissue, and therefore slow equilibration with blood, is not 
known. The general pattern of equilibration, however, is suggestive of a long mean 
residence time in tissue spaces. For important excretory organs, such prolonged 
tissue residence could be due to selective tissue uptake with slow elimination (as 
might occur, for example, if tissue uptake was mediated by a relatively efficient influx 
system, while removal was mediated by an inefficient efflux system). This 
explanation would be unlikely, however, for brain. 
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An alternative explanation for prolonged tissue residence would be relatively 
tight binding to proteins in tissue. The binding of rifampin to blood proteins is high 
(>95% protein bound; data not shown). It is likely that binding is more substantial in 
several tissues, at least, as compared to plasma, leading to partition coefficients 
approaching 10. Assuming that unbound concentrations in plasma and tissues are 
equal at distribution equilibrium, a standard assumption underlying the equilibrium 
condition, rifampin would need to be 99.5% bound in tissue to achieve an equilibrium 
partition coefficient of 10. While this degree of binding certainly is possible, 
additional experiments would be required to confirm binding as a mechanism of 
tissue accumulation for this drug. 
 
An extremely high bound fraction in brain tissue would not explain the brain 
partitioning data, as the partition coefficient was much less than 1. The slow 
approach to equilibrium partitioning in brain may be due to very tight binding to 
proteins in brain, such that the kinetics of egress from the brain are rate-limited by 
offset of rifampin from binding sites. This type of kinetic system, i.e., rate-controlled 
loss of substrate from tissue due to tight binding of the substrate to a limited number 
of macromolecules, exemplifies a phenomenon termed “target-mediated 
pharmacokinetics” (Mager, 2006). 
Regardless of the underlying mechanism(s), slow equilibration of rifampin 
between a target tissue and plasma would potentially complicate extrapolating 
single-dose data to the multiple-dose condition. It is noteworthy, therefore, that the 
model developed to describe rifampin disposition after administration of a single 
dose (Fig. 3) provided a reasonable prediction of rifampin concentrations after 
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administration of 5 daily doses. In general, predicted tissue concentrations were in 
good agreement with observed behavior during the fifth dosage interval. The 
exception to this conclusion is the liver, which had substantially lower rifampin 
concentration at the end of the fifth dosing interval than the model predicted. The 
reason for the failure to accurately predict rifampin concentrations in the liver is not 
known, but is suggestive of a time-dependent decrease in the residence time of 
rifampin in that organ. Such a time dependency would be consistent with 
autoinduction of a clearance mechanism, either transport out of the organ (into bile 
or sinusoidal blood) or biotransformation. Further studies would be required to 
address this point. 
 
In summary, the present study recovered plasma and tissue concentration vs. 
time data after oral administration of a pharmacologically relevant dose of rifampin in 
mice. These data were amenable to compartmentally-based pharmacokinetic 
modeling. The results of this modeling effort allowed prediction of rifampin 
concentration-time data after once-daily rifampin administration for 5 days. The 
ability of this model to predict rifampin concentrations suggests that it will be useful 
for rational dosing schedule optimization to achieve a pre-specified target 
concentration. 
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Figure 1. Disposition of rifampin in mice after a single 250-mg/kg oral dose. Data 
are presented as mean ± SD (n = 4 per time point). Rifampin 
concentrations in brain were not detectable at 48 hours post-dose. 
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Figure 2. Time course of tissue-to-blood concentration ratios for rifampin in mice 
after a single 250-mg/kg oral dose. Data are presented as the ratio of 
mean values at each time point (n = 4). Variance associated with the 
individual tissue averages is displayed in Fig. 1.  
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Figure 3. Fit of the pharmacokinetic model to the rifampin concentration-time 
data after oral administration of 250 mg/kg. Symbols indicate mean 
concentration (n=4); lines display fit of the model to the data. The 
model consisted of 5 tissue compartments, a plasma compartment, 
and an absorption site driving first-order absorption into the serum 
compartment. Systemic clearance (from plasma compartment) and all 
intercompartmental clearances (between plasma and each tissue 
compartment) were assumed to be linear. 
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Figure 4. Model predictions of rifampin disposition in mice during 5 days of once-
daily dosing (250 mg/kg orally). 
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Parameter Estimate SE 
CL/F (mL/hr/kg) 126 20 
V/F (L/kg) 1.03 0.18 
ka (hr-1) 0.689 0.208 
CLin,liver (mL/hr/kg) 1.14 0.24 
CLout,liver (mL/hr/kg) 0.362 0.102 
CLin,intestine (mL/hr/kg) 0.108 0.041 
CLout,intestine (mL/hr/kg) 0.073 0.031 
CLin,brain (mL/hr/kg) 0.082 0.023 
CLout,brain (mL/hr/kg) 2.08 0.58 
CLin,kidney (mL/hr/kg) 0.135 0.046 
CLout,kidney (mL/hr/kg) 0.127 0.049 
CLin,lung (mL/hr/kg) 0.008 0.004 
CLout,lung (mL/hr/kg) 0.012 0.007 
 
Table 1. Parameter estimates recovered from rifampin concentration-time data 
after a single 250-mg/kg oral dose. 
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Group Time 
(hr) 
Plasma 
(ng/l) 
Liver 
(ng/mg) 
Brain 
(ng/mg) 
Duodenum 
(ng/mg) 
Jejunum 
(ng/mg) 
Ilium 
(ng/mg) 
Kidney 
(ng/mg) 
Lung 
(ng/mg) 
 
1x 
 
2 
 
169 
(38) 
 
 
 
54.2 
(23.2) 
[0.32] 
 
 
3.4 
(0.5) 
[0.02] 
 
 
94.5 
(12.6) 
[0.56] 
 
 
52.6 
(19.5) 
[0.31] 
 
 
42.5 
(15.7) 
[0.25] 
 
 
61.6 
(6.3) 
[0.37] 
 
 
46.9 
(14.3) 
[0.28] 
 
 
5x 
 
2 
 
157 
(92) 
 
 
 
144 
(57) 
[0.91] 
 
 
13.5 
(1.4) 
[0.09] 
 
 
384 
(156) 
[2.44] 
 
 
300 
(52) 
[1.91] 
 
187 
(127) 
[1.19] 
 
 
205 
(51) 
[1.30] 
 
 
110 
(44) 
[0.70] 
 
  
RA 
 
0.93 
 
 
2.65 
 
 
3.92 
 
4.06 
 
5.72 
 
4.40 
 
3.32 
 
2.33 
 
 
1x 
 
24 
 
30.5 
(8.6) 
 
 
 
211 
(23) 
[6.93] 
 
 
6.3 
(2.6) 
[0.21] 
 
 
44.1 
(14.7) 
[1.45] 
 
 
75.9 
(18.4) 
[2.49] 
 
 
49.7 
(18.9) 
[1.63] 
 
 
123 
(37) 
[4.04] 
 
 
38.3 
(5.4) 
[1.26] 
 
 
5x 
 
24 
 
21.1 
(9.1) 
 
 
 
63.0 
(13.5) 
[2.99] 
 
 
4.4 
(0.9) 
[0.21] 
 
 
35.4 
(15.0) 
[1.68] 
 
 
37.7 
(13.3) 
[1.79] 
 
 
35.7 
(17.1) 
[1.69] 
 
 
51.0 
(23.6) 
[2.42] 
 
29.0 
(19.4) 
[1.37] 
 
  
RA 
 
0.69 
 
0.30 
 
0.69 
 
0.80 
 
0.50 
 
0.72 
 
0.41 
 
0.76 
 
 
Table 2. Plasma and tissue concentrations of rifampin at 2 hr and 24 hr after a 
single (1x) or multiple (5x) dose (250 mg/kg/day). Data are presented 
as mean (SD). Tissue to plasma concentration ratios are shown in 
[brackets]. RA is the accumulation ratio at each time point. 
CHAPTER 5 
 
 
 
 
 
ENHANCEMENT OF BRAIN EXPOSURE TO PACLITAXEL VIA CHEMICAL  
P-GLYCOPROTEIN INHIBITION: 
EXPERIMENTAL AND PHARMACOKINETIC LIMITATIONS 
 
 
 
 
 
 
 
 
 
 
This chapter is constructed as a mini-review for the Journal of Pharmaceutical 
Sciences, and is written in the style of that journal 
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INTRODUCTION 
Although neurological and mental disorders constitute 13% of the disease 
burden worldwide (Jamison 2006), few effective CNS drugs exist to treat these 
disorders, including only two drugs approved by the FDA for treatment of brain 
tumors (CBTRUS 2005).  In light of the continually poor outcomes and the relative 
expense associated with this disease, improving therapy for brain tumors is an 
important research goal. 
There are currently three standard approaches for treating brain tumors: 
surgery, radiation and chemotherapy.  As evidenced by survival statistics, none of 
these therapeutic modalities is desirably effective, alone or in combination.  Brain 
tumors are a difficult therapeutic target in part because the brain, a highly-organized 
organ without significant regenerative capacity, is distinctly sensitive to damage.  
Many therapeutic interventions themselves carry a risk of long-term neurological 
damage, a serious problem in light of the numerous fundamental functions of this 
organ.  This challenge is compounded by the fact that brain tumors are generally 
more diffuse than other solid tumors: tumor cells migrate extensively, interdigitating 
with normal cells up to 4 cm from the identifiable tumor mass (Kelly et al. 1987).  
Local tumor progression or recurrence is the most common cause of death (Ashby 
and Ryken 2006; Marsh 2005).  Long-term cure thus requires an approach that is 
capable of killing or arresting growth of tumors, but can be applied globally 
throughout the brain to treat what is essentially an infiltrative disease. 
By virtue of dense vascularity and high blood flow in the brain, a 
chemotherapeutic approach allows global therapy, making it inherently well-suited to 
overcome a major obstacle in brain tumor therapy, regrowth of distant tumor cells.  
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The efficacy of cancer chemotherapeutics against tumor cells, however, varies 
widely by mode of action (e.g., cytotoxic vs. cytostatic, cell cycle-specific vs. 
nonspecific), target tumor and other factors.  This approach has been avoided for 
brain tumors due to lack of efficacy, but recent studies support a role for 
chemotherapy, particularly nitrosoureas, in a multimodal approach (Parney and 
Chang 2003).  For example, meta-analysis of 220 studies of high-grade glioma 
found that nitrosourea-based chemotherapy added to any treatment increased 
median overall survival (18 vs. 11 months) (Hauch et al. 2005).  Unlike other 
approaches, the applicability of chemotherapy is limited less by risk of permanent 
neurological damage than by low efficacy: contributing factors include development 
of drug resistance, tumor heterogeneity, and importantly, sub-therapeutic levels of 
drug reaching the brain (Siegal and Zylber-Katz 2002).  In light of the relative 
success of nitrosoureas (among the few antineoplastics with good CNS penetration) 
and the potency of some CNS-excluded drugs against brain tumor cells in vitro but 
not in vivo (Kimmel et al. 1987), increasing brain penetration of antineoplastics could 
improve the efficacy of many drugs, which also would minimize problems related to 
drug resistance.   
Flux of substrates between systemic circulation and brain parenchyma is 
regulated by the blood-brain barrier (BBB), a functional system of physical and 
biochemical features at the interface between these two environments.  
Transcellular and paracellular uptake of small polar substances is attenuated by 
physical features of the BBB such as tight junctions between vascular endothelial 
cells, few pinocytotic vesicles or fenestrations on endothelial cells, and glial cells 
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tightly surrounding the vasculature (Persidsky et al. 2006).  The unbound fraction of 
lipophilic, low molecular weight compounds can diffuse passively across cell 
membranes. However, while some antineoplastics should enter the brain based on 
these properties, CNS penetration is limited by biochemical BBB features: 
degradative enzymes and several types of efflux transporters including P-
glycoprotein (P-gp) (Ghersi-Egea and Strazielle 2001; Golden and Pollack 2003).  
Transporters play multiple roles in cancer chemotherapy.  Initially studied as 
mediators of drug resistance in tumors (Kartner et al. 1983), they are now known to 
have physiologic functions in tissue defense against xenobiotics (Thiebaut et al. 
1987).  P-gp removes drugs, e.g., antineoplastics, from brain into systemic 
circulation (Tsuji et al. 1992).  Although the BBB is often “leaky” within tumors, P-gp 
contributes to limited drug penetration (Gallo et al. 2003)  
Several strategies for bypassing or defeating the BBB have been tested. One 
major effort includes structural modifications to drugs, aimed at increasing 
lipophilicity, decreasing efflux transporter affinity, attaching drugs to uptake vectors 
or using carriers such as liposomes or nanoparticles.  Varying degrees of success 
have been noted (Mayer 1998), although most of these approaches are drug-
specific.  A second, more aggressive category of approaches physically instills drug 
directly into the brain. The success of intraventricular delivery is limited, likely by 
excessive drug clearance due to slow diffusion through cerebrospinal fluid, barrier 
features at the interface between cerebrospinal fluid and brain, and a surface area 
1000-fold smaller than that of the BBB (Lee et al. 2001).  Intratumoral delivery by 
indwelling catheter, reservoir, or drug-loaded polymers has been more effective, 
particularly polymer-based delivery of BCNU (Brem et al. 1995).  These approaches 
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are restricted by tumor location and limited drug diffusion (Kemper et al. 2004).  A 
third strategy is physical disruption of the BBB.  A method that has been examined in 
detail and used clinically, intra-arterially infused hyperosmolar mannitol, causes 
osmotic shrinkage of brain endothelial cells, transiently disrupting tight junctions to 
allow antineoplastics into the brain. The risks (e.g., neurologic deficits, seizures, 
vascular injury, mortality) associated with disrupting bulk flow, ion and nutrient 
gradients, as well as allowing the contents of systemic circulation into brain may 
outweigh the modest benefits (Bredesen et al. 2006).  
A less-disruptive approach involves chemical modulation of drug transporters 
to increase penetration of substrate drugs into brain.  P-gp has been a popular 
target, as it plays a substantial role in the exclusion of some substrate drugs from 
the CNS.  A striking example is the 90-fold increase in brain concentrations of the 
antiparasitic ivermectin in P-gp deficient vs. competent mice, associated with 50- to 
100-fold greater sensitivity to the drug (Schinkel et al. 1994).  P-gp effects have 
been noted for other drug classes including antineoplastics, suggesting that 
transporter inhibition may be a viable therapeutic approach.   
Generations of chemical inhibitors of P-gp have been developed based on 
promising results in preclinical studies.  For example, in a mouse brain tumor model, 
the P-gp inhibitor valspodar increased brain levels of paclitaxel, resulting in 90% 
reduction in tumor volume (Fellner et al. 2002).  Clinical studies have been 
somewhat disappointing, largely due to difficulty achieving sufficient systemic 
unbound concentrations of inhibitor without prohibitive toxicity (Breedveld et al. 
2006).  This approach is necessarily limited by the fact that applicability is restricted 
to efflux transporter substrates.  However, many potent antineoplastics fall into this 
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category.  Inhibition of transporter function in the BBB, or other organs that are 
“sanctuary sites” or mediate drug removal from the body, is not without risk.  As P-gp 
is expressed in liver, intestine, kidney and elsewhere (Thiebaut et al. 1987), side 
effects such as altered substrate pharmacokinetics have been noted (Kemper et al. 
2003).  In the case of modulating P-gp function in the BBB, one way to avoid 
systemic drug-drug interactions would be to target transporter inhibition to the brain.   
Interest in the nasal route for CNS-targeted drug delivery has been stimulated 
by observations of the uptake of some drugs and viruses into the CNS via the nose 
at rates greater than can be explained by systemic distribution (Chow et al. 1999). 
This most rapid, but poorly-understood “direct pathway” represents only one of three 
routes by which nasally administered drugs enter brain, including entry via systemic 
circulation and retrograde axon transport via olfactory neurons (Illum 2000). 
Although there is a general assumption that intranasal delivery avoids the BBB, P-gp 
has recently been identified on olfactory epithelial cells and endothelial cells within 
the olfactory bulb.  These transporters appear functional, limiting uptake of nasally 
delivered substrates (Graff and Pollack 2005). 
Based on this evidence, a series of studies in this laboratory explored the 
feasibility of combining nasal administration with chemical P-gp inhibition to improve 
CNS penetration of P-gp substrates.  Initial studies demonstrated that nasal delivery 
of a P-gp inhibitor (rifampin) could dose-dependently increase brain uptake of a 
nasally delivered P-gp substrate (verapamil) by 4-fold, to the level observed in P-gp 
deficient mdr1a(-/-) mice.  Although the maximum effect on systemically-delivered 
substrate was lower, it was noted that compared to systemically-delivered inhibitor 
and substrate, maximum P-gp inhibition effect was similar, but associated with a 
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400-fold lower ED50 (Graff and Pollack 2005).  Spatial trends in brain drug 
distribution (along a rostral to caudal gradient) were noted, and relevant 
pharmacokinetics were elaborated by compartmental modeling.  Further 
experiments confirmed the pharmacodynamic relevance of this approach, using a 
hotplate model of antinociception (Graff 2004).  These data demonstrate that this 
approach is feasible for increasing CNS penetration to levels associated with altered 
pharmacodynamic effects.   
 
The purpose of this chapter is to summarize the various approaches taken 
toward the development of a viable experimental model for assessing the practicality 
of a nasal delivery approach for targeted inhibition of P-gp at the BBB.  Various 
chemical inhibitors of P-gp, including quinidine, rifampin, and GF120198 were 
evaluated for their ability to improve brain exposure to the antineoplastic compound 
paclitaxel, which served as the model P-gp substrate for all studies.   
 
Characterizing CNS pharmacokinetics of a model P-gp substrate, paclitaxel.   
Preliminary experiments were conducted to characterize the 
pharmacokinetics of paclitaxel in mouse plasma and brain.  A secondary goal of 
these experiments was to inform the design of subsequent studies by establishing 
brain paclitaxel levels achievable in vivo in the absence of P-gp inhibition, at a well-
tolerated dose in an animal model appropriate for studies involving tumor 
implantation (immunodeficient mice).  Male BALB/c mice carrying a homozygous 
Foxn1nu mutation (athymic nude immunodeficient mice, 20-35 g) received paclitaxel 
(as the clinical formulation, Taxol) as a single 10-mg/kg dose intravenously by tail 
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vein.  Whole brain and trunk blood were collected by decapitation at 10 pre-
determined time points (n = 3-4 per time point).  Paclitaxel in plasma and brain 
homogenate was assayed by reverse phase high performance liquid 
chromatography and tandem mass spectrometry (LC/MS/MS) as described in 
Chapter 2.  
Concentrations of paclitaxel in plasma declined biphasically, decreasing to 
concentrations below the limit of detection (5 nM) at 18 hr post-dose.  (Fig.1a).  
Brain partitioning of paclitaxel, as the ratio of concentrations in brain and plasma vs. 
time (Fig. 1b), appeared to increase through the time point at which the last 
detectable concentration was measured in brain and plasma.  To characterize the 
brain partitioning at post-distributional equilibrium (DE), additional time points were 
incorporated into the brain partitioning vs. time profile by administering multiple 10-
mg/kg doses of Taxol at 12-hr intervals (to maintain concentrations at detectable 
values).  Based upon the fit of an empirical model to these data, it was determined 
that paclitaxel attains DE in the mouse brain by approximately 70 hr.  The tissue 
partition coefficient calculated at DE (Kp, brain), expressed as the ratio of 
concentrations in brain vs. plasma at the time point closest to DE, was 4.55 ± 0.95; 
(mean ± SD).   
In order to pursue P-gp inhibition as a strategy to elicit a clinically meaningful 
increase in antineoplastic activity, it was necessary to ensure that, under conditions 
of complete P-gp inhibition, a significant (several-fold) increase in brain 
concentrations of paclitaxel could be achieved.  Due to drug solubility limitations, 
paclitaxel was administered as the clinical formulation, Taxol.  Because the vehicle 
in Taxol, Cremophor EL, is reported to have P-gp inhibitory activity (Fjallskog et al. 
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1994; Schuurhuis et al. 1990), it was necessary to ensure that any P-gp inhibitory 
effects attributable to the excipient would not significantly mask the effect of an 
experimentally-administered P-gp inhibitor.  
To document the magnitude of the influence of P-gp on Kp, brain,  male CF1 
mdr1a (+/+) and mdr1a (-/-) mice (35-45 g) received three 10-mg/kg bolus doses of 
paclitaxel via tail vein, administered at 12-hr intervals.  Trunk blood and brain were 
collected via decapitation 12 hr after the last dose of paclitaxel.  In mdr1a (+/+) mice, 
plasma and brain tissue concentrations of paclitaxel at DE were approximately 3-fold 
lower than in BALB/c nude mice, as described above.  Kp, brain values in P-gp-
competent animals thus remained in good agreement between these two studies.  
Kp, brain in P-gp-deficient animals was 83, vs. 5 in P-gp-competent animals, 
representing an 18-fold P-gp effect (Fig. 1c).  A significant, 25-fold increase (128 nM 
vs. 3195 nM) in absolute concentrations of paclitaxel in brain was observed 
(p<0.05).  Based on these data, complete chemical P-gp inhibition would elicit a 
marked effect on brain penetration of paclitaxel, potentially providing a clinically 
relevant antineoplastic effect.   
 
Effect of nasally-administered P-gp inhibitors on brain uptake of paclitaxel 
administered systemically. 
 The majority of P-gp inhibition studies involve pre-administration of the 
inhibitor relative to the substrate, although no justification for this experimental 
design generally is offered.  In the context of nasal delivery, the timing of substrate 
administration could be particularly important, if the substrate, or a portion of the 
substrate dose, diffuses from the site of administration caudally through the brain.  
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Previous studies in this laboratory indicated that the interval between administration 
of nasal inhibitor and systemic substrate impacted the observed effect on P-gp 
function (Graff and Pollack 2005).  With a nasal delivery method already in place, 
the initial approach in the development of a nasal P-gp inhibitor delivery strategy to 
augment paclitaxel brain exposure thus focused on optimizing the timing of the nasal 
inhibitor dose, relative to substrate administration.   
Initial studies examined the effects of various P-gp inhibitors delivered nasally 
between 2 and 60 min prior to systemic administration of paclitaxel.  Substrates (or 
vehicle) were administered as a liquid formulation (solution or suspension, 
depending on the compound) to anesthetized mice (ketamine/xylazine; 100/10 
mg/kg i.p) placed in a supine position to limit liquid flow down the trachea.  In mice, 
the small size of the nasal cavity imposes a significant limitation on the volume of 
substrate which may be delivered, a maximum of approximately 5 L per nostril.  
The selection of a nasal inhibitor dose was based primarily upon the upper limit of 
solubility in a vehicle compatible with potential chronic administration (i.e., 
concentrations of organic solvents were minimized in order to limit nasal tissue 
damage).   
For the purposes of consistency with previous pharmacokinetic studies, a 10-
mg/kg i.v. bolus dose of the substrate, paclitaxel, was administered as the clinical 
formulation, Taxol, via tail vein.  Brain and trunk blood samples were collected by 
decapitation in all cases at 5 min post-administration of paclitaxel, and samples were 
stored at -80°C until analysis by LC/MS/MS.  In light of the potential for a gradient 
effect from olfactory bulb caudally through the brain, all brain samples were divided 
midsagittally to obtain separate tissue samples representative of olfactory bulb and 
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whole brain from each animal, for investigation of potential constraint of the P-gp 
inhibitor effect to the site of administration.  Differences between brain 
concentrations of paclitaxel thus reflected the effect of various time intervals 
between nasal inhibitor and systemic substrate administration.   
Illustrated in Fig. 2a, increased paclitaxel concentrations in whole brain (1.6-
2.4-fold) and olfactory bulb (1.1-2.4-fold) were observed in response to nasal 
delivery of the P-gp inhibitor quinidine (circles) vs. saline (line).  Although the 
magnitude of the inhibitor effect was modest, a temporal relationship between 
paclitaxel concentration and inhibitor pretreatment interval was observed in whole 
brain samples.  This relationship was less apparent in the olfactory bulb samples, 
likely due to rapid penetration and distribution of the inhibitor.  Indeed, a relationship 
between inhibitor pretreatment interval and quinidine concentration was observed in 
olfactory bulb, with a marked decrease in concentration as the pretreatment interval 
exceeded 5 min (Fig. 2b).  The plasma concentration-time profile of quinidine is 
consistent with absorption into systemic circulation (Fig. 2c).  Although modest in 
magnitude, these data supported the hypothesis that intranasal delivery of chemical 
P-gp inhibitors would improve brain penetration of systemically-administered 
paclitaxel. 
Additional experiments with other P-gp inhibitors confirmed the region-
dependent differences in P-gp inhibition.  For example, in an identically-designed 
pilot experiment using the P-gp inhibitor GF120918, paclitaxel concentrations were 
approximately 4-fold higher in olfactory bulb vs. whole brain, with an apparently time-
dependent trend in P-gp inhibition in olfactory bulb which was not observed in whole 
brain (Fig. 3). 
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Effect of nasally-administered P-gp inhibitors on brain uptake of paclitaxel 
during brain perfusion. 
Due to the observed differences between olfactory bulb vs. whole-brain 
concentrations of paclitaxel, preliminary in situ brain perfusion experiments were 
conducted in order to further scrutinize the regionality of P-gp inhibitor-induced brain 
uptake of paclitaxel and the spatial relationship between the distribution of inhibitor 
and substrate in 13 brain regions.  An in situ perfusion method allows for the 
evaluation of brain uptake of a constant concentration of compound, avoiding the 
potentially confounding influence of systemic pharmacokinetics.  Due to the small 
volumes of the microdissected tissue samples, both substrate and inhibitor were 
radiolabeled, allowing the use of a more sensitive scintillation counting assay for 
quantitation of drug concentrations.  
In situ brain perfusion was conducted as described in a previous publication 
from this laboratory (Dagenais et al. 2000).  Briefly, male CF-1 mice were 
anesthetized (ketamine/xylazine; 100/10 mg/kg i.p) and the right common carotid 
artery was exposed and ligated caudally.  The external carotid was ligated at the 
point of bifurcation with the common carotid and the right internal carotid was 
perfused via a polyethylene catheter inserted in the right common carotid, with the 
heart severed immediately before perfusion. Brains were perfused for 60 s with 
Krebs-bicarbonate buffer (pH 7.4, 37°C) containing [14C]paclitaxel (45 µM, 0.8 
µCi/mL) followed by a saline washout for 10 s.  At 10 min prior to start of perfusion 
with paclitaxel, [3H]quinidine (5 mg/kg) containing 300 µCi/mL or vehicle (5 
µL/nostril) was administered nasally. Right hemispheres were isolated and 
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microdissected into 13 anatomical regions according to a published method (Zapala 
et al. 2005).  Paclitaxel and quinidine concentrations in brain tissue were determined 
by liquid scintillation counting.   As only the right brain hemisphere was perfused, 
concentrations of drug in the whole hemisphere were calculated as (sum of drug 
mass in all substructures / sum of mass of all substructures).   
Pretreatment with nasally-delivered [3H]quinidine in a [14C]paclitaxel brain 
perfusion model resulted in 2.3- and 1.6-fold increased paclitaxel concentrations in 
olfactory bulb and right hemisphere, respectively, (Fig.4a) in agreement with 
observations from in vivo studies (Fig. 2a).  Paclitaxel concentrations measured in 
olfactory bulb and calculated in right brain also were similar in magnitude to values 
determined in vivo.  A P-gp inhibition effect (maximum 3.4-fold) was observed in 
most brain regions.  Rostral areas and some deep brain regions exhibited the largest 
magnitude of change, with the lowest levels of effect observed in caudal areas.  
Quinidine concentrations (Fig. 4b) also were similar in magnitude to values 
determined in vivo (Fig. 2b).  Quinidine was detectable in all brain regions except 
midbrain, indicating that, by 11 minutes (following a 10-minute pre-treatment interval 
and a 70 s brain perfusion), quinidine had distributed throughout the brain from the 
site of nasal administration.  Although a positive correlation between regional 
inhibitor concentration and magnitude of change in P-gp substrate concentration 
was anticipated, this relationship was not observed.  It is likely that additional 
variables may impinge upon this relationship, including the density of P-gp or other 
efflux or uptake transporter expression, brain parenchyma physicochemical 
composition, vascular density, or blood flow rate.   
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Evaluation of P-pg effect prior to attainment of paclitaxel brain-to-blood 
distribution equilibrium. 
 Among the three P-gp inhibitors (quinidine, rifampin, and GF120918) tested 
for ability to inhibit P-gp at the BBB via the nasal delivery route, the maximum P-gp 
effect observed in whole brain (2.5-fold, quindine) was observed under conditions of 
systemic paclitaxel administration.  When individual brain sub-regions were 
evaluated for potentially higher regional effects of the inhibitor, a maximum 3.5-fold 
P-gp effect was observed in some midbrain regions.  Although these modest fold-
changes in paclitaxel brain exposure could potentially translate to a small but 
biologically significant difference in antineoplastic effect, they represent only a 15-
20% inhibition of P-gp function, relative to the 18-fold difference in P-gp effect 
observed in the P-gp-competent vs. –deficient mice under steady-state paclitaxel 
administration.   
  P-gp effect is generally evaluated under conditions of brain-to-blood 
distribution equilibrium (DE), where the rates of change in substrate concentrations 
become equivalent in both tissues.  This equilibrium translates into a ratio of brain 
vs. plasma concentrations which approaches a constant, plateau value with time, as 
illustrated in Fig. 1b.  In light of the unusually slow brain equilibration of paclitaxel, 
however, effects of P-gp inhibitors were evaluated at time points from one (brain 
perfusion) to five (i.v. bolus administration) minutes after paclitaxel administration, in 
order to allow more rapid screening of inhibitor effects.   
To determine whether the minimal effect of the P-gp inhibitors was related to 
low mass delivery or low potency of the inhibitor, or whether it was related to 
sampling very early in the paclitaxel brain equilibration vs. time relationship, a 
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subsequent experiment was conducted.  As a positive control for the ability to detect 
a P-gp effect of inhibitors at very early time points relative to attainment of DE, P-gp-
competent and P-gp-deficient mice received [14C]paclitaxel by brain perfusion, and 
brain concentrations of paclitaxel were determined at 60 s.  Illustrated in Fig. 5, the 
maximum P-gp effect observed was a 4.9-fold difference between brain uptake of 
paclitaxel in the presence of fully-functional vs. completely absent P-gp efflux.  By 
increasing the paclitaxel perfusate concentration up to 50 nM, it was demonstrated 
that saturation of P-gp efflux is not a contributing factor to the low P-gp effect 
observed at the unbound concentration range relevant to in vivo experiments (0.02 
to 0.5 nM).  The results of this key experiment support the interpretation that the low 
P-gp effect observed in the preceding studies was due, at least in part, to evaluation 
of the inhibitor effect at time point too early in the process of brain equilibration of 
paclitaxel.   
 
Effect of nasally-administered chemical P-gp inhibitors on steady-state brain 
partitioning paclitaxel. 
 In order to assess the effect of nasally-delivered P-gp inhibitors on paclitaxel 
concentrations at DE (70 hr post-administration), various paclitaxel administration 
approaches were considered.  As evident from the results of the preceding studies, 
nasal delivery is a relatively variable technique, owing in part to the very small 
volumes of solute administered, the low solubility of the inhibitors in biologically 
appropriate solvents, and the potential for loss of an unknown fraction of substrate 
into the gastric tract.  Under conditions of steady-state substrate administration via 
multiple bolus doses, the effect of the inhibitor must be determined in relation to 
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rapidly-changing substrate concentrations.  To reduce this additional potential 
source of experimental variability, a reverse experimental design was selected in 
which the substrate was present under steady-state conditions prior to 
administration of the inhibitor.  Infusion from implanted osmotic minipumps was used 
to achieve steady-state paclitaxel concentrations.   
Preliminary calculations had indicated that the maximum paclitaxel 
concentrations achievable in brain and blood by osmotic infusion would be near the 
lower limit of detection for the LC/MS/MS assay implemented for this drug.  The 
maximum flow rate for pumps capable of delivering drug for at least 70 hr was 1 
L/hr.  Loading of the pump with paclitaxel as the undiluted clinical formulation, 
Taxol, (6 mg/mL) would result in a delivery rate of 0.006 mg/hr (approximately 2 
mg/12 hr /kg).  Accordingly, a pilot study evaluated brain and plasma concentrations 
of paclitaxel at time points from 48 through 122 hr to confirm attainment of steady-
state, and to determine whether sample concentrations would be measurable.   
As the drug vehicle (Cremophor EL and ethanol) was incompatible with the 
interior surface of the minipump, an external coil of polyethylene tubing was wrapped 
around the pump, loaded with paclitaxel (6 mg/mL), and pre-equilibrated per the 
manufacturer instructions. Osmotic minipumps then were implanted subcutaneously 
into male CF-1 mice.  Brain and trunk blood were collected at 48, 72, 96, and 122 hr 
post implantation and paclitaxel in both tissues was analyzed by LC/MS/MS.  With 
modifications to the LC/MS/MS assay (liquid-liquid extraction, followed by sample 
evaporation and concentration) to decrease the limit of detection to 0.1 nM, 
paclitaxel concentrations in brain and plasma were detectable in all samples.  
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Although tissue concentrations were near the limit of detection, a limited P-gp 
inhibition experiment was initiated.   
The influence of P-gp inhibition on paclitaxel brain uptake was explored with 
an experimental design analogous to a classic pulse-chase paradigm. This 
experiment evaluated the ability of a single nasal dose of inhibitor to perturb the 
brain exposure of paclitaxel under conditions of constant-infusion paclitaxel 
administration.  Paclitaxel-loaded minipumps were implanted in mice as described 
above.  At 100 hr post-implantation, animals received the P-gp inhibitor rifampin 
intranasally (5 mg/kg).  Brain and trunk blood were collected by decapitation at 10 
min, 30 min, 1 hr, 4 hr, and 8 hr post-administration of the inhibitor.  Brain and 
plasma concentrations, determined via the modified LC/MS/MS assay, were 
undetectable in approximately two-thirds of the samples evaluated.  In light of the 
constraints on the paclitaxel infusion rate and the detection limits of the assay, an 
alternative experimental design was evaluated.   
 
Effect of steady-state administration of P-gp inhibitors on brain uptake of 
paclitaxel. 
While it was not feasible to administer the model P-gp substrate, paclitaxel, at 
steady-state conditions, it was reasoned that a similar pulse-chase type design could 
be used to evaluate the impact of steady-state inhibitor administration on brain 
exposure to paclitaxel following a bolus dose of the substrate.  As a proof of 
concept, an experiment was conducted using the P-gp inhibitor rifampin, 
administered via a multiple oral dose scheme.  Under this administration approach, 
as determined based upon previous studies conducted in this laboratory (Chapter 4), 
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brain-to-blood DE conditions were achieved by 24 hr following a 250-mg/kg dose of 
rifampin, administered by oral gavage.   
To ensure that rifampin concentrations would be detectable in brain tissue at 
24 hr after the initial exposure, two rifampin doses were administered 24 hr apart to 
male CF-1 mice.  Control animals received an oral gavage of vehicle (1:1 
water:DMSO) only.  Concurrent with the second rifampin (or vehicle) dose, a 5-
mg/kg dose of paclitaxel was administered by intraperitoneal injection.  Brain and 
trunk blood samples were collected by decapitation at 0.25, 0.75, 2, 4, 6 and 12 hr 
following paclitaxel administration.  A limited multiple-dose experiment was 
conducted by following the first two rifampin or vehicle doses with two additional 
doses at 24 hr intervals.  Paclitaxel administration was repeated at 12 hr intervals 
during rifampin dosing.  Brain and blood samples were collected at 2 hr or at 12 hr 
following the final (concurrent) doses of rifampin and paclitaxel.  Paclitaxel 
concentrations in plasma and brain were determined by LC/MS/MS. 
Fig. 6 illustrates the effect of steady-state administration of the P-gp inhibitor 
by comparing brain exposure to paclitaxel (AUC0-12 hr), and the brain tissue partition 
ratio, in rifampin vs. vehicle-treated animals.  Brain tissue paclitaxel concentrations 
were consistently lower, and peaked later, than plasma concentrations.  However, 
an effect of rifampin treatment was observed in both tissues, with a 2.6-fold increase 
in plasma exposure to paclitaxel and an 11.9-fold increase in brain exposure (as 
AUC0-12 hr,brain and AUC0-12 hr,plasma, respectively; Table 1).   The inhibitor-related 
changes represented a 4.55-fold change in brain partitioning.   
The effects of single vs. multiple doses of rifampin on total paclitaxel 
exposure (AUC) at 2 hr (Table 2) also were compared.  It appears that while brain 
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concentrations of paclitaxel were higher after multiple-dosing, plasma paclitaxel 
concentrations decreased slightly in the absence of, and increased slightly in the 
presence of, multiple doses of rifampin. Calculated in terms of accumulation ratios in 
each tissue, rifampin altered the paclitaxel accumulation ratio (RA) in brain by 3.4-
fold, and in plasma by 0.5-fold.  The net impact of rifampin on the accumulation ratio 
in brain, relative to plasma, was thus a 6.8-fold increase.  In essence, multiple doses 
of the P-gp inhibitor rifampin caused a slight decrease in the concentration of the co-
administered P-gp substrate paclitaxel in plasma, while increasing concentrations in 
brain.  The mechanism for the change in plasma concentrations in unclear, but may 
be related to the effect of chronic rifampin treatment as an inducer of P-gp 
expression (Matheny et al. 2004).    
Although the P-gp effects observed with single- and multiple-systemic doses 
of rifampin were greater than those observed via intranasal inhibitor delivery under 
the experimental conditions described above, these still represented only one 
quarter of the 18-fold P-gp effect observed in the absence of P-gp expression in 
mdr1a (-/-) vs. mdr1a(+/+) mice.  Considering the extremely large dose of rifampin 
used in these studies (250 mg/kg), it appears that despite the brain exposure 
advantage associated with the nasal delivery route (Chapter 3), it would not be 
possible to achieve a similar level of inhibition in the brain under conditions of nasal 
delivery, due to the limitations on mass delivery by this route.   
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Conclusions. 
In the aggregate, these studies reveal several fundamental problems with the 
current experimental system as a means to demonstrate an increase in paclitaxel 
brain exposure by targeted nasal delivery of chemical P-gp inhibitors.  The major 
difficulty encountered during the course of the above-described experimentation was 
the ability to accurately determine the effect of P-gp inhibition on brain partitioning of 
paclitaxel at DE.  The prolonged time required for paclitaxel to attain blood-to-brain 
DE initially prompted the evaluation of the P-gp inhibitor effect at brief (e.g., 1 – 5 
min) time points.  It was demonstrated by brain perfusion studies conducted in P-gp-
competent vs. P-gp–deficient mice that the truncated sampling times utilized in these 
preliminary experiments were compromising the ability to detect any sizeable effect 
of P-gp inhibition.  Efforts to evaluate the effect of nasally-administered inhibitors 
under conditions of steady-state paclitaxel administration, achieved by implanted 
osmotic minipumps, suffered from solubility and mass delivery limitations.  It was 
conceived that, alternatively, it might be possible to administer a chemical inhibitor to 
steady-state conditions, then evaluate the effect on the brain partitioning of paclitaxel 
vs. time.  As proof of concept, an oral steady-state rifampin administration strategy 
was employed in order to ensure measurable concentrations of the inhibitor for this 
preliminary assessment.  Somewhat surprisingly, despite the large mass of rifampin 
delivered systemically, with a resultant substantial rifampin exposure in brain, only a 
modest change in P-gp effect was observed.  Considering the restrictions on mass 
delivery via the nasal route, it was deemed that this type of approach would not be 
feasible using the nasal administration route. 
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Given the significant limitations associated the nasal delivery approach, 
including the small size and relative inaccessibility of the nasal cavity in mice, and 
the limits on the total mass deliverable by the nasal route (documented in Chapter 
3), the use of a nasal delivery approach to target P-gp inhibitors to the brain for the 
purpose of increasing brain exposure of a P-gp substrate in preclinical rodent 
species was concluded to not be feasible.  In addition, the extensive time required 
for paclitaxel to reach DE in the brain limited the ability to evaluate the effects of very 
small quantities of chemical P-gp inhibitors on the kinetics of the substrate.   
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Fig. 1. Time course of paclitaxel concentrations in mdr1a (+/+) mouse plasma 
and brain after a single 10-mg/kg i.v. bolus dose of paclitaxel (a) and 
associated brain-to-plasma partitioning during multiple dosing with 10 
mg/kg i.v. paclitaxel (b). Panel c displays paclitaxel concentrations and 
brain partition ratios in P-gp-competent vs. P-gp-deficient mice during 
multiple dosing. All data are presented as mean ± SD (n=4 per group). 
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Fig. 2. Paclitaxel (a) and quinidine (b) in whole brain and olfactory bulb, and 
paclitaxel and quinidine in plasma (c) at 5 min after a 10-mg/kg i.v. 
dose of paclitaxel with or without nasal pre-administration of quinidine 
(5 mg/kg). Lines indicate mean concentrations of paclitaxel averaged 
across time following nasal delivery of saline.  All data are presented 
as mean ± SD (n=5 per group). 
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Fig. 3.   Paclitaxel in whole brain and olfactory bulb at 5 min after a 10-mg/kg 
i.v. dose of paclitaxel with or without nasal pre-administration of 
GF120918 (1 mg/kg).  Lines indicate mean concentrations of paclitaxel 
averaged across time following nasal delivery of saline.  Symbols 
indicate pilot data from single animals.  
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Fig. 4. Regional brain distribution of paclitaxel following 1 min of in situ brain 
perfusion with paclitaxel under conditions of pre-administered nasal 
quinidine or vehicle (a), and associated regional brain distribution of 
quinidine (b). Panel a also displays the fold change in paclitaxel 
concentrations in the presence vs. the absence of quinidine. 
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Figure 5. Initial uptake clearance vs. paclitaxel concentration during in situ brain 
perfusion in P-gp-competent mice.  Pgp-effects, calculated relative to 
uptake clearance in P-gp-deficient mice, are indicated in parentheses. 
Data are presented as mean ± SD (n=5 per group).  
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Fig. 6. Brain and plasma concentrations of paclitaxel following i.p. 
administration of paclitaxel (10 mg/kg) in conjunction with either 250 
mg/kg rifampin (+RIF) or saline (-RIF), administered orally.  Data points 
indicate means of 5 animals per time point.  Error bars are omitted for 
clarity. 
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Metric Paclitaxel Paclitaxel + Rifampin 
AUC0-12hr,brain (nM*hr) 39.5 469 
AUC0-12hr,plasma (nM*hr) 2210 5750 
Kp,brain 0.0179 0.0815 
Fold change in Kp,brain  4.55 
 
 
 
Table 1. Impact of steady-state administration of rifampin (250 mg/kg, i.g.) on 
brain exposure metrics for single-dose paclitaxel (10 mg/kg, i.p.). 
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Paclitaxel Paclitaxel + Rifampin Rifampin Effect 
Single Dose    
brain 6.90 19.1 2.77 
plasma 346 1690 4.88 
Kp,brain 0.0199 0.0113 0.567 
Multiple Dose    
brain 19.3 182 9.40 
plasma 418 1050 2.51 
Kp,brain 0.0462 0.173 3.74 
Accumulation    
RA, brain 2.80 9.50 3.39 
RA, plasma 1.21 0.62 0.51 
RA,brain* 2.32 15.3 6.60 
 
Table 2. Paclitaxel brain and plasma exposure (AUC; nM * hr) and calculated 
brain tissue partition coefficients following 10-mg/kg i.p. dose(s) of 
paclitaxel alone or in conjunction with single-dose or multiple-dose oral 
administration of rifampin (250 mg/kg per day).  Accumulation ratios 
(RA) are calculated as the ratio of paclitaxel exposure associated with 
multiple dose vs. single dose administration. Rifampin effect is 
calculated as the ratio of paclitaxel exposure under conditions of 
rifampin presence vs. absence. 
CHAPTER 6 
 
 
 
 
 
INFLUENCE OF TIME TO ACHIEVE DISTRIBUTION EQUILIBRIUM ON 
EXPRESSION OF THE P-GLYCOPROTEIN EFFECT AT THE BLOOD-BRAIN 
BARRIER 
 
 
 
 
 
 
 
This chapter will be submitted to Brain Research, and is formatted in the style of  
that journal. 
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ABSTRACT 
Purpose.  Accurate estimation of how asymmetric blood-brain barrier (BBB) 
transport alters brain uptake is assumed to require attainment of distribution 
equilibrium. As sampling post-distribution equilibrium is not feasible in many 
experimental paradigms (e.g., in situ brain perfusion), understanding the relationship 
between apparent degree of efflux (e.g., calculated BBB P-glycoprotein [P-gp] effect) 
and time remaining to distribution equilibrium (expressed as fractional time to 
distribution equilibrium; FTDE) would be advantageous. This study employed a 
simulation strategy to explore this relationship utilizing hypothetical P-gp substrates 
of varying intrinsic transport properties.  Methods. Plasma and brain concentration-
time profiles based on the P-gp substrate, paclitaxel, were simulated with a 4-
compartment system (blood; peripheral tissues; BBB endothelium; brain). P-gp-
mediated attenuation of apical-to-basolateral flux was incorporated as a 
unidirectional endothelium-to-blood rate constant.  A parameter space was selected 
to simulate an 18-fold P-gp effect, calculated as Kp,brain at distribution equilibrium in 
the absence [Kp,brain =82] vs. presence [Kp,brain =4.5] of P-gp-mediated flux, similar to 
Kp,brain observed for paclitaxel in P-gp-competent and P-gp-deficient mice.  
Compounds with different P-gp effects were simulated by perturbing the rate 
constant representing P-gp-mediated efflux.  Results. Kp,brain increased consistently 
until equilibrium was achieved; the calculated P-gp effect peaked prior to distribution 
equilibrium (FTDE=0.379). Error in the calculated P-gp effect was maximal at early 
simulated measurement times (1 min, consistent with in situ perfusion experiments; 
FTDE=0.016), and decreased with time through FTDE~0.3 for all substrates. The 
maximal error in P-gp effect estimates differed among strong (P-gp effect=60), 
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intermediate (P-gp effect=18), and weak (P-gp effect=3) substrates (75%, 73% and 
54%, respectively).  Relationships between measurement error and FTDE were 
biphasic, with early (FTDE<0.009) and late (FTDE>0.8) sampling times under-
predicting, and intermediate points over-predicting, theoretical P-gp effects. 
Conclusions. Calculating P-gp effects based on sampling prior to attainment of 
distribution equilibrium can result in substantial error. However, error becomes 
modest (<20%) at FTDE>0.3, indicating that reasonably accurate P-gp effect 
estimates can be obtained relatively early in the net distributional phase.  Potential 
errors associated with non-equilibrium calculations of the P-gp effect are dependent 
on both the P-gp-mediated and P-gp-independent components of flux across the 
BBB. 
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INTRODUCTION 
Pharmacotherapeutics with sites of action inside the brain must be able to 
penetrate into the central nervous system (CNS) to be effective.  The development 
of efficacious, CNS-targeted pharmacotherapeutics is complicated primarily by the 
existence of an effective system of barriers between the brain and systemic 
circulation (the blood-brain barrier; BBB), and by physiological and technical 
limitations which hinder the study of interactions between the BBB and drug 
exposure to the brain.  In order to design compounds that can reach therapeutic 
concentrations in brain tissue, it is necessary to be able to accurately evaluate the 
impact of barrier functions on drug disposition into brain.   
The blood-brain barrier. The BBB, as the functional interface between the 
systemic circulation and the brain parenchyma, primarily regulates the rate and 
extent of disposition of chemicals in the brain.  Physical components of the BBB, 
including specialized capillary endothelial cells (e.g., enriched with tight junctions, 
largely devoid of pinocytotic vesicles and fenestrations), and a layer of glial cells 
tightly surrounding the vasculature, attenuate the passive influx of most compounds 
[29].  Although the unbound fraction of lipophilic, low molecular weight compounds 
can diffuse across cell membranes passively, brain uptake may be restricted by 
biochemical components of the BBB.  These functional, as opposed to structural, 
elements of the barrier include various families of degradative enzymes as well as 
several categories of membrane transporters which recognize and efflux of a wide 
range of compounds.  Efflux transporters expressed at the BBB include organic 
cation and anion transporters [17,27], multidrug resistance associated proteins 
(MRP) [14], and several ATP-binding cassette (ABC) family proteins [7].   
172 
 
P-glycoprotein.  Although many types of efflux transporters are expressed at 
the BBB, the functional effects of each type of transporter on CNS drug exposure 
vary significantly.  The most important, in terms of significantly limiting brain 
exposure of many pharmaceuticals, is P-glycoprotein (P-gp), a member of the ABC 
family of efflux transport proteins [28].  In the brain, this 170 kD transmembrane 
protein is expressed primarily, although not exclusively, at the luminal surface of 
endothelial cells [2,11].  Although the mechanism is currently unclear, this protein 
binds a wide range of substrates [20], including many therapeutically-relevant 
compounds, and moves them back into the blood against the concentration gradient 
that drives passive diffusion.   
Rationale for assessment of P-gp function.  Transporters such as P-gp 
will, in many cases, dictate the rate of substrate equilibration between brain tissue 
and blood, as well as the overall exposure profile in the target tissue, often with 
significant pharmacodynamic consequences.  P-gp-mediated exclusion has been 
cited as a major factor hindering the ability of drugs to enter the brain, and thus an 
important source of therapeutic failure for potential CNS-active agents [3].  For this 
reason, the role of efflux transporter proteins has received a great deal of attention.  
Although many compounds may exhibit P-gp substrate characteristics, not all are 
excluded from the brain to the same degree.  
Experimental systems to manipulate transporter function.  The 
magnitude of P-gp-mediated drug exclusion from the CNS and other tissues 
generally is studied with two major types of in vivo experimental paradigms.  One 
makes use of P-gp-deficient animal models.  Two forms of P-gp in mice are encoded 
by the mdr1a and mdr1b genes.  A strain of naturally mdr1a-deficient mice was 
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identified serendipitously by their extreme sensitivity to a P-gp substrate, ivermectin 
[25].  Subsequently, mdr1b (-/-) and mdr1a/1b (-/-) knockout mice have been 
generated [24] and serve as important research tools.  A second major paradigm for 
studying P-gp function is the use of chemical compounds that are P-gp inducers or 
inhibitors.  Although many compounds have been identified or developed for this 
purpose [20], interpretation of results from studies that employ this paradigm is 
complicated by differing potencies and a sometimes significant overlap in function 
(e.g., substrate / inhibitor) and specificity for P-gp vs. other transporters.  By 
comparing various metrics of brain exposure between systems with functional vs. 
impaired (via genetic or chemical manipulation) P-gp activity, the net effect of the 
transporter on brain exposure can be evaluated. 
Quantifying transporter effects: rate of exposure.  Drug disposition within 
the brain, and the impact of transporters upon that disposition, may be evaluated in 
terms of effects on both the rate and extent of brain exposure.  The rate of substrate 
entry into the brain is determined primarily by the rate of cerebral blood flow and 
substrate permeability through BBB endothelial cells [26].  More important, however, 
in terms of dictating pharmacologic effect, is the rate of substrate equilibration 
between brain and blood.  Immediately upon systemic administration, substrate 
resides essentially entirely in the systemic circulation. With time, substrate 
exchanges between blood, brain, and other tissue spaces, eventually reaching a 
brain-to-blood distribution equilibrium (DE) at which the rate of change in 
concentration in both tissues becomes equivalent.  The amount of time required for 
a compound to attain distribution equilibrium in the brain, (time to distribution 
equilibrium; TDE), differs widely between compounds. Some opioids such as 
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alfentanyl achieve DE as rapidly as 2 min; and other compounds, such as the 
antineoplastic drug paclitaxel, require several days to establish equilibrium (TDE = 
70 hr) [15].   
Few studies have investigated the factors which dictate the rate of substrate 
equilibration between brain tissue and blood (i.e., the amount of time required to 
attain DE).  Such factors may include the ratio of partitioning into tissue vs. blood, 
perfusion rate, and the volume of the tissue compartment of interest [12].  Liu et al. 
[19] identified high BBB permeability and low binding to brain tissue as predictors of 
rapid attainment of brain to blood DE in a test set of seven model compounds.   
The magnitude of partitioning between brain and blood at DE reflects the 
clinically-relevant level of brain exposure relative to blood concentration (i.e., under 
conditions of regular administration).  Accurate determination of the time to achieve 
DE in brain tissue is important not only for designing pharmaceuticals which exert 
effects over a specified time frame (e.g., rapid-effect antiepileptics to interrupt 
seizure activity), but also for correctly interpreting measurements of the extent of 
brain exposure.  During the period between initiation of drug administration and 
attainment of DE, brain partitioning changes from zero to the equilibrium value. 
Thus, measurement of brain partitioning at any point prior to DE will produce a 
different, ostensibly lower, estimate of brain partitioning, dependent largely upon 
sampling time.   
Quantifying transport effects:  extent of exposure.  Although no standard 
definition exists, the extent of drug exposure to the brain (particularly as measured 
under physiological conditions) is generally expressed as a partition coefficient 
between brain tissue and blood [5,18]. This brain tissue partition coefficient, Kp,brain, 
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is appropriately calculated based upon the ratio of brain vs. blood concentrations at 
DE, upon the ratio of steady-state concentration values in brain vs. blood (by 
definition, post-DE), or upon the ratio of AUC (extrapolated through infinite time after 
a single dose of substrate, or calculated over a steady-state dosing interval during 
multiple applications of the agent) in brain vs. blood.  Calculation based upon a 
concentration ratio at a discrete point in time is most common, as it is less labor-and 
animal-intensive than determination of AUC.  This is particularly important in drug 
development, where large numbers of potential CNS-targeted agents are screened 
for brain partitioning greater than unity (i.e., “good” brain exposure).  Reported Kp,brain 
values range from approximately 0.01 to 10 [6].   
Factors which influence the extent of brain exposure for a compound include 
the degree of binding to proteins in blood vs. in brain, lipophilicity, ionization, CSF 
bulk flow, metabolism, and BBB efflux transporters [15].  Although the interaction 
between these factors and the effect on brain exposure is not completely 
understood, initiatives such as screening to identify efflux transporter substrates as 
potentially problematic compounds early in the CNS-targeted drug development 
process has become common [22].  As with assessment of brain partitioning in 
general, an often overlooked factor influencing the impact of efflux transport, 
specifically, on brain distribution is the influence of sampling time relative to DE.    
The term “P-gp effect” has been used to express the magnitude of the impact 
of P-gp on the extent and rate of brain uptake, and is calculated as the ratio of brain-
to-blood partitioning in the presence vs. the absence of efflux activity.  As brain-
blood partitioning is understood to increase with time to a plateau value (at DE), 
comparison of systems in the presence vs. absence of efflux activity would result in 
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a time-dependent estimation of P-gp effect.  It is logical to conclude that the impact 
of a transporter (the P-gp effect, for example) on brain exposure should thus be 
reported at DE as well. However, potential differences resulting from calculation of 
this metric under varying conditions of disequilibrium have not been evaluated 
prospectively.  
Experimental limitations.  In light of the wide range of times required for 
various compounds to attain brain-to-blood DE, it becomes experimentally difficult to 
evaluate brain partitioning, and the influence of efflux transport on brain partitioning, 
across many compounds with a single experimental paradigm.  For compounds with 
very long TDE, e.g., paclitaxel (70 hr), Kp,brain cannot be determined following a 
single bolus dose, as concentrations fall below a detectable limit well before DE is 
achieved.  This same problem may affect compounds with shorter TDE, if the 
degree of brain partitioning is particularly low relative to the assay limit of detection.  
Use of radiolabeled substrates may lower the limit of detection, but may be 
complicated by significant accumulation of derived metabolites prior to attainment of 
DE.  Although in some cases such problems may be resolved via a modified 
experimental approach (e.g., chronic infusion via implanted osmotic pumps), 
practical considerations may preclude the use of such approaches for assessing 
large numbers of compounds.   
In cases when it is not possible or convenient to sample at DE, it would be 
useful to know the relationship between sampling time prior to DE and the P-gp 
effect calculated at that sampling time.  Depending on the rate of change in 
calculated P-gp effect vs. time prior to DE, it could be possible to sample at a time 
prior to DE with an acceptably low degree of error.  If the degree of error could be 
177 
 
calculated relatively precisely across the range of theoretical sampling times, it may 
be possible to calculate P-gp effect at any point in time and use a scaling factor to 
correct for sampling time.   
Study rationale and goals.  The objectives of the current simulation study 
were two-fold.  The first objective was to test the global hypothesis that a 
relationship could be identified between time prior to DE and the magnitude of the 
calculated P-gp effect, and that factors such as P-gp effect magnitude and TDE may 
influence this relationship.  The second objective was to illuminate basic principles of 
substrate partitioning into brain under the simplest relevant conditions in order to 
inform the design of studies to evaluate the multitude of other factors which influence 
brain distribution in general (e.g., protein binding, metabolism).   
Accordingly, a simple simulated system was constructed to represent blood, 
brain, a barrier (a unidirectional clearance process from endothelial cells to blood, 
representing P-gp) and a peripheral tissue compartment.  A parameter space was 
selected to represent a model P-gp substrate, and the relationships between time 
and Kp,brain, P-gp effect, and the resulting error in the P-gp effect calculated prior to 
vs. at DE were determined.  Subsequently, individual parameters were manipulated 
to simulate compounds varying in magnitude of P-gp effect and TDE, as well as 
other factors identified as potentially relevant to the relationship of interest, including 
administration route and depth of a peripheral tissue compartment.   
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RESULTS 
 
Relationship between observed P-gp effect and sampling time.   
The starting point for this simulation study was evaluation of the plasma and 
brain concentration vs. time relationships within the parameter space describing a 
specific model P-gp substrate, paclitaxel.  Beginning with model 1 (bolus 
administration), concentrations in each compartment were simulated in the absence, 
and then in the presence, of P-gp-mediated efflux (PSe = 0 or 17.8, respectively) 
through the point in time at which numerical solutions to the model became unstable 
(that is, as mass remaining in the system approached zero).   
Bolus input.  In Fig. 2a, the simulated concentrations in the brain and plasma 
compartments are plotted as Cbrain / Cplasma through 144 hr.  Per the definition of this 
model compound, when P-gp function was absent, Cbrain / Cplasma reached a plateau 
value of 1 (Kp, brain = 1), and rose to 95% of this value by 70 hr (TDE = 70 hr).  In the 
presence of P-gp function (simulated by changing only the PSe term), Cbrain / Cplasma 
reached its plateau value (Kp, brain = 0.056) more rapidly than in the absence of P-gp 
function, with a calculated TDE of 45 hr.  As specified for this model compound, an 
18-fold P-gp effect,DE was observed. 
Calculated P-gp effect vs. time values are plotted in Fig. 2b.  The rate of 
change of this function was highest at early time points, with the sharpest increase 
within three minutes of drug administration into the central compartment (inset).  
Although the early (≤ 3 min) rates of change in Cbrain / Cplasma ratios (Fig. 2a, inset) 
increased with apparent linearity, the early rates of change in P-gp effect,t (Fig. 2b, 
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inset) were clearly not a linear function of time, peaking and beginning to level off 
within the same time frame.  
The difference between P-gp effect,t and P-gp effect,DE is expressed as % 
calculation error vs. time in Fig. 2c.  As an inverse function of the relationship in Fig. 
2b, the magnitude of error was highest when the P-gp effect value was calculated at 
early time points, particularly prior to 3 minutes.  Calculation error dropped below 
50% by 5 minutes, and below 20% by 24 hr.   
In order to express these results in terms relevant to experimental situations, 
values for Cbrain / Cplasma, P-gp effect, and % error are reported at 5 seconds, 5 
minutes, 12 hr and 72 hr, time points relevant to experimental paradigms such as 
brain uptake index, short- and long term sampling after single doses in vivo, and 
sampling after multiple-dosing in vivo, respectively.  As reported in Table 1, under 
the current simulation scenario, sampling brain and plasma concentrations at 5 
seconds would result in the calculation of a 1.6-fold P-gp effect,t, a 91% error in the 
estimation of the P-gp effect,DE for this simulated compound.  Within 5 minutes, the 
calculated P-gp effect,t would rise to 9.2-fold, approximately 50% of the final value.  
During the span from 5 minutes to 12 hours, however, the degree of error drops by 
only 19%, to ~31%. The remaining error decreases to <1% over the course of the 
final 60 hours.   
Infusion input.  Repetition of this simulation using the infusion administration 
model revealed trends in the rate of change of Cbrain / Cplasma, P-gp effect, and % 
error vs. time that were similar to those observed under a bolus administration 
scheme.  Administration route-related differences included longer TDE (>100 hr), 
and correspondingly slower rates of change for each of the endpoint indices.  In 
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order to represent the results of this simulation in terms relevant to experimental 
paradigms employing infusion administration, values for Cbrain / Cplasma, P-gp effect, 
and % error were reported at 60 seconds, 60 minutes, 12 hr and 14 days, as 
relevant to paradigms such as in situ brain perfusion, isolated brain perfusion, in vivo 
infusions via syringe pump and via implanted osmotic minipump, respectively.  As 
reported in Table 1, ~71% error would result from evaluation of P-gp effect at 60 
seconds, slightly higher than the corresponding error at this time point under the 
bolus-dose administration scheme (64%).   
Data generated in this laboratory (described in Chapter 5) examining 
paclitaxel brain distribution via in situ brain perfusion in P-gp-competent and P-gp-
deficient mice are consistent with simulated results.  This P-gp effect,t calculated as 
described in [8] following 60 sec of brain perfusion, revealed a value (~5.01-fold), 
similar to the P-gp effect,t simulated at 60 secs of paclitaxel infusion (5.17-fold). This 
comparison serves, in part, as an internal validation of the simulated system.  
   
Influence of P-gp effect magnitude.  
The next simulation experiment, depicted in Figs. 3a-f, was conducted to 
assess the influence of magnitude of P-gp effectDE  on the relationship between 
sampling time and accuracy of P-gp effectDE estimation.  Using the bolus input 
model, parameter spaces were selected via manipulation of the PSe term only to 
produce simulated systems with P-gp effectDE values of 3-fold (as would constitute a 
marginal P-gp substrate, e.g., methadone) and 60-fold (representing the upper limit 
of reported P-gp efflux activity, e.g., for loperamide) (Figs. 3a-c).  These simulations 
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were repeated with the infusion input model, using identical sets of parameter values 
(Figs. 3d-f).   
Bolus input.  For systems with bolus input, the resulting Cbrain / Cplasma vs. 
time profiles, simulated in the presence and absence of P-gp efflux activity for each 
compound are depicted in Fig. 3a.  As observed with the original simulated model 
compound (P-gp effect,DE = 18-fold), which is plotted on the same coordinates for 
reference, the steepest rate of increase in Cbrain / Cplasma  occurred at the earliest 
time points, particularly within the first 3 seconds.  Consistent with the first simulation 
study, increases in the PSe term (increasing P-gp effect,DE) resulted in more rapid 
attainment of DE, with TDE values of 70 hr, 60 hr, 45 hr, and 36 hr observed for 
compounds with 0-, 3-, 18-, and 60-fold P-gp effect,DE values, respectively.    
The P-gp effect vs. time profile for each compound is presented in Fig. 3b.  
As described for the original model compound, initial rates of increase in P-gp effect,t 
were highest at early time points.  The relative rates of increase, however, differed 
between compounds.  By one second, the 3-fold P-gp effect,DE compound achieved 
51% of its P-gp effect,DE value, whereas the 18- and 60-fold P-gp effect,DE 
compounds had attained 33.7% and 31.5% of their P-gp effect,DE values, 
respectively.  At late time points, these differences became minimal. 
Error associated with calculation of a P-gp effect prior to DE is depicted in 
Fig. 3c. Error decreased with time most rapidly at early points.  Consistent with the 
more rapid increase in P-gp effect,t observed with smaller P-gp effect,DE, calculated 
% error vs. time also was lowest for low P-gp effect,DE compounds.  Error decreased 
to less than 20% by 20, 28, and 32 hr for compounds with 3-, 18-, and 60-fold P-gp 
effects, respectively.   
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Infusion input.  As observed in earlier simulations, under conditions of 
infusion vs. bolus input, Cbrain / Cplasma values increased more slowly, resulting in 
uniformly larger TDE values (Fig. 3d).  As with bolus-input systems, TDE varied 
based upon magnitude of P-gp effectDE, with TDE values of 80, 100 and 120 hr 
calculated for systems with 3-, 18- and 60-fold P-gp effect,DE values, respectively.   
Similar trends were evident for administration route-dependent changes in the 
P-gp effect,t vs. time and % error vs. time profiles (Fig. 3e,f).  Systems with lower P-
gp effectDE values exhibited larger rates of increase in P-gp effect,t, and lower P-gp 
effect calculation error, at each time point, with differences between compounds 
most apparent at early time points. Finally, relative to bolus input conditions, lower 
P-gp effect,t values and higher calculation error were observed at each point in time.   
P-gp effect,t and % error values relevant to various experimental paradigms 
are presented in Table 1 for each of the three compounds simulated under bolus 
and infusion input schemes.   
 
Influence of time to achieve brain-blood distribution equilibrium.   
The following simulation experiment was undertaken to test the hypothesis 
that regardless of the rate of brain exposure (and thus, TDE), it is possible to predict 
the sampling time at which P-gp effect,DE can be calculated with a given degree of 
accuracy.  By expressing TDE in units of fractional time to distribution equilibrium 
(FTDE), error vs. FTDE profiles should be similar between compounds which exhibit 
different real-time TDE values, allowing prediction of P-gp effect calculation error at 
any hypothetical sampling time point.  In order to test this hypothesis, compounds 
were simulated to represent the range of reported rates of brain exposure.  
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Beginning with the simulated 3-fold P-gp effect,DE compound illustrated in Fig. 3a, 
CL, CLd, PSa, PSb and  PSe values were modulated independently to simulate 
compounds with approximately 3-fold P-gp effect,DE values, reaching DE (in the 
absence of P-gp efflux) at short (2 min, as reported for the opioid analgesic 
alfentanyl), intermediate (1.5 hr), and long (70 hr, as determined for the model 
compound, paclitaxel) time points.  
Bolus input Cbrain / Cplasma vs. time profiles plotted in the presence and 
absence of P-gp efflux for compounds with TDE values of 2 min, 1.5 hr, or 70 hr are 
illustrated in Fig. 4a.  Cbrain / Cplasma profiles for all compounds simulated in the 
absence of P-gp efflux collapsed to approximately the same shape when plotted in 
terms of fractional time to distribution equilibrium, regardless of TDE.  The same was 
true for compounds simulated in the presence of P-gp efflux. However, as observed 
under previous simulation conditions, the rate of increase in Cbrain / Cplasma was 
higher, corresponding with the increase in PSe.  For all simulations, the initial rates 
of increase in Cbrain / Cplasma were highest at early time points.   
As TDE was observed not to influence the shape of the Cbrain / Cplasma vs. 
FTDE profile under conditions of P-gp presence or absence, P-gp effect,t profiles 
and % error profiles also were identical regardless of TDE when plotted vs. FTDE 
(Fig. 4b,c).  For all simulated compounds, error dropped below 20% by FTDE <0.24.   
Infusion input.  Compounds which were simulated to exhibit TDE values of 2 
min, 1.5 hr, and 70 hr under bolus-dose administration conditions reached DE more 
slowly under infusion administration conditions.  Uniformly lower rates of increase in 
Cbrain / Cplasma vs. time were observed, increasing TDE for all compounds.  This effect 
is highlighted in Fig. 4d, where Cbrain / Cplasma profiles are plotted vs. the FTDE value 
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originally calculated under bolus-dose input conditions.  At FTDE = 1 (calculated for 
bolus input conditions), the infused compounds had not yet reached DE.  
Accordingly, P-gp effect,t values were lower (Fig. 4e) and P-gp effect calculation 
error values were higher (Fig. 4f) at each point in the fractional time to DE calculated 
for bolus-administered compounds.  When FTDE values were adjusted for the 
infusion-related increases in TDE, this difference was eliminated (data not shown).  
No effect of administration route was noted on the relationship between long and 
short TDE compounds when normalized for FTDE.   
 
Influence of peripheral pharmacokinetic compartment volume.   
During manipulation of parameter values to construct the requisite parameter 
spaces for each simulation experiment, it was noted that when the peripheral 
compartment volume (Vp) was large, Cbrain / Cplasma vs. time profiles often exhibited 
an unusual shape.  These profiles were characterized by an early peak, followed by 
a decrease with time, rather than consistently increasing to a plateau value, as other 
simulations have reflected and as is generally observed experimentally.  This 
“overshoot” in Cbrain / Cplasma potentially complicates the assessment of P-gp effect.  
Accordingly, another simulation experiment was undertaken, in order to investigate 
the relationship between the shape of the Cbrain / Cplasma vs. time profile and Vp.  
Beginning with the original simulated model P-gp substrate (Vp = 50 mL/kg), 
compounds with lower (Vp = 5) and higher (Vp = 500, 1000) peripheral compartment 
volumes were simulated by changing only the Vp parameter value.  Simulations were 
conducted in the presence and absence of P-gp function in order to investigate the 
influence of Vp on calculated P-gp effect values. 
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Bolus input.  In both the presence and absence of P-gp-mediated efflux, 
increasing Vp resulted in the appearance of an initial peak, followed by a time-
dependent decrease, in Cbrain / Cplasma which was not present with the original model 
compound (Fig. 5a).  Regardless of the value of Vp, all compounds eventually 
reached identical Kp, brain values (1 and 0.056 in the absence and presence of P-gp 
efflux activity, respectively).  As Vp increased from 500 to 1000 mL/kg, the degree of 
overshoot increased.  The relative magnitude of increase (from 1.7- to 2.2-fold the 
Kp, brain value) was identical for compounds simulated with and without P-gp efflux 
activity.  Increasing Vp from 500 to 1000 mL/kg also delayed the time at which the 
overshoot peaked, from 36 to 42 hr in the presence of, and from 42 to 48 hr in the 
absence of, P-gp-mediated efflux activity.  Decreasing Vp to 5 mL/kg resulted in 
Cbrain / Cplasma vs. time profiles that increased consistently to a plateau value, as 
observed when Vp = 50 mL/kg. The decrease in Vp did, however, change the shape 
of the Cbrain / Cplasma vs. time profiles relative to the original model compound, 
producing a slower rate of initial increase in Cbrain / Cplasma vs. time.  In all cases, 
initial rates of increase in Cbrain / Cplasma were higher as Vp increased.   A more 
complex relationship was observed between TDE and Vp.  In the presence of P-gp-
mediated efflux, as Vp increased from 5 to 50 mL/kg, TDE decreased from 48 to 30 
hr.  However, as Vp increased to 500 and 1000 mL/kg, TDE increased from 96 to 
108 hr.  The same trends were evident for compounds simulated in the absence of 
P-gp efflux.  The relationship between increased PSe and decreased TDE was 
preserved; all compounds reached DE more rapidly in the presence vs. the absence 
of P-gp efflux.   
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As Vp increased from 5 to 50 mL/kg, the effect on the P-gp effect vs. time 
profile was negligible (Fig. 5b).  However, as the Vp term increased to 500 and 1000 
mL/kg, P-gp effect,t increased above the original 18-fold P-gp effect,DE, to maximum 
values of 22 and 25. The size of the Vp term had no effect on the value of P-gp 
effect,DE, as all compounds eventually reached a P-gp effect,DE of 18.   
As compounds with Vp ≥ 500 mL/kg reached, exceeded, and then returned to 
their P-gp effect,DE values, the P-gp effect prediction error vs. time profile differed 
from other simulated compounds by including regions of under- and over-prediction 
of P-gp effect,DE (Fig. 5c).  For all compounds, the percentage of error remained 
maximal at the earliest simulated time points.  Compounds with Vp ≤ 50 mL/kg 
evidenced consistent decreases in underprediction error with time until reaching 
zero percent error.  However, compounds with Vp ≥ 500 mL/kg had prediction errors 
that diminished rapidly to zero underprediction error, then proceeded to evidence 
overprediction error, peaking at 18 and 36% overprediction of P-gp effect,DE before 
returning to zero error.   
Infusion input.  Under conditions of infusion input, none of the simulated 
compounds evidenced overshoot in the Cbrain / Cplasma vs. time profile (Fig. 5d).  As 
with bolus-dose administration, however, increases in peripheral compartment depth 
were associated with higher initial rates of increase in Cbrain / Cplasma vs. time.  Also 
consistent with bolus-administered compounds, a linear relationship between TDE 
and Vp was not observed.  However, the U-shaped relationship (longer, then shorter, 
TDE as Vp increased) observed under bolus administration conditions was reversed 
under infusion administration conditions.  Increasing Vp from 5 to 50 mL/kg 
increased TDE (240 to 264 hr, in the presence of P-gp efflux), while increasing Vp to 
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500 and 1000 mL/kg decreased TDE (to 192 and 96 hr, in the presence of P-gp 
efflux).  These trends were identical for compounds simulated in the absence of P-
gp efflux; however, all compounds reached DE more slowly, associated with the 
uniform increase in PSe.   
As no overshoot in Cbrain / Cplasma vs. time profiles was observed under 
infusion conditions, P-gp effect vs. time profiles approached but did not exceed their 
P-gp effect,DE values (Fig. 5e).  P-gp effect vs. time profiles were similar for all 
simulated compounds, particularly at the earliest and latest simulated time points. 
Vp- related differences in P-gp effect,t peaked around 100 hr, with a maximum of 
approximately 6% difference between compounds with the lowest and highest P-gp 
effect,t values at this point.   
P-gp effect prediction error consistently decreased with time under all 
simulation conditions (Fig. 5f).  Thus, although the fold-difference in percent error 
was highest at approximately 190 hr, with 2.9-fold differences between compounds 
with the lowest and highest % error at this point (Vp = 1000 mL/kg and Vp = 5 mL/kg, 
respectively), the absolute difference in percent error between compounds was 
higher at earlier points.  This absolute difference peaked at approximately 96 hr with 
6.7% vs. 12% error for compounds with Vp = 5 vs. 1000 mL/kg, respectively.   
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DISCUSSION 
 
The present series of simulation experiments was undertaken in order to 
investigate the relationship between sampling time prior to DE and the accuracy of 
P-gp effect estimation.  By simulating the behavior of a simple system composed of 
blood, brain, a barrier function, and a peripheral tissue space, this study sought to 
elucidate general principles relevant to understanding the kinetics of substrate 
distribution into brain.  These experiments examined the potential impact of several 
factors upon the relationship between sampling time and accuracy of P-gp effect 
determination, including administration route, magnitude of P-gp effect, rate of 
attainment of DE, and the depth of a peripheral distributional compartment.   
Relationship between FTDE and P-gp effect,t.  Using a paclitaxel-like 
hypothetical model compound, simulations demonstrated that the rate of change in 
Cbrain / Cplasma was most rapid at initial time points.  Thus, the magnitude of difference 
between compounds with and without P-gp-mediated efflux changed most rapidly at 
early time points as well.  Although the rate of change in P-gp effect vs. time would 
be expected to diminish as DE is approached, it is not necessarily obvious that the 
earliest time points would exhibit the greatest rates of change.  It has been 
suggested that substrate concentrations in the brain may constitute the driving force 
for P-gp-mediated transport. Thus, substrates may require time to accumulate inside 
the brain before the effects of efflux transport will be apparent.  The model used in 
the present study specified brain endothelial cell concentrations as the driving force 
for efflux transport.  As endothelial cell volume is orders of magnitude smaller than 
brain volume, concentrations in endothelial cells, and thus P-gp mediated transport, 
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were nearly instantaneously attained.  The present model accurately reflected 
values calculated in this laboratory (Chapter 5) for paclitaxel P-gp effect in P-gp-
competent vs. P-gp–deficient mice at DE (72 hr, following twice-daily i.v. 
administration) and at 60 seconds post-dose (following in situ brain perfusion).   
Due to the rapid rates of increase in Cbrain / Cplasma and P-gp effect at early 
time points, it was demonstrated that calculation of P-gp effect was possible with 
reasonable accuracy relatively early in the net distributional phase.  Calculated error 
in P-gp effect determination dropped below 20% by 30 hr (< 0.5 TDE) after bolus-
dose administration, and by 70 hr with infusion administration.  Although the 
relationship between FTDE and P-gp effectt was demonstrated for a single 
hypothetical model compound, subsequent simulations were undertaken to 
determine how other factors might impinge upon this relationship.  As a substantial 
influence of administration modality was identified, subsequent simulations were 
conducted using models of both administration routes. 
Mode of administration.  The selection of a particular administration 
modality often is based upon factors such as solubility limitations, convenience, or 
replicating the relevant clinical route of administration.  There are, however, 
fundamental differences between the pharmacokinetics of systems with different 
modes of input.  The two administration modes compared in this study were an 
intravascular bolus dose and a continuous, constant-rate infusion.  The major 
difference between these administration modes is that in the former, administration 
is instantaneous.  Essentially, the entire concentration-time profile reflects 
distribution and elimination behavior.  The latter involves constant input; thus, the 
profile reflects a continuous balance of input into and output from the system.  
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During preliminary experiments to establish a parameter space for the 
hypothetical model compound, it was noted that the experimentally-determined 
paclitaxel Kp, brain values could be simulated using the bolus-dose administration 
model, but not the infusion administration model.  Fundamental differences between 
distributional kinetics under constant-rate infusion vs. instantaneous bolus injection 
have been addressed mathematically in studies by Gibaldi and others [5,9], where it 
is noted that Kp, brain is generally lower under infusion vs. bolus injection conditions.   
A brief simulation experiment revealed that when all aspects of the model 
structure and all parameters were held constant, the maximum Kp, brain value that 
could be simulated under infusion input conditions was 1, while it was possible to 
achieve Kp, brain values substantially larger or smaller than unity with bolus input (Fig. 
6a, b).   
Examination of concentration vs. time relationships in each compartment 
reveals that under bolus-dose administration conditions (Fig 6c), the entire substrate 
mass exists initially in the plasma compartment, constituting a significant driving 
force for the movement of mass into all other tissue compartments.  As plasma 
concentrations decline via clearance from the central compartment, some substrate 
is retained in the peripheral and brain compartments as the rate of clearance from 
plasma exceeds the rate of re-input from these peripheral compartments into 
plasma.  In particular, the extremely small volume (and thus, driving force mass) of 
the endothelial cell compartment contributes to the relatively longer retention of 
substrate in brain vs. plasma.   
Under infusion conditions (Fig. 6d), concentrations simply increase to the 
same steady-state value in each compartment, as is true in the absence of factors 
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such as protein binding, active transport, and metabolism.  Upon cessation of the 
infusion (data not shown), concentrations change in a manner similar to that under 
bolus administration conditions, and the Kp, brain value exceeds unity.  Thus, the 
continuous infusion input into the system appears to mask the distributional behavior 
responsible for retention of substrate in brain under bolus administration conditions.   
In terms of relevance to evaluation of P-gp effect, the fundamental difference 
between bolus-dose and infusion regimes is that under infusion conditions, while an 
identical P-gp effect is eventually achieved under both input conditions, all simulated 
compounds reached DE more slowly (increased TDE).  The practical conclusion is 
that experimentation involving infusion vs. bolus-dose administration will necessitate 
longer sampling times in order to determine P-gp with the same degree of accuracy.   
Magnitude of P-gp effect.  In order to determine whether the magnitude of 
the P-gp effect influences the relationship between sampling time and error in P-gp 
effect calculation, a single hypothetical compound with no efflux activity (PSe = 0) 
was simulated.  By manipulating only the PSe value, compounds with 3-, 18- and 60-
fold P-gp effects were simulated for comparison of Kp, brain, P-gp effect, and the 
resulting error vs. time relationships.  In each case, as with the original hypothetical 
model compound, the resulting error was greatest at early points, decreasing rapidly 
over the first several minutes, then slowly approaching zero.  Whike the trend was 
similar for all three compounds, a modest influence of P-gp effect magnitude was 
observed, with the 3-fold P-gp effect compound exhibiting the lowest error vs. time.  
Although the simulation study was intended to assess hypothetical 
compounds with different P-gp effects and equivalent TDE, it was noted that in the 
absence of P-gp function (per the model compound definition) DE was attained at 70 
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hr, but as PSe increased, TDE decreased such that the compound with the greatest 
P-gp efflux reached DE at 45 hr.  The degree of P-gp effect calculation error reflects 
the time-dependent discrepancy in the rate of approach to DE between systems with 
P-gp efflux present vs. absent.  Thus, when PSe is greatest, this discrepancy results 
in the greatest degree of P-gp effect calculation error.   
One implication of these results is that the study of compounds with large P-
gp effects necessitates sampling at time points closer to DE to maintain a low level 
of P-gp effect calculation error.  Similarly, when using an experimental model system 
with incomplete inhibition of efflux function (e.g., chemical inhibitors vs. genetic 
knockouts), the discrepancy in the rate of DE attainment between efflux-competent 
vs. efflux–inhibited systems will be minimized, and the time-related P-gp effect 
calculation error will be smaller.   
Notably, differences in the time course of P-gp effect calculation error due to 
the magnitude of P-gp effect were modest.  As the system appears most sensitive to 
changes in P-gp effect magnitude at the low end of the P-gp effect spectrum, 
compounds with vanishingly small P-gp effects would evidence the largest P-gp 
effect calculation error.  However, as a 3-fold P-gp effect (the lowest simulated in 
this study) is likely to have only modest biological significance, it is reasonable to 
assume that the majority of compounds of interest would fall within the error range 
simulated in this study.  In a practical sense, relative to the experimental error 
associated with determination of the Cbrain / Cplasma ratio when PSe is large (i.e., a 
small absolute difference in brain vs. plasma concentrations), the time-dependent 
calculation error is likely to be functionally unimportant.    
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Time to distribution equilibrium.  A major question in this study was 
whether fundamental differences in the P-gp effect vs. time relationship exist 
between compounds with different intrinsic TDE.  If no differences exist, it should be 
possible to predict the time-dependent calculation error for all compounds based 
upon expression of time as a fraction of the time required to attain DE.  Compounds 
with TDE values of 2 minutes through 70 hr indeed collapsed to identical Cbrain / 
Cplasma vs. FTDE profiles. The results of this simulation study suggest that if TDE is 
known, it is possible to predict P-gp effect calculation error at any point in time, 
avoiding the need to manipulate an experimental paradigm to allow for sampling 
through DE.  Of note, it would be necessary to calculate TDE independently under 
conditions of bolus-dose and infusion administration.  As infusion administration 
resulted in uniformly longer TDE in all simulated conditions, separate P-gp effect 
calculation error vs. time relationships must be determined for each administration 
modality.  
 
Apparent volume of a peripheral distributional compartment.  The 
relationships between peripheral distribution volume and the shape of the 
relationships between Cbrain / Cplasma or P-gp effect and time were unexpected, with 
regions of substantial deviation from, rather than a consistent increase to, the 
plateau values for each relationship.  These relationships were probed by simulating 
hypothetical compounds which were identical except for Vp, and comparing the 
impact on the Cbrain / Cplasma, P-gp effect and calculational error vs. time 
relationships.   
When the peripheral distribution volume was less than approximately 50 
mL/kg, the Cbrain / Cplasma profiles approached their equilibrium values monotonically 
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with time, as observed in other simulations.  However, at a Vp of 500 mL/kg or 
greater, Cbrain / Cplasma values substantially exceeded, then returned to, Kp, brain 
values.  Accordingly, an overshoot also was observed in the P-gp effect vs. time 
profile, and a time-dependent region of over-prediction error also was identified.  
Although the overall prediction error was greatest at early time points, the fluctuation 
between positive and negative prediction error along the error vs. time profile 
complicates the ability to predict the true P-gp effect based on values calculated 
prior to DE, particularly when experimental error is introduced into the system.  In 
addition, this overshoot phenomenon potentially complicates determination of Kp, brain 
and TDE values, since it is generally assumed that the observation of a maximum 
Cbrain / Cplasma value reflects the attainment of DE, and thus reflects the true Kp, brain 
value.  In cases when Cbrain / Cplasma values are not determined through the declining 
phase of the overshoot, estimations of Kp, brain, TDE, and the P-gp effect would be 
erroneous, substantially overpredicting P-gp effect. 
Although uncommon, this overshoot phenomenon has occasionally been 
observed experimentally.  For example, the brain partitioning vs. time profile for the 
antiepileptic compound valproic acid (VPA) has been consistently reported to 
evidence a decline with time, rather than a monotonic increase to a plateau value.  
This trend in VPA brain partitioning has been observed in several species, under 
conditions of bolus-dose, but not infusion administration, consistent with the input 
mode-dependent overshoot simulated in this study [1].  Although various ideas have 
been offered to explain the unusual decline in the VPA Cbrain / Cplasma  vs. time profile 
[10,13], it is noteworthy that VPA evidences a large peripheral distribution volume, 
due to sequestration of VPA in an enterohepatic cycling “loop” [21].  This 
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sequestration of VPA as a metabolite, prior to enzymatic re-release in the gut and 
re-absorption of parent into blood, functions as a deep peripheral pharmacokinetic 
compartment.  Further simulations and experimental evaluation would be required to 
determine whether the VPA brain partitioning vs. time profile is consistent with the 
behavior of the simulated system in the current study. 
Notably, no overshoot was observed in association with a large simulated Vp 
under infusion administration conditions.  In light of the apparent masking of 
distributional behavior via continuous input of mass into the system, discussed 
above and illustrated in Fig. 6, it would be reasonable to hypothesize that the large 
peripheral compartment interferes with the distributional behavior of the substrate 
between brain and plasma, and that the constant substrate input under infusion 
conditions masks this effect of a large Vp.   
 Conclusions. Attainment of blood-brain distribution equilibrium (DE) prior to 
collection of blood and brain tissue samples is assumed to be requisite for accurate 
calculation of the effect of efflux transporters such as P-gp at the BBB.  However, 
this simulation study demonstrated that even in relatively uncomplicated systems, 
although it is possible to calculate a P-gp effect prior to DE, blood-brain distribution 
behavior in the presence of efflux transport is not straightforward.  Factors such as 
administration mode and peripheral distribution volume influence the kinetics of brain 
partitioning, and thus accuracy in calculation of the P-gp effect.   
A large and complex body of work has been dedicated to explaining and 
integrating the effects of transporters, protein binding, ionization, CSF bulk flow, 
diffusion, metabolism, and other factors on the rate and extent of drug exposure to 
the brain.  Although evaluating and understanding brain exposure is complicated, 
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simulation of basic relationships between components of this system can inform 
appropriate study design and aid in the interpretation of experimental results. 
Prospective confirmation of these simulation results are required to generate robust 
recommendations for experimental design directed towards assessing the influence 
of efflux transport on the kinetics of brain uptake.  
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METHODS 
 
Definitions.   Brain-to-blood distribution equilibrium (DE) was defined as the 
point at which the ratio of brain to plasma concentrations (Cbrain / Cplasma) became 
constant (to three significant figures) over the remainder of the simulated time 
domain.  Kp,brain, an index of the extent of brain exposure under therapeutically-
relevant conditions, was defined as the ratio of Cbrain / Cplasma calculated at DE.  The 
term Cbrain / Cplasma,t  refers to the brain-to-plasma concentration ratio calculated at 
any point in time prior to DE.  The amount of time required to attain brain-to-blood 
distribution equilibrium (TDE; an index of the rate of brain exposure) was defined as 
the first simulated time point (to the nearest hour) at which the ratio of Cbrain / Cplasma,t 
reached 95% of the Kp,brain value.  The term P-gp effect,DE, an index of the capacity 
of this barrier protein to attenuate brain exposure under therapeutically relevant 
conditions (i.e., at DE), was defined as the ratio of Kp,brain in the absence / presence 
of P-gp-mediated flux. The term P-gp effect,t denotes the apparent ability of P-gp to 
attenuate brain exposure when calculated prior to DE (as the ratio of Cbrain / Cplasma,t  
in the absence / presence of P-gp-mediated flux). The degree of error associated 
with determination of a P-gp effect at points prior to attainment of DE (P-gp effect,t) 
relative to the therapeutically-relevant value calculated at DE (P-gp effect,DE) was 
expressed as (1-(P-gpEt / P-gpEDE)) * 100.  
Model compound.  In order to construct a parameter space from which to 
initiate the simulation experiments, the above-defined values were determined for a 
model P-gp substrate, paclitaxel, based upon the time course of brain to plasma 
concentration ratios calculated following i.v. bolus administration of paclitaxel (as the 
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clinical formulation, Taxol) every 12 hr to P-gp-competent (mdr1a +/+) and P-gp-
deficient (mdr1a -/-) mice.  These data revealed that Kp,brain (+/+) = 4.5; Kp,brain (-/-) = 82; 
TDE = 70 hr; P-gp effect,DE = 18 (CHAPTER 5).   
 Model structure.  The schemes presented in Fig. 1 depict the systems used 
to evaluate the relationships between observed P-gp effect and sampling time prior 
to DE.  These schemes were developed based upon a published 3-compartment 
model for efflux transport at the BBB [16].  In this system, passive permeability, 
represented with bidirectional first-order rate constants, was indicated to exist 
between blood and brain endothelium (PSa), and between brain endothelium and 
brain (PSb).  Consistent with the localization of P-gp at the luminal surface of brain 
endothelial cells, P-gp-mediated attenuation of apical-to-basolateral flux was 
represented as a unidirectional first-order rate constant from endothelium to blood 
(PSe).  Clearance from the system was assumed to occur from the central 
compartment only, depicted by a unidirectional first-order process (CL).  In order to 
improve the ability to simulate Kp, brain, TDE, and P-gp effect,DE observed for the P-gp 
substrate paclitaxel, the model was adapted to include a peripheral tissue 
compartment with a bidirectional first-order process representing passive 
permeability between the peripheral and blood compartments (the distributional 
clearance CLd).  Either i.v. bolus (Model I) or infusion (Model II) inputs were 
incorporated in order to evaluate the relationships of interest under conditions 
relevant to a range of experimental paradigms.   
 Parameter selection. Simulations were performed using WinNonlin 5.0.1 
(Pharsight).  A initial parameter space was established (using model 1), to simulate 
an 18-fold P-gp effect,DE and a TDE of 70 hr, such that in the absence of active 
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transport (PSe=0), Kp, brain = 1 at DE.  This Kp, brain value was selected in order to 
evaluate fundamental system behavior in the absence of complicating factors such 
as protein binding, metabolism, and additional active uptake or efflux mechanisms. 
Distribution volumes for unbound drug in plasma (Vc), endothelial cells (Vec) and 
brain (Vbr) were fixed based upon physiologic values in the mouse (50, 0.014, and 
14 mL/kg, respectively) [4,23].  Compounds differing in magnitude of P-gp effect,DE 
or differing in terms of peripheral compartment distribution kinetics were simulated 
by perturbing PSe or Vp, respectively.  Compounds with identical P-gp effect,DE 
values, but differing in TDE, were simulated by perturbing CL, CLd, PSa, PSb and  
PSe.   
In all cases, system behavior under infusion input conditions was evaluated 
using the set of parameter values determined for the bolus input model (rather than 
re-establishing a parameter space for each infusion input condition), in order to more 
directly compare the influence of mode of administration.  Accordingly, although 
Kp,brain values were identical between the two types of simulations, TDE was not 
necessarily the same.   
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Figure 1. 
Structural representation of the models, differing in administration mode, used in 
simulation experiments.  Vc, Vp, Vec, and Vbr refer to apparent volumes of the central, 
peripheral, endothelial cell, and brain compartments, respectively. PSa and PSb are 
the permeability-surface area products for passive diffusion between compartments. 
PSe is the apparent permeability-surface area product associated with efflux from 
the endothelial cell compartment. CL is the systemic clearance, and CLd is the inter-
compartmental distributional clearance between the central and peripheral 
compartments.   
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Figure 2. 
Simulated Cbrain / Cplasma (a,d), calculated P-gp effect (b,e) and % P-gp effect 
prediction error (c,f) vs. sampling time following i.v. bolus (a-c) or infusion (d-f) 
administration.   Lines represent compounds simulated in the absence (dashed) and 
presence (solid) of P-gp efflux activity.  Parameter values:  Vp=50; CL=0.1; CLd=3.9; 
PSa=1; PSb=1.   PSe = 0 in absence of P-gp activity and 17.8 in the presence of P-gp 
activity. 
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Figure 3. 
Simulated Cbrain / Cplasma (a,d), calculated P-gp effect (b,e), and % P-gp effect 
prediction error (c,f) vs. sampling time following i.v. bolus (a-c) or infusion (d-f) 
administration.   Lines represent compounds with 0- (dashed), 3- (gray), 18- (blue), 
or 60-fold (black) P-gp effects.  Parameter values:  Vp=50; CL=0.1; CLd=3.9; PSa=1; 
PSb=1.   PSe = 0, 2.1, 17.8, 62 for compounds with simulated 0, 3, 18, and 60-fold P-
gp effects, respectively. 
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Figure 4. 
Simulated Cbrain / Cplasma (a,d), calculated P-gp effect (b,e), and % P-gp effect 
prediction error (c,f) vs. fractional time to DE (FTDE) following i.v. bolus (a-c) or 
infusion (d-f) administration.   Lines represent compounds with 3-fold P-gp effects, 
which reach DE following i.v. bolus dose at 70 hr (blue), 1.5 hr (gray) or 2 min 
(black).  Dashed lines (a,c) represent B:P ratios simulated in the absence of P-gp-
mediated efflux. Parameter values:  70-hr TDE compound: Vd=50; CL=0.1; CLd=3.9; 
PSa=1; PSb=1; PSe=0 or 2.1.  1.5-hr TDE compound: Vd=50; CL=0.1; CLd=100; 
PSa=40; PSb=40; PSe=0 or 85. 2-min TDE compound: Vd=50; CL=0.0016; CLd=1.6; 
PSa=0.55; PSb=0.55; PSe=0 or 1.2.  
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Figure 5. 
Simulated Cbrain / Cplasma (a,d), calculated P-gp effect (b,e), and % P-gp effect 
prediction error (c,f) vs. sampling time following i.v. bolus (a-c) or infusion (d-f) 
administration.  Lines represent compounds with 18-fold P-gp effects, and peripheral 
compartment volumes of 5 (black), 50 (light gray), 500 (blue), or 1000 (dark gray) 
mL/kg.  Dashed lines (a,d) represent B:P ratios simulated in the absence of P-gp-
mediated efflux. Parameter values:  CL=0.1; CLd=3.9; PSa=1; PSb=1; PSe=0 or 17.8.  
Vd = 5, 50, 500 or 1000 mL/kg.   
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Figure 6. 
Simulated Cbrain / Cplasma  vs. time profiles following bolus (a) or infusion (b) input. The 
corresponding mass vs. time relationships are depicted in panels (c) and (d) for 
bolus and infusion input, respectively. 
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BOLUS P-gp Effectt (% error) 
Time 3-fold P-gp EffectDE 18-fold P-gp EffectDE 60-fold P-gp EffectDE 
5 s 1.07 (64.4%) 1.64 (90.9%) 3.53 (94.1%) 
5 min 1.96 (34.7%) 9.16 (49.1%) 29.4 (50.9%) 
12 hr 2.34 (22.0%) 12.4 (31.2%) 40.7 (32.2%) 
72 hr 3.01 (-0.199%) 18.2 (-0.835%) 60.8 (-1.35%) 
INFUSION P-gp Effectt (% error) 
Time 3-fold P-gp EffectDE 18-fold P-gp EffectDE 60-fold P-gp EffectDE 
60 s 1.46 (51.3) 5.17 (71.3%) 15.9 (73.6%) 
60 min 2.05 (31.7%) 9.90 (45.0%) 32.0 (46.7%) 
12 hr 2.21 (26.2%) 11.3 (37.3%) 36.8 (38.6%) 
14 days 3.02 (-0.644%) 18.3 (-0.695%) 60.6 (-1.09%) 
 
Table 1. 
Apparent P-gp effect calculated at different points in time prior to attainment of 
distribution equilibrium after bolus-dose administration or during continuous infusion. 
% error refers to the relative difference between the P-gp effect expressed at any 
point in time t and the actual degree to which P-gp impairs substrate uptake into 
brain. 
CHAPTER 7 
 
 
 
TIME DEPENDENCIES IN THE BRAIN-TO-BLOOD PARTITION COEFFICIENT 
CAN BE INFLUENCED BY THE KINETICS OF SUBSTRATE PARTITIONING 
INTO A PERIPHERAL PHARMACOKINETIC COMPARTMENT 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to Pharmaceutical Research, and is formatted  
in the style of that journal. 
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ABSTRACT  
Purpose.  The development of CNS-targeted agents often focuses on identification 
of compounds with “good” CNS exposure by screening for brain-to-blood partitioning 
exceeding unity.  The partition coefficient, Kp,brain (as Cbrain / Cplasma), should be 
reported at distribution equilibrium.  In some cases, Cbrain / Cplasma may rise above 
and then decrease to a plateau (equilibrium) value, rather than increasing 
monotonically to this value (overshoot phenomenon; OS).  Studies of compounds 
undergoing enterohepatic recycling (ER) suggest that distribution into a peripheral 
pharmacokinetic compartment may underlie this OS phenomenon.  This study 
developed mathematical descriptors of the relationship between substrate 
distribution into a peripheral compartment and changes in the Cbrain / Cplasma vs. time 
profile.  Methods.  Simulations employed a 3-compartment model with distributional 
clearances between central and brain (CLbr) and central and peripheral (CLd) 
compartments, and irreversible clearance from the central compartment (CL).  
Beginning with a default parameter space (physiological rat plasma and brain 
volumes, clearances at 2.5 mL/min/kg), parameter values were varied to investigate 
the relationship between OS behavior and Vp and between OS behavior and 
relevant compartmental parameter values.  OS was quantified in terms of both the 
peak Cbrain / Cplasma value, as a percentage of the plateau value (%OS,plateau), and the 
time at which Cbrain / Cplasma attained its plateau value (time to reach plateau; TRP).  
Results.  Within the default parameter space, increasing peripheral compartment 
volume (Vp) prolonged TRP and increased %OS,plateau (maximum 64%).  Increasing 
brain (Vbr) or central (Vc) volumes of distribution eliminated OS due to large Vp, and 
absolute increases in clearances (0.25 to 25 mL/min/kg) shortened TRP, but did not 
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alter %OS,plateau.  Increasing individual clearances from 0.1 to 10-fold relative to 
other clearance terms increased maximum %OS,plateau from 31 to >700% (CL; CLd), 
and decreased the maximum %OS,plateau from 1630 to 4.82% for CLbr.  Increasing Vp 
increased %OS except for systems with high CLd.  Conclusions.  Cbrain / Cplasma may 
overshoot plateau substantially.  The present study demonstrates that substrate 
distribution into a peripheral compartment can cause OS in Cbrain / Cplasma.  This 
observation suggests potential for erroneous assessment of brain disposition, 
particularly for compounds which undergo ER or otherwise exhibit a large Vp, and 
emphasizes the need for complete understanding of distributional kinetics when 
evaluating brain uptake. 
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INTRODUCTION 
 
Pharmacotherapeutics cannot be effective unless they reach their sites of 
action within the body at a sufficient rate and extent to produce the desired 
pharmacologic effect.  Relatively few effective pharmaceuticals exist for brain and 
central nervous system (CNS) disorders; the majority of CNS diseases are 
essentially refractory to small-molecule drug therapy (4). This is due, in large part, to 
the existence of a network of specialized physical and biochemical features at the 
interface between the systemic circulation and the brain parenchyma, collectively 
termed the blood-brain barrier (BBB), which tightly regulates the passage of 
xenobiotics between these two environments.   
The vast majority of small-molecule therapeutics are not able to penetrate 
through the BBB to reach biologically effective concentrations in the CNS (1). Often, 
this is a useful characteristic, as it limits CNS toxicity associated with agents 
developed to treat non-CNS diseases.  For CNS drug development, however, a 
major goal is identification of compounds which are capable of penetrating the BBB 
to achieve sufficient brain exposure (2).   
The relationships among drug physicochemical properties, brain exposure, 
and efficacy are complicated.  Factors which influence the rate and extent of drug 
exposure in the brain include passive membrane permeability, protein binding, 
ionization, metabolism, active uptake and efflux by protein transporters at the BBB, 
and CSF bulk flow (3).  Factors which influence the relationship between exposure 
and efficacy obviously add another level of complexity to the most important 
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relationship: that between the properties of a drug and its ability to elicit the desired 
pharmacologic response.   
A thorough investigation of the interacting factors that dictate brain exposure 
is not feasible when screening the pharmacokinetic and pharmacodynamic 
properties of large numbers of compounds. The pharmaceutical industry has 
therefore historically based its lead optimization strategy for CNS compounds largely 
upon measurement of the ratio of substrate partitioning between brain tissue and 
blood (2).  Drugs with partition ratios greater than unity are somewhat arbitrarily 
considered to have “good” CNS penetration.  
This ratio, termed the brain-to-blood tissue partition coefficient, Kp, brain, is 
generally calculated as the ratio of the area under the concentration-time curves 
(AUC) in brain vs. plasma (AUCbrain / AUCplasma), or the ratio between concentrations 
in brain vs. blood at a discrete point in time during or following drug administration 
(Cbrain / Cplasma).  The utility of this metric has been debated.  It arguably is somewhat 
simplistic, and in reality compounds that exhibit therapeutic efficacy in brain may 
have Kp, brain values substantially lower than unity (4).  Nevertheless, Kp, brain remains 
common as a fairly straightforward and useful general metric of brain exposure.   
One important factor that can complicate the use of partition coefficients to 
assess brain exposure is the time-dependency of this measurement.  As the entire 
mass of substrate initially exists in the systemic circulation immediately following 
intravenous or intra-arterial administration, the ratio of substrate concentration in 
brain vs. blood increases from zero with time as the substrate equilibrates between 
these two compartments (5).  The point in time at which substrate concentrations in 
brain and blood change in parallel is referred to as brain-to-blood distribution 
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equilibrium (DE).  The degree of brain partitioning at DE represents the partitioning 
under physiologically- and pharmacologically-relevant conditions (i.e., repeated 
administration).  Therefore, Kp, brain is appropriately calculated from brain-to-blood 
concentration ratios when they are measured at DE, or at steady-state, which 
assumes attainment of DE.   
Although very little discussion exists in the literature, it is generally assumed 
that the partition coefficient increases monotonically from time zero through the 
attainment of DE.  A simulation study, which evaluated the relationship between 
sampling time prior to DE and the observed Cbrain / Cplasma ratio in the presence vs. 
absence of BBB efflux transport, indicated that in some cases Cbrain / Cplasma rose to 
an initial peak value, then decreased to a value which remained constant with time 
(Chapter 6).  It was noted that this initial overshoot of the plateau (Kp, brain) value 
occurred when hypothetical compounds were simulated with relatively large 
peripheral volumes of distribution.   
Although this overshoot behavior was observed in mathematical simulations, 
some compounds have been reported to evidence a similar overshoot behavior. One 
relevant example is the branched-chain fatty acid anticonvulsant drug, valproic acid 
(6).  Interestingly, valproic acid (VPA) is known to undergo enterohepatic recycling, 
which confers unique peripheral pharmacokinetics (7). VPA is metabolized to the β-
glucuronide conjugate in the liver, accounting for approximately 50% of the 
metabolic clearance of this drug in rats (8). The glucuronide is excreted in bile, which 
is eventually secreted into the intestine. The conjugate is reconverted to the parent 
compound primarily by bacterial β-glucuronidase (9).  The temporary sequestration 
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of unconjugated VPA within this enterohepatic loop essentially functions as a large 
peripheral pharmacokinetic compartment (7).   
Kp, brain is an important metric used for determining substrate partitioning into 
brain, and the accuracy of this measurement (relative to physiologically-relevant 
conditions) depends upon identification of the plateau Cbrain / Cplasma  ratio.  Thus, the 
existence of a region of overshoot in the Cbrain / Cplasma vs. time profile could 
complicate assessment of brain partitioning, particularly if the peak partition ratio is 
assumed to represent the ratio which would be observed at DE (Kp, brain).  Moreover, 
the existence of this currently unexplained partition coefficient overshoot reveals that 
there are fundamental aspects of brain-to-blood partitioning kinetics which have not 
been appreciated.   
Based upon the relationship, observed in preliminary simulations, between 
substrate partitioning into a peripheral pharmacokinetic compartment and the 
association between overshoot in the VPA Cbrain / Cplasma vs. time profile and a large 
functional peripheral compartment, the present simulation study was undertaken to 
investigate the influence of distribution into a peripheral pharmacokinetic 
compartment on the Kp, brain vs. time profile.  Secondary objectives of this study were 
to develop mathematical descriptors of the shape of the Kp, brain vs. time profile and 
to elucidate the relationship between these and relevant pharmacokinetic 
parameters in a simple simulated system. 
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MATERIALS AND METHODS 
  
 Definitions.  In order to evaluate the effect of peripheral compartment 
distribution on the shape of the Cbrain / Cplasma vs. time profile, it was necessary to 
establish terminology to describe the shape of this profile.  The Cbrain / Cplasma value 
calculated under physiologically-relevant conditions (i.e., at brain-to-blood 
distribution equilibrium) is generally termed Kp, brain.  For the purposes of this study, 
this value was referred to as the “plateau” Cbrain / Cplasma value for a given compound, 
and was defined as the Cbrain / Cplasma ratio that remains constant through the 
remainder of the simulated time domain (up to the point at which numerical solutions 
to the model become unstable as substrate mass in the system approaches zero).  
Overshoot behavior (OS) was defined as a Cbrain / Cplasma value that exceeded 
plateau by >10%.  The degree of overshoot for each simulated compound was 
quantified in terms of both magnitude (as the peak Cbrain / Cplasma value, expressed 
as a percentage of the plateau value; %OS,plateau) and duration.  The duration of the 
overshoot (as time of return to plateau; TRP) is defined as the first time point at 
which the Cbrain / Cplasma value falls to within 10% of the plateau value.   
 
 Pharmacokinetic models.  Fig. 1 illustrates the structure of the 
pharmacokinetic model utilized in this simulation study.  This 3-compartment model, 
representing brain, plasma, and a peripheral compartment, was constructed as the 
simplest system in which to evaluate the influence of distribution into a peripheral 
pharmacokinetic compartment on substrate between brain and plasma.  
Distributional clearances between the systemic circulation (plasma) and brain (CLbr) 
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and between plasma and the peripheral compartment (CLd) were assumed to be 
bidirectional, first-order processes.  Systemic clearance (CL), mediated from the 
central compartment, was assumed to be unidirectional.  In all cases, input was 
modeled as a single i.v. bolus dose at time zero.  The appropriate differential 
equations are presented below. 
Eq. 1  brbrbrbrcbr VCLCCLCdt
dC /)( •−•=  
Eq. 2  pdpdcp VCLCCLCdt
dC
/)*( −•=  
Eq. 3  cbrdpbrbrdpp VCLCLCLCCLCCLCdt
dC
/))(( ++•−•+•=  
 In order to characterize fundamental aspects of system behavior, 
relationships between model parameters and the various descriptive indices (e.g., 
%OS,plateau, TRP) of the brain partitioning vs. time profile were evaluated with 
empirical models (Emax or sigmoidal Emax models, presented below). 
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All simulation and modeling was conducted using WinNonlin 5.0.1 (Pharsight, 
Mountain View, CA).  
Parameter selection.  A default parameter space {P}D was established as 
both a starting point for initiation of simulation experiments and as a template 
against which to compare the effects of parameter manipulation.  This parameter 
space consisted of the three clearance terms, each set at 2.5 mL/min/kg, brain and 
219 
 
plasma volumes fixed at representative physiological values in the rat (15 and 50 
mL/kg, respectively), and a peripheral distribution volume (Vp) of zero.  These 
parameter values were selected such that manipulation of the Vp term upward from 
zero would elicit the appearance of a range of overshoot behavior in the associated 
Cbrain / Cplasma vs. time profiles.  For the purposes of this simulation study, Vp values 
were varied from zero through 50,000 mL/kg. 
Three different parameter spaces (created by manipulating the Vp term within 
{P}D) were selected to produce Cbrain / Cplasma vs. time profiles representative of low, 
intermediate or high degrees of overshoot.  These three representative parameter 
spaces, termed {P}1, {P}2, and {P}3, respectively, were used as starting points for 
evaluation of the effect of manipulating various parameters (other than Vp) on 
overshoot behavior in systems in which the degree of Vp-related overshoot was 
initially low, intermediate, or high.  The effects of each parameter on the shape 
(%OS,plateau, TRP) of the Cbrain / Cplasma vs. time profile were investigated 
independently or in parallel by perturbing each parameter value relative to its default 
({P}D) value.  Brain and plasma volumes were varied up to 50-fold relative to the 
default values.  Perturbation of clearance values was constrained to an upper limit of 
25 mL/min/kg. 
220 
 
RESULTS 
 
Peripheral compartment volume.  In order to evaluate the relationship 
between disposition of a substrate into a peripheral compartment and the shape of 
the Cbrain / Cplasma vs. time profile, an initial simulation experiment was conducted 
with the goals of exploring the range of system responses and informing the design 
of subsequent simulation studies.  Beginning with the default parameter space 
({P}D), the disposition of several different hypothetical compounds was simulated by 
manipulating the Vp parameter alone.  The resulting Cbrain / Cplasma vs. time 
relationships, simulated by altering Vp to 2, 20, 100, 500, 5000, or 50,000 mL/kg 
from {P}D. , are illustrated in Fig. 2a 
Several trends were identified in association with the changes in peripheral 
volume of distribution.  First, plateau values (Kp, brain) clearly were influenced by Vp., 
although to a somewhat modest extent (<33% relative change).  As Vp increased 
from 2 to 20 mL/kg, the plateau Cbrain / Cplasma value decreased from 1.3 to 1.2.  
Further increases in Vp produced progressively smaller decrements in the plateau 
Cbrain / Cplasma value, to a minimum of 0.95 at the largest peripheral compartment 
volume evaluated.  Second, although the rate of the initial rapid increase in Cbrain / 
Cplasma immediately post-dose appeared similar for all compounds, when Vp was 
greater than 20 mL/kg, this early increase in Cbrain / Cplasma persisted for a longer 
period of time, and Cbrain / Cplasma evidenced overshoot relative to plateau.  As Vp 
increased from 100 to 50,000, the maximum observed value of Cbrain / Cplasma 
increased in both absolute and relative (to plateau value) terms, peaking at a Cbrain / 
Cplasma  of 1.7 (64 %OS,plateau).    
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The relationship between overshoot magnitude and Vp is depicted in Fig. 2b.  
A sigmoidal Emax model (Eq. 4) was fit to these data in order to identify fundamental 
parameters descriptive of this relationship (Table 1).  The model fit to the data 
generated an estimate of a theoretical maximum possible %OS,plateau value of 64% 
(Emax), achievable by increasing Vp within {P}D.  The Vp associated with a half-
maximal overshoot (Vp50) was 131 mL/kg.   The gamma value, describing the 
steepness of the sigmoidal relationship, was 1.24.  The coefficients of variation for 
parameter estimates recovered with this empirical model were all below 10%.   
As Vp was the parameter of primary interest in these simulations, this 
%OS,plateau vs. Vp profile, resulting from manipulation of Vp within {P}D, served as a 
template for evaluation of the effects of manipulating other parameters.  The term 
“MPO” was defined as the maximum possible %OS,plateau value achievable by 
perturbing Vp within {P}D (64% %OS,plateau).  Based upon the fit of the Emax model to 
this profile, three parameter spaces ({P}1, {P}2, and {P}3, respectively) were created 
by adjusting Vp within {P}D to create Cbrain / Cplasma vs. time profiles with %OS,plateau 
values which were 10%, 50%, or 90% of MPO (insets, Fig. 2b).  These three 
parameter spaces were used in subsequent simulation studies as starting points for 
examination of the effect of manipulating parameters other than Vp on overshoot 
behavior in systems for which the degree of Vp-related overshoot was initially low, 
intermediate, or high.   
Finally, increasing Vp extended the amount of time required to achieve the 
final plateau Cbrain / Cplasma value (Fig. 2a).  For compounds with Vp smaller than 100 
mL/kg, the plateau Cbrain / Cplasma value was attained earliest, as no overshoot was 
present.  Although compounds with larger Vp values had slightly lower plateau 
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values, the time at which Cbrain / Cplasma returned to within 10% of its plateau value 
(TRP) increased in a log-linear manner with increases in Vp (Fig. 2c).  As the 
compounds with the lowest Vp values evidenced no functionally-defined overshoot 
(<10 %OS,plateau), only four compounds are represented in Fig. 2c.  The Cbrain / 
Cplasma ratio for the compound with the largest Vp (50,000 mL/kg) did not decrease to 
within 10% of its plateau value until approximately 160 hr vs. 45 hr for the compound 
with Vp = 100 mL/kg.  
 
Relative mass in each compartment.  To examine how Vp influences the 
disposition of substrate in brain and plasma, the time course of substrate disposition 
in each compartment was illustrated under conditions of both small and large Vp, 
producing low and high degrees of overshoot, respectively.  The two representative 
parameter spaces were selected (by altering Vp within {P}D, as described above) to 
produce Cbrain / Cplasma vs. time profiles with %OS,plateau values that were 10% and 
90% of MPO ({P}1 and {P}3, respectively).  For {P}1 (Fig 3a) and {P}3 (Fig. 3b), the 
substrate mass in each compartment was plotted vs. time.  Based upon visual 
comparison, it is apparent that manipulation of Vp alters the time course of substrate 
disposition in all three compartments.   
Within the small Vp ({P}1; Fig 3a) parameter space , the mass in the brain and 
peripheral compartments peaked relatively early (approximately 20 hr), with the 
mass in the peripheral compartment remaining lower than in plasma, but higher than 
in brain.  Mass in all three compartments began to fall at a fixed ratio (indicating 
attainment of distribution equilibrium) by approximately 30 hr, and declined at a 
consistent rate in each compartment throughout the remainder of the time domain.   
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Within the large Vp ({P}3; Fig. 3b) parameter space , a larger fraction of the 
system mass accumulated in the peripheral compartment, where it was almost 
completely retained over the illustrated time domain.  Accordingly, mass in the brain 
and plasma compartments declined at a higher initial rate, with the rate of loss from 
plasma exceeding the rate of loss from brain (i.e., producing overshoot in the ratio of 
Cbrain / Cplasma).  At approximately 60 hr, a slowing in the rate of loss of mass from 
brain and plasma was observed, and the system attained distribution equilibrium by 
approximately 125 hr.  At these late time points, mass in all three compartments was 
declining more slowly, relative to conditions observed within {P}1, where Vp was low.   
 
Influence of absolute clearances.  As the previous experiments 
demonstrated a clear influence of Vp on overshoot behavior within {P}D, the following 
simulation studies were conducted to determine whether the influence of Vp could be 
modified by manipulation of compartmental clearances.  The first of these 
simulations evaluated the effect of changing the absolute values of the three 
clearance terms by perturbing CL, CLd and CLbr (in parallel, to retain the relative 
relationship between the terms) 10-fold upward and 10-fold downward from the {P}D 
values of 2.5 mL/min/kg.   
Beginning with {P}D (in which all clearances are 2.5 mL/min/kg), six different 
parameter spaces were established by incorporating Vp values ranging from 2 to 
50,000 mL/kg.  Within each parameter space, Cbrain / Cplasma vs. time profiles were 
simulated, and %OS,plateau and TRP were determined and plotted vs. Vp (Fig. 4a, and 
4b, respectively; gray circles).  As the compounds with the lowest Vp values 
evidenced no functional overshoot, only four compounds are represented in Fig. 4b.  
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Subsequently,  all clearance values were either decreased, at a 1:1:1 ratio, to 2.5 
mL/min/kg or increased to 25 mL/min/kg within each of these six parameter spaces.  
The effect of decreased (open circles) or increased (black circles) absolute 
clearance values on the Vp vs. %OS,plateau and Vp vs. TRP relationships are plotted in 
Fig. 4a and 4b.    
The sigmoidal relationship between %OS,plateau and Vp remained static 
regardless of the absolute clearance values (Fig. 4a).  The relationship between 
TRP and Vp remained log-linear, with increasing Vp associated with increased TRP 
(Fig. 4b).  However, as clearances decreased from 2.5 to 0.25 mL/min/kg, the 
steepness of this relationship increased; at the lowest Vp, TRP increased from 20 to 
450 hr, and at the highest Vp, from 160 to 1400 hr.  Conversely, as clearances 
increased from 2.5 to 25 mL/min/kg, the Vp vs. TRP relationship became less steep, 
with consistent reductions in TRP.  The magnitude of the rate change decreased as 
TRP approached the lower boundaries of the time required to return to plateau value 
for Cbrain / Cplasma.   
 
Influence of relative clearances: varying CL.  In order to investigate the 
ability of changes in relative clearance values to perturb the overshoot vs. Vp 
relationship within {P}D, each of the three clearance terms were manipulated 
independently, relative to the other clearance terms within a given parameter space.   
In the first set of simulations, the rate of clearance out of the system from the 
central compartment, CL, was manipulated relative to CLd and CLbr.  Beginning with 
{P}D (all clearances at 2.5 mL/min/kg), six parameter spaces were established by 
incorporating Vp values of 2, 20, 100, 500, 5,000 or 50,000 mL/kg.  The resulting 
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Cbrain / Cplasma vs. time profiles, identical to those illustrated in Fig. 2a, are presented 
in Fig. 5aii, for comparative purposes.  The CL values in each of the six parameter 
spaces were then decreased 10-fold to 0.25 mL/min/kg or increased 10-fold to 25 
mL/min/kg, while holding the other clearance terms constant.  The resulting profiles 
for Cbrain / Cplasma vs. time are illustrated in Fig. 5ai and 5aiii, respectively.  For each 
set of Cbrain / Cplasma vs. time profiles, %OS,plateau and TRP were calculated, and were 
plotted vs. Vp, (Fig. 5b and 5c, respectively).  White, gray, and black symbols 
indicate values calculated from the Cbrain / Cplasma vs. time profiles in Fig. 5ai, 5aii and 
5aiii, respectively, which were simulated from parameter spaces with CL values of 
0.25, 2.5, and 25 mL/min/kg, respectively.   
As CL increased, %OS,plateau values associated with a given Vp increased.  
The relationship between %OS,plateau and Vp remained consistent, with increasing Vp 
resulting in an increase in %OS,plateau up to a maximum value (Fig. 5b).  An Emax 
model (Eq. 5) best fit all three %OS,plateau vs. Vp profiles.  Model fits are represented 
by lines through each of the three relationships in Fig. 5b.  Based on the model fit, 
the maximum %OS,plateau achievable by increasing Vp (Emax) increased from 31.0 to 
66.2 to 795%, as CL increased from 0.25 to 2.5 to 25 mL/min/kg.  These values, 
along with the predicted volumes associated with half-maximal %OS,plateau values 
(Vp50) are presented in Table 2.   
As apparent in Fig. 5ai through iii, increasing CL relative to other clearance 
terms also changed the plateau values achieved by altering Vp within {P}D.  When 
CL was relatively small, all hypothetical compounds reached nearly identical plateau 
Cbrain / Cplasma values.  When CL was relatively large, the plateau Cbrain / Cplasma 
values ranged from approximately 1.3 through 7.9.  The log-linear relationship 
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between TRP and Vp, within {P}D (Fig. 4b), was altered when CL was modulated 
relative to the other two clearance terms.  Although the Vp-dependent increase in 
TRP was still observed, this relationship became increasingly steep as CL 
decreased relative to other clearance terms (Fig. 5c).    
 
Influence of relative clearances: varying CLd.  A comparable set of 
simulations was performed to examine the impact of varying the distributional 
clearance between the central and peripheral compartments on the overshoot vs. Vp 
relationship within {P}D.  In this second set of simulations, the same six parameter 
spaces, simulated by incorporating Vp values of 2, 20, 100, 500, 5,000 or 50,000 
mL/kg into the default parameter space, were used to generate representative 
profiles for Cbrain / Cplasma vs. time, illustrated again for reference in Fig. 6aii.  The CLd 
values in each of the six parameter spaces were then decreased 10-fold or 
increased 10-fold relative to the other two clearance terms, which were maintained 
at {P}D values.  The Cbrain / Cplasma vs. time profiles resulting from decreasing and 
increasing CLd are illustrated in Fig. 6ai and 6aiii, respectively.  The corresponding 
%OS,plateau and TRP values calculated from each group of profiles are plotted vs. Vp 
in Figures 6b and 6c, respectively.   
As CLd increased from 0.25 to 2.5 to 25, the %OS,plateau associated with low 
Vp values became lower, with a CLd of 25 mL/min/kg ablating the overshoot 
observed with Vp values of 20 and 100 mL/kg Vd.  Interestingly, at high Vp values 
(between 100 and 500 mL/kg) this relationship reversed, with increasingly large 
%OS,plateau values associated with increases in CLd.  These three %OS,plateau vs. Vp 
relationships also were well-fit with an Emax model.  The relevant parameters are 
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presented in Table 2.  Increasing the relative value of CLd increased the maximum 
%OS,plateau achievable by altering Vp (Emax) from 31.5 to 736%.  Although these Emax 
values were similar to those observed with altered CL, the VP50 values differed 
markedly.  When CLd was relatively small, VP50 was 13.6 mL/kg, whereas when CL 
was relatively small, VP50 was 159 mL/kg.  When the CLd and CL terms were 
modulated upward individually, the VP50 values were 110 and 5220 mL/kg, 
respectively.   
Although increasing CL relative to the other clearance terms resulted in 
increasingly different plateau Vp-related Cbrain / Cplasma values, and decreasing the 
term caused all simulated systems to reach the same plateau Cbrain / Cplasma value, 
the opposite relationship was observed when manipulating CLd.  In all cases, 
increasing the relative value of CLd reduced the TRP associated with changes in Vp.  
The positive relationship between Vp and TRP, while apparently log-linear when CLd 
was less than or equal to the other clearance terms, reversed when CLd was 
relatively large, causing a decrease in TRP with increasing Vp.   
 
Influence of relative clearances: varying CLbr.  The third set of simulations 
investigating relative clearance effects involved manipulation of the relative rate of 
the distributional clearance between brain and the central compartment.  These 
simulations were conducted in a manner comparable to those in the preceding two 
experiments.  Figures 7ai and 7aiii depict the Cbrain / Cplasma vs. time relationships 
resulting from manipulation of CLbr 10-fold below (Fig. 7ai), and 10-fold above (Fig. 
7aii) their {P}D values within the six parameter spaces described above.  The original 
relationship, with all clearance terms at equal values, is illustrated again for 
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reference in Fig. 7aii.  %OS,plateau and TRP vs. Vp relationships under each of the 
three relative CLbr conditions are illustrated in Fig. 7b and 7c, respectively.   
The basic relationship between %OS,plateau and Vp was not affected by 
manipulating the relative value of CLbr.  However, at a given Vp, increasing CLbr 
resulted in a decrease, rather than an increase, in %OS,plateau.  Emax model fits to the 
%OS,plateau vs. Vp relationships associated with the three different relative Vbr values 
are illustrated with lines in Fig. 7b.  Emax values at low and high relative CLbr values 
were 1630 and 4.82 %OS,plateau, respectively.  The Vp values associated with half-
maximal overshoots in each condition were 4330 and 29.1 mL/kg, respectively.   
As with increasing the relative value of CLd, increases in the relative value of 
CLbr caused the simulated Cbrain / Cplasma vs. time profiles to reach nearly equal 
plateau Cbrain / Cplasma values.  TRP values remained virtually identical upon 
increasing the relative value of CLbr.  However, decreasing CLbr resulted in minimally 
shorter TRP when Vp was low, and increasingly large lengthening of TRP when Vp 
was 5,000 and larger.  In all cases, increasing Vp remained associated with 
increasing TRP.  
 
Influence of brain and plasma compartment volume.  Manipulation of only 
the Vp term within {P}D allowed an indirect evaluation of the influence of the brain 
and plasma compartment volumes (relative to peripheral compartment volume) on 
the shape of the Cbrain / Cplasma  profile.  The independent influences of the brain and 
plasma compartment volumes on the Cbrain / Cplasma  vs. time profile were assessed 
in the following set of simulations.  As described above, based upon Emax model fit to 
the Vp vs. %OS,plateau relationship within {P}D, (in which a maximum possible 
229 
 
%OS,plateau of 64% could be achieved), three model parameter spaces representing 
low (10% MPO), intermediate (50% MPO), and high (90% MPO) degrees of 
overshoot behavior ({P}1, {P}2, and {P}3, respectively) were created by altering Vp 
within {P}D.  Beginning with these three parameter spaces, values of Vbr or Vc were 
manipulated independently over a 50-fold range, relative to their initial values (15 
and 50 mL/kg, respectively).   
Figure 8a illustrates the relationship between %OS,plateau and Vbr under 
conditions of low (open circles), intermediate (gray circles), and high (black circles) 
degrees of Vp-related overshoot, simulated from {P}1, {P}2, and {P}3, respectively.  
When Vp was low ({P}1), increasing Vbr from the default value of 15 mL/kg by 10-fold 
to 750 mL/kg caused loss of the already low degree of overshoot.  When Vp was 
intermediate ({P}2), increasing Vbr from 15 to 30 mL/kg caused an initial increase in 
%OS,plateau; however, when Vbr increased above 30 mL/kg, a decrease in, followed 
by a complete loss of, overshoot behavior was observed.  When Vp was large ({P}3), 
such that further increases in Vp would have saturated the overshoot magnitude 
within {P}D, increasing Vbr from 15 to 75 mL/kg caused overshoot to increase up to a 
maximum of 107 %OS,plateau, which was higher than the MPO value observed. 
The relationship between overshoot and Vc , evaluated by altering the Vc 
value alone, was investigated beginning with the same three representative 
parameter spaces, {P}1, {P}2, and {P}3 (Figure 8b).  In all cases, increasing Vc 
decreased %OS,plateau.  The relationship between low %OS,plateau and low Vp, and 
high %OS,plateau and high Vp, was preserved; however, when Vc was increased to 
5,000 mL/kg, overshoot was completely ablated, regardless of Vp. 
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DISCUSSION 
 
Summary of study results.  The present study demonstrated the significant 
influence of substrate distribution into a peripheral compartment on the tendency of 
the brain-to-blood partition ratio to substantially overshoot its plateau (equilibrium) 
value.  The relationship between increased Vp and overshoot magnitude was 
capacity-limited; however, the relationship with the duration of the overshoot 
phenomenon was essentially log-linear.  In addition, the relationship between 
%OS,plateau or TDE and Vp was modifiable by perturbing clearances as well as 
apparent distribution volumes of other system compartments.  Overall, this 
simulation effort provides a robust framework from which to evaluate the system 
aspects that might lead to overshoot of the equilibrium value of the tissue-to-blood 
partition coefficient.  Although this effort was predicated on consideration of 
partitioning into brain, the principles developed herein are transferable to any tissue 
space in equilibrium with blood, and are not dependent on the existence of a 
specialized barrier, such as the BBB, between that tissue space and the systemic 
circulation.  This phenomenon will be apparent when a deep peripheral 
pharmacokinetic compartment is present and does not contain the tissue space of 
interest.  As long as the simulated clearance rates between this organ and the 
systemic circulation were within the range of physiological blood flow values, the 
simulation results would be applicable to any such organ.    
 
Implications for brain partitioning behavior.  The influence of peripheral 
compartment depth upon the time-dependent brain partitioning of a substrate has 
231 
 
not, to the author’s knowledge, been commented on previously in the literature.  
Although not specifically stated, a general assumption, borne out by an abundance 
of examples, is that a tissue-to-blood partition coefficient always increases 
monotonically from a value of zero at the time of systemic administration to a plateau 
value reflecting tissue-to-blood distribution equilibrium (5).  The illustration of the 
effect of Vp on substrate mass in each compartment (Fig. 3.) indicates that when Vp 
is very large, the initial rapid uptake of substrate into the peripheral compartment 
persists longer; in addition, the larger peripheral space will retain substrate for a 
longer period of time.  The substantial diversion of substrate into the peripheral 
compartment initially draws substrate out of the central compartment more rapidly 
than out of the brain compartment, resulting in an overshoot of the plateau value for 
Cbrain / Cplasma.  As net uptake into the peripheral compartment crests and this 
compartment begins to slowly re-input mass into the system, the brain and blood 
compartments begin to equilibrate, resulting in the attainment of DE.    
In the absence of appreciation of this relatively simple kinetic explanation for 
overshoot and a time-dependent decrease in the brain-to-blood partition ratio, more 
complicated explanations for this behavior could be proposed (6, 11).  Potential 
alternative explanations for this type of behavior might reasonably include 
concentration-dependent uptake into brain from blood, or the existence of an active 
transport system to rapidly clear substrate out of the brain.  Experimental 
approaches for investigating this behavior could thus be streamlined based upon the 
consideration of the relationships identified by the current simulations.   
One caveat pertaining to the extrapolation of this influence of Vp on tissue 
partitioning behavior is that, as noted in Chapter 6, the appearance of this overshoot 
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is administration mode-dependent.  In a simulated system with overshoot in the 
Cbrain / Cplasma vs. time profile, the appearance of overshoot can be completely 
abolished by manipulating only the mode of input; from an instantaneous bolus, to a 
continuous constant-rate infusion.  It appears, based on the above-referenced 
simulation study, that the continuous input into the system is capable of masking the 
distributional kinetics between brain and blood in the presence of a deep peripheral 
compartment.   
 
Limitations of simulation studies.  The relationship between overshoot and 
Vp has been demonstrated to be relatively robust within the simulated system 
developed here.  In the present study, all system parameters were perturbed, either 
independently or in parallel.  In most cases, the presence of overshoot was fairly 
persistent over at least an order of magnitude for each parameter evaluated.  The 
appearance of overshoot in the Cbrain / Cplasma vs. time profile also was not limited to 
simulated systems with the same model structure; in the study described in Chapter 
6, the simulated system included an additional compartment (endothelial cells 
interfacing the brain and systemic compartments), as well as a unidirectional rate 
constant representing transporter-mediated efflux from endothelial cells to the 
central compartment.  Overshoot was consistently observed in this system when 
peripheral distribution volumes were large, regardless of the presence of efflux 
transport. 
 
Despite the apparent reproducibility of the overshoot effect in simulated 
systems, several limitations of the current simulation study are acknowledged.  First, 
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this study incorporated no uncontrolled error.  Biological variability, experimental 
assay sensitivity, and general experimental error could potentially obscure some of 
the relationships detected.  In particular, the ability to determine the time at which a 
system reaches a plateau Cbrain / Cplasma value would be affected by experimental 
error.  For the purposes of this study, as no variability was present, no statistical 
definition of TDE could be implemented.  For this reason, TDE was functionally 
defined as 10% of the final Cbrain / Cplasma value observed, although the variability in 
experimental measurement would likely exceed 10%.  Secondly, although simulated 
clearance rates were constrained to an upper limit below the cardiac output rate in 
the rat, the range within which parameter values were manipulated in some cases 
spanned several orders of magnitude.  Thus, the range of the parameter values 
simulated in these studies may not reflect conditions which would be commonly 
observed in vivo pharmacokinetic systems.  The evaluation of a wide range of 
parameter values was intended to clarify relationships which might exhibit low 
sensitivity in rate of change relative to another parameter of interest.  Thirdly, the 
simulated system utilized in this study is substantially, although intentionally, 
simplistic.  Protein binding in brain and plasma, physical and biochemical barriers to 
uptake or efflux (e.g., the BBB), metabolism, and other factors would influence the 
distribution of substrate in a physiological system.  This study was intended to 
evaluate overshoot behavior under the simplest relevant conditions for the purposes 
of providing a generalized description of the fundamental behavior of the system, in 
the absence of any other potentially confounding factors.  Based upon 
understanding of the behavior of this simple system, further experiments could be 
designed to probe the additional complexity contributed by each of these factors.    
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Published data supporting simulation conclusions.  Although the current 
study, simulation-related caveats aside, has clearly and consistently demonstrated 
that overshoot can occur in the Cbrain / Cplasma vs. time profile, this phenomenon has 
also been observed experimentally and reported in the literature. The antiepileptic 
agent valproic acid (VPA) has been documented to exhibit an unusual decline in 
brain-to-blood partitioning with time. This pattern of time-dependent decrease in 
partitioning after bolus-dose administration has been observed in a variety of 
preclinical, in vivo experimental systems, including brain-to-blood partitioning in the 
cat (6) and rat (12) and CSF-to-blood partitioning in rats (11). Interestingly, VPA 
undergoes extensive enterohepatic recycling (ER), wherein parent drug, 
metabolized and excreted into bile, is re-converted to parent drug within the intestine 
by intestinal β-glucuronidase and re-absorbed into the systemic circulation.  This 
recycling loop, which retains parent compound prior to re-release into the systemic 
circulation, essentially functions as a large peripheral pharmacokinetic compartment 
(7). A relevant question, in the context of the current simulation study, is whether the 
overshoot in equilibrium brain-to-blood partitioning occurs for VPA simply because 
this compound recycles so extensively.  A corollary question is, if recycling of VPA 
was ablated, would the partitioning overshoot phenomenon disappear?  
As a post-hoc confirmation of the results of this simulation study, a thorough 
literature search on VPA brain partitioning was conducted.  Examples of VPA 
overshoot are provided in Fig. 9 (6) and Fig. 10 (11).  The ability of constant-rate 
infusion administration to abolish this overshoot behavior is also supported by the 
lack of overshoot behavior in studies which utilized continuous infusion 
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administration modes (12).  Thus, this data-mining exercise in the presence of intact 
VPA recycling appears to support the validity of the current series of simulations. 
The relationship between overshoot in the brain-to-blood partition ratio and Vp 
is supported by at least two types of experimental evidence for VPA.  In this 
analysis, the degree of recycling is assumed to correspond with the apparent volume 
of a distributional compartment, as demonstrated previously (7).  First, a study 
conducted by Liu and Pollack (13) evaluated the systemic and brain disposition of 
VPA and two structural analogs, cyclohexanecarboxylic acid (CCA) and 1-methyl-1-
cyclohexanecarboxylic acid (MCCA). These compounds differ in degree of ER: 
VPA>MCCA>>CCA.  The rank order of degree of ER among these compounds 
corresponds to the degree of overshoot behavior (observed as a time-dependent 
decrease in Cbrain / Cplasma) for each compound (Fig. 11).  A second line of evidence 
pertains to the ontological development of ER capacity in the rat.  Young rats, (under 
60 days postpartum), do not to exhibit intact ER (Fig. 12a) (14).  The corresponding 
brain-to-blood partition coefficients (unpublished data) indicate that age-dependent 
appearance of ER behavior corresponds to the age-dependent appearance of 
overshoot in the brain partitioning profile.   
While comparisons of model simulations to historical data provide an 
intriguing level of validation, they fall short of the mark established by prospective 
experimentation. VPA represents an interesting compound with which to evaluate 
the relationship between VP and overshoot, because there are several potential 
approaches to experimentally interrupting ER.  These approaches include 
exteriorization of bile flow through bile duct cannulation (15), inhibition of β-
glucuronidase activity at the level of the gut to prevent re-release of parent VPA (16), 
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orally administered active charcoal to decrease substrate reabsorption from the gut, 
and inhibition of VPA-glucuronide elimination into bile by inhibiting the activity of the 
canalicular efflux transporter Mrp2 (17).  These approaches all represent a means to 
experimentally perturb the apparent volume of a distributional compartment, 
something that would be required for prospective evaluation of this system but 
extraordinarily difficult to achieve with typical distributional behavior. This 
prospective analysis of the system will be the topic of Chapter 8 of this dissertation. 
 
Implications for accurate use of the Kp, brain metric.  In summary, the 
current simulation study emphasizes several caveats relevant to the use of Kp, brain 
as a metric for brain exposure.  Firstly, it suggests that compounds undergoing ER, 
or with otherwise unusually large peripheral distribution volumes, might be subject to 
the appearance of overshoot in the brain-to-blood partition coefficient vs. time 
profiles.  Potentially, extra measures, such as longer sampling time to ensure 
attainment of DE, might be prudent for such compounds.  Secondly, the utility of 
Kp,brain as a metric for relatively high-throughput screening of brain partitioning 
behavior, (e.g., as a part of a pharmaceutical lead optimization strategy) is 
cautioned.  Particularly when sampling time is limited by constraints related to the 
high volume of samples processed, it is important to avoid the assumption that the 
peak Cbrain / Cplasma  value measured necessarily constitutes the true, or 
physiologically-relevant, Kp, brain value.  As illustrated in Fig. 7ai, where CLd is the 
lowest clearance in the system, the peak overshoot value persists for a relatively 
long time before returning to the plateau Kp, brain value.  Assumption that this 
persistent overshoot peak represents Kp, brain would result in the erroneous pursuit of 
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a compound which only appears to partition significantly into the brain.  Lastly, other 
types of experimental observations dependent upon calculation of brain partitioning 
behavior could be impacted by the erroneous assumption of an overshoot phase as 
a plateau value.  As discussed in Chapter 6, evaluation of the influence of barrier 
functions on brain exposure could be impacted significantly by an erroneous 
assumption of brain-to blood DE prior to its true attainment.  Because compounds 
which exhibit efflux activity in the brain-to-blood direction reach DE more rapidly than 
in the absence of efflux, evaluation of the effect of a barrier on brain exposure prior 
to DE could reflect the period of time in which one system has attained DE, while the 
other would still be in flux.  The net result would be an erroneous interpretation of the 
difference between partitioning behavior in the two systems reflecting only the effect 
of a barrier function at the BBB.   
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CONCLUSION.  The current study demonstrates the appearance of overshoot in the 
brain-to-blood partition coefficient vs. time profile.  This unexpected phenomenon 
belies a somewhat complex distributional behavior between an isolated 
pharmacokinetic compartment such as brain and the systemic circulation in the 
presence of a large Vp.  Based upon the data mining experiments described above, 
the relationship between overshoot behavior and Vp demonstrated in the simulated 
system is likely to exist in physiological systems as well.  However, it will be 
necessary to conduct a prospective validation study to evaluate the model 
predictions experimentally.  
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Figure 1. 
Structure of the 3-compartment model used for simulation studies. 
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Figure 2. 
In the default parameter space ({P}D) increasing Vp altered the Cbrain / Cplasma  vs. 
time profile (a).  A sigmoidal Emax model (Eq. 4) was fit (line) to the relationship 
between %OS,plateau and Vp determined within {P}D.  Arrows indicate 10%, 50% and 
90% MPO, as determined by model fit (Vp = 23.4, 140, and 833 mL/kg), and inset 
figures illustrate representative Cbrain / Cplasma profiles at each MPO value listed (b).  
The relationship between Vp and TRP within {P}D appeared log-linear (c). 
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Figure 3. 
Manipulation of Vp altered the time course of substrate disposition in all tissue 
compartments. Simulated mass vs. time data under conditions producing 10% MPO 
(a) or 90% MPO (b), determined by model fit (Table 2) are shown. 
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Figure 4. 
Under the default parameter space ({P}D), the sigmoidal relationship between Vp and 
%OS,plateau was identical regardless of the absolute value of the clearance terms (a).  
Increasing absolute clearance values in a 1:1:1 ratio from 0.25 (open circles) to 2.5 
(grey circles) to 25 (black circles) mL/min/kg altered the relationship between Vp and 
TRP within {P}D (b).   
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Figure 5. 
Within {P}D, altering CL 10-fold below (ai) and 10-fold above (aiii) the default value 
(aii) altered the relationship between Vp and Cbrain / Cplasma.  The resulting 
relationships between Vp and %OS,plateau were sigmoidal (lines represent fit to Emax 
model, Table 3).  As CL increased from 0.1- (open circles) to 1- (grey circles) to 10-
fold (black circles) relative to other clearance terms, maximum %OS,plateau increased 
(b) and TRP became shorter (c). 
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Figure 6. 
Within {P}D, altering CLd 10-fold below (ai) and 10-fold above (aiii) the default value 
(aii) altered the relationship between Vp and Cbrain / Cplasma.  The resulting 
relationships between Vp and %OS,plateau were sigmoidal (lines represent fit to Emax 
model, Table 3).  As CLd increased from 0.1- (open circles) to 1- (grey circles) to 10-
fold (black circles) relative to other clearance terms, maximum %OSplateau increased 
(b), and TRP became shorter (c). 
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Figure 7. 
Within {P}D, altering CLbr 10-fold below (ai) and 10-fold above (aiii) the default value 
(aii) altered the relationship between Vp and Cbrain / Cplasma.  The resulting 
relationships between Vp and %OS,plateau were sigmoidal (lines represent fit to Emax 
model, Table 3).  As CLbr increased from 0.1- (open circles) to 1- (grey circles) to 10-
fold (black circles) relative to other clearance terms, maximum %OSplateau decreased 
(b), and TRP became shorter (c). 
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Figure 8. 
 
Beginning with parameter spaces producing 10% (open circles), 50% (grey circles) 
or 90% (black circles) MPO (as determined by sigmoidal Emax model fit, Table 2), Vbr 
and Vc were increased separately up to 50-fold from the starting values (15 and 50 
mL/kg, respectively).  Increasing Vbr resulted in an initial increase, then a decrease, 
in %OSplateau, with greater initial %OSplateau associated with a rightward shift of this 
relationship (a).  Increasing Vc resulted in decreased OS under all conditions (b). 
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Figure 9. 
VPA data obtained from Hammond et al. (6) demonstrating an initial peak in B:P 
ratio followed by time-dependent decrease over 90 minutes.  Adult cats were 
administered VPA as a 3-minute infusion into inferior vena cava.  Cerebral cortex 
and plasma were collected at 9 time points following cessation of the infusion, and 
VPA concentrations were determined in brain and plasma by gas-liquid 
chromatography.  
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Figure 10. 
Valproic acid (VPA) data obtained from Golden et al. (11), demonstrating an early 
overshoot followed by time-dependent decrease in CSF:serum ratio.  Male rats were 
administered a VPA bolus followed by  infusion, and CSF and serum samples were 
collected via brain microdialysis and jugular vein cannulation.  Serum VPA 
concentrations were converted to estimated unbound concentrations prior to data 
analysis based on separate protein binding experiments. 
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Figure 11. 
Plasma concentration vs. time (a-c) and brain partitioning
 
vs. time (d-f) data obtained 
following i.v. bolus administration to rats, from (13). Compounds are subject to high 
(VPA), moderate (MCCA) or no (CCA) ER, as evidenced by the size of secondary 
peaks in the plasma concentration-time profile (a-c, respectively). OS in the VPA 
and MCCA Kp, brain vs. time profiles (75 mg/kg dose) peaks at approximately 15 
(VPA) and 5 (MCCA) min, with the apparent relative degree of OS (VPA > MCCA > 
CCA) (d-f, respectively) corresponding to the apparent relative degree of ER (VPA > 
MCCA > CCA) (a-c).  
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Figure 12. 
Data adapted from (14) illustrating ontological development of VPA ER capabilities 
in rats (a).  ER, absent in rats at 5 (open circles) and 10 days (open triangles) 
postpartum, begins to develop at 20 days postpartum (closed circles), and is fully 
developed by 60 days postpartum (closed triangles).  Unpublished data from (14), 
showing brain partitioning of VPA in the same rats (b-e).   
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Parameter Emax Vp50 γ 
Estimate 63.7 131 1.24 
Std. Error 1.68 11.3 0.124 
CV (%) 2.64 8.60 9.95 
 
Table 1. 
Parameter estimates, standard error, and % CV associated with the fit of the 
sigmoidal Emax model (Eq. 2) to the data presented in Fig. 5. Vp50 refers to the 
volume, under the specified conditions, associated with a half-maximal degree of 
OS. 
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Table 2. 
%OS vs. Vp profiles presented in Figs. 8, 9 and 10 were fit with an Emax model (Eq. 
3) to obtain fundamental descriptors (Emax; maximum %OS and Vp50; Vp producing 
half-maximal OS) of the relationship between relative clearance rates and maximum 
%OS. Relative value refers to the fold-difference relative to the remaining two 
clearance terms. 
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CL 31.0 
(1.95) 
159 
(40.7) 
795 
(40.2) 
110 
(23.9) 
CLbr 1630 (25.1) 
4330 
(259) 
4.82 
(0.0978) 
29.1 
(3.67) 
CLd  31.5 (1.25) 
13.6 
(3.82) 
66.2 
(2.49) 
154 
(29.9) 
736 
(9.96) 
5220 
(264) 
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INFLUENCE OF ENTEROHEPATIC RECYCLING ON THE TIME COURSE OF 
BRAIN-TO-BLOOD PARTITIONING OF VALPROIC ACID IN RATS 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to the Journal of Pharmacology and Experimental 
Therapeutics, and is written in the style of that journal 
256 
 
ABSTRACT  
A widely-used metric of brain exposure to a substrate is the brain-to-blood partition 
coefficient (Kp, brain), as Cbrain / Cserum reported at brain-to-blood distribution 
equilibrium.  In some cases, Cbrain / Cserum can peak and then decrease with time (as 
opposed to monotonically increasing to a plateau), precluding an accurate 
estimation of brain distribution.  This overshoot in the brain partitioning vs. time 
profile has been observed in studies of compounds which undergo enterohepatic 
recycling (ER) such as valproic acid (VPA).  Simulation experiments have identified 
a relationship between the extent of distribution into a peripheral pharmacokinetic 
compartment (e.g., an ER compartment) and the degree and duration of overshoot 
in the Kp, brain vs. time profile.  The present study was conducted to explore, via 
prospective experimentation, model predictions of a relationship between overshoot 
in the brain partitioning vs. time profile and peripheral distribution volume.  Initial 
experiments evaluated the ability of activated charcoal, antibiotics, and Mrp2 
transporter deficiency to impair VPA ER in rats.  Mrp2 deficiency (significantly) and 
antibiotic treatment (moderately) interrupted VPA ER.  Subsequent evaluation of 
brain partitioning in the presence vs. the absence of these two ER-interrupting 
manipulations revealed that overshoot (as a time-dependent decrease in brain 
partitioning) was significantly truncated by ER interruption.  In separate experiments, 
ER-interrupting treatments were determined not to substantially affect steady-state 
Kp,brain, or brain permeability to VPA.  These data indicate that Kp, brain may overshoot 
plateau values substantially and in relation to degree of peripheral compartment 
distribution.  Consideration of this information, particularly for compounds which 
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undergo significant ER, may be necessary in order to avoid erroneous estimation of 
brain distribution.  
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INTRODUCTION  
 
A commonly-used metric for brain exposure to a substrate is the brain-to-
blood partition coefficient, Kp, brain (Summerfield et al., 2007).  Accurate determination 
of brain exposure is imperative for both CNS-targeted therapeutics, for which 
extensive brain exposure is desirable, and for non-CNS-targeted compounds or non-
therapeutic xenobiotics, for which significant CNS exposure could result in 
undesirable neurotoxicity.  The blood-brain barrier (BBB), a network of physical and 
biochemical barriers between the brain and systemic circulation, effectively 
attenuates the penetration of a vast majority of compounds, both toxic and 
therapeutic, into the central nervous system (CNS).  Consequently, the rate and 
extent of brain exposure to a given chemical is not easily predicted based simply 
upon physicochemical properties (Hammarlund-Udenaes et al., 1997; Liu et al., 
2005).  For these reasons, experimental determination of Kp, brain is of particular 
importance. 
Kp, brain, which reflects the net influence of a number of different factors upon 
the extent of brain exposure, often is screened in the context of lead development 
for CNS drug discovery programs (Raub, 2006).  Compounds with a brain partition 
ratio exceeding unity are, somewhat arbitrarily, considered to exhibit “good” CNS 
exposure (Kalvass and Pollack, 2007).  Brain partitioning is a time-dependent 
process; Kp, brain at the time of systemic administration is zero and increases until a 
state of distributional equilibrium (DE) between brain and blood is attained (Gibaldi, 
1969). Kp, brain generally is calculated at a point in time when the concentration ratio 
has become stable (DE).  This approach limits the variability associated with 
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determination of Kp, brain because it occurs under conditions of no net flux, and also 
reflects therapeutically-relevant partitioning behavior, as would be observed under a 
chronic administration schedule.  This ratio may be appropriately calculated as the 
ratio of areas under the concentration-time curve (AUC) in brain / serum, or as the 
tissue concentration ratio (Cbrain / Cserum) at DE or at steady state (Lin et al., 1982).   
The Cbrain / Cserum ratio generally is assumed to increase monotonically with 
time to a plateau value at DE.  A recent study, described in Chapter 7, demonstrated 
via mathematical simulation that this behavior is not universal.  In fact, distribution 
into a deep peripheral pharmacokinetic compartment can impact the distributive 
behavior between brain and the systemic circulation, resulting in a period of time 
during which Cbrain / Cserum values may significantly overshoot the eventual plateau 
value (Kp, brain).  This overshoot phenomenon also has been reported in the literature; 
valproic acid (VPA), an antiepileptic compound, shows a rapid peak in Cbrain / Cserum, 
which decreases with time (Hammond et al., 1982; Golden et al., 1993; Liu and 
Pollack, 1994). 
The relationship, identified in simulation studies in Chapter 7, between 
overshoot and substantial distribution into a peripheral compartment is consistent 
with the overshoot observed in VPA brain partitioning.  VPA undergoes significant 
enterohepatic recycling (ER). The acyl glucuronide metabolite of VPA, excreted via 
the bile into the intestinal tract, is hydrolyzed back to the parent by β-glucuroinidase 
in the gut, and the liberated VPA can be reabsorbed into the systemic circulation.  
This ER loop, which relies on the reversible metabolism of VPA to the glucuronide 
conjugate, essentially functions as a large peripheral pharmacokinetic compartment 
(Pollack and Brouwer, 1991).   
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At least two lines of evidence supporting the relationship between overshoot 
in the VPA brain partitioning profile and ER weredentified in the published literature.  
First, in a study of VPA and two analog compounds, cyclohexanecarboxylic acid 
(CCA) and 1-methyl-1-cyclohexanecarboxylic acid (MCCA), which differ in terms of 
their degree of ER, the rank order of the degree of ER corresponds with the rank 
order of degree of overshoot in the brain partitioning profile (Liu and Pollack, 1993).  
This suggests that ER is quantitatively important in the overshoot phenomenon. The 
second line of evidence concerns the ontological development of ER capabilities, 
which do not appear until at least 60 days of postnatal age in Sprague-Dawley (S-D) 
rats (Haberer and Pollack, 1994).  Corresponding unpublished data from these 
studies indicate that the appearance of ER during rat postnatal development 
corresponds to the appearance of overshoot in the VPA brain partitioning profile at 
the same developmental stage.   
The simulations studies discussed in Chapter 7, as well as multiple lines of 
post-hoc evidence from the literature, support the hypothesis that overshoot in a 
brain partitioning profile results from extensive peripheral distribution.  However, this 
hypothesis has not been experimentally validated.  VPA presents a particularly 
interesting model compound for the study of overshoot behavior, by virtue of the 
significant peripheral compartment arising from ER.  Several methods for 
interrupting the ER process, and thus manipulating the size of the peripheral 
distributional compartment, are known.  One approach to interrupting ER is the 
inhibition of excretion of VPA-glucuronide metabolite from the liver into the intestinal 
tract.  This can be accomplished either by inhibition of the efflux transporter, Mrp2 
(Wright and Dickinson, 2004), or by exteriorization of the common bile duct flow .  A 
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second method involves abolishing liberation of VPA from the glucuronide conjugate 
in the GI tract by killing the gut flora which furnish the β-glucuronidase required for 
conjugate hydrolysis (Gott and Griffiths, 1987; Takasuna et al., 1996).  A third 
method involves binding of the liberated parent VPA in the gut with orally-
administered activated charcoal to prevent reabsorption of VPA into blood via the 
portal circulation (Neuvonen et al., 1983). 
The objective of the current study was to test the hypothesis that, in ER-
competent animals, an overshoot in the brain partitioning vs. time profile for VPA will 
be observed.  An extension of this primary hypothesis is that reduction of the size of 
the peripheral pharmacokinetic compartment by interrupting VPA ER will result in a 
reduction or complete abolition of this overshoot behavior.  This study, undertaken 
using a rat model, tested the ability of charcoal administration, pretreatment with 
antibiotics, and genetic Mrp2-deficiency to ablate the ER of VPA, based upon 
comparison of the serum concentration-time profiles in treated vs. untreated 
animals.  Secondly, the effect of this ER interruption on the brain partitioning vs. time 
profile was evaluated.  Subsequent experiments were conducted to determine 
whether the ER-interrupting treatments influenced other aspects of VPA brain 
exposure in a manner unrelated to the interruption of ER.   
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METHODS 
 
Chemicals and reagents.  [4,5-3H] Valproic acid (51 Ci/mmol) was 
purchased from Moravek Biochemicals (Brea, CA) and [14C]inulin (2.1 mCi/g) was 
purchased from American Radiolabeled Chemicals (St. Louis, MO).  Valproic acid 
sodium salt, cyclohexanecarboxylic acid, and streptomycin sulfate were obtained 
from Sigma-Aldrich (St. Louis, MO).  All other chemicals and reagents used in this 
study were of the highest grade available from commercial sources.   
Animals.  Male Sprague-Dawley rats (225-300 g), male Wistar rats (225-275 
g) and male TR- rats [Abcc2 (-/-), 225-250 g] were purchased from Harlan 
(Indianapolis, IN).  With the exception of jugular vein-cannulated rats, which were 
housed individually following surgical preparation, all rats were housed 2-4 per cage 
on a 12-hour light-dark cycle, with free access to food and water.  All procedures 
were approved by the Institutional Animal Care and Use Committee of The 
University of North Carolina at Chapel Hill.   
 Interruption of VPA enterohepatic recycling.  All rats were anesthetized 
with i.p. ketamine (160 mg/kg) and xylazine (8 mg/kg), and a silicone rubber cannula 
(0.047 in o.d., 0.025 in i.d.) was implanted in the right jugular vein, at least 24 hr 
before the experiment.  On the day of experimentation, a single dose of VPA (75 
mg/kg i.p.) was administered to all rats (n=20).  Three experimental treatments were 
evaluated for ability to interrupt ER of VPA.  Rats in the first treatment group (n = 3, 
Sprague Dawley) received a 200-mg/mL suspension of activated charcoal (100-400 
mesh) in water via oral gavage.  Two doses (1200 mg/kg each) were administered, 
the first at the time of VPA administration and a second 2 hr later.  Rats in the 
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second treatment group (n = 5, Sprague-Dawley) received penicillin G (2 mg/mL) 
and streptomycin (4 mg/mL) in drinking water for 3 days (125 mg/kg/day penicillin G, 
250 mg/kg/day streptomycin) prior to experimentation.  At 24 hr prior to 
experimentation, an additional dose of penicillin G and streptomycin (40 and 80 
mg/kg, respectively) was administered by oral gavage.  The third treatment group (n 
= 4, TR-) consisted of mutant rats deficient in Mrp2 transporter function due to an 
autosomal recessive mutation on the Abcc2 locus.  Two control groups were 
evaluated concurrently: the first (n = 4, Sprague-Dawley) as strain-specific controls 
for the charcoal- and antibiotic-treated groups, and the second (n = 4, Wistar) as 
strain-specific controls for the TR- rats.  Both control groups received VPA doses 
with no other manipulation prior to experimentation.  Upon VPA administration, 0.2-
0.3 mL blood samples (replaced with 0.3 mL saline) were collected from each rat via 
the implanted jugular cannula at 0.25, 0.5, 1, 1.5, 2.5, 4, 5, 6 and 8 hr post-dose.  
Serum was harvested from blood and stored at -20°C until analysis. 
 Effect of ER interruption on VPA brain partitioning.  The VPA interruption 
experiment (see “Results”) indicated that a partial interruption of VPA ER was 
achieved by pretreatment with antibiotics, and nearly complete interruption of VPA 
ER was observed in TR- rats.  Thus, an experiment to evaluate the relationship 
between the shape of the VPA brain -to- blood  partition coefficient vs. time profile 
and the degree of VPA ER was conducted using antibiotic-treated vs. control 
Sprague-Dawley rats, and TR- vs. control Wistar rats.  Penicillin G and streptomycin 
were administered in drinking water for 3 days prior to experimentation, and as a 
bolus dose 24 hr prior to experimentation, as described above.  At the time of 
experimentation, all rats received a single dose of VPA (100 mg/kg, i.p.).  Trunk 
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blood and brain were collected by decapitation at 5, 10, 15, 20, 30, 45, 60, 75, 90, 
120, 150, 180, 240 and 360 min post-dose from antibiotic-treated and control 
Sprague Dawley rats and at 5, 10, 15, 25, 40, 60, 90 and 120 min post-dose from 
TR- and control Wistar rats (n = 3 per time point).  Serum and brain samples were 
stored at -20°C until analysis. 
 VPA brain partitioning under steady-state conditions.  In order to 
evaluate whether ER-interrupting manipulations altered the overall degree of VPA 
partitioning into brain tissue, a steady-state administration experiment was 
conducted using antibiotic-treated and control Sprague-Dawley rats, and TR- and 
control Wistar rats.  VPA was administered in drinking water (6 mg/mL) to all rats for 
3 days (~700 mg/kg/day) prior to experimentation.  Antibiotic-treated rats received a 
combination of VPA, penicillin G and streptomycin in drinking water for three days, 
followed by a bolus dose of penicillin G and streptomycin by oral gavage as 
described above.  At the end of the 12-hr dark cycle following 3 days of drug 
administration, trunk blood and brain were collected by decapitation.  Serum and 
brain samples were stored at -20°C until analysis. 
 VPA brain uptake index.  To identify any potential alterations in brain 
permeability to VPA resulting from manipulations to interrupt VPA ER, a brain uptake 
index experiment was conducted to compare the extent of brain uptake of VPA 
relative to the reference compound inulin in antibiotic-treated and control Sprague-
Dawley rats, and TR- and control Wistar rats.  Penicillin G and streptomycin were 
administered in drinking water for three days prior to experimentation, and as a 
bolus dose 24 hr prior to experimentation, as described above.  At the time of 
experimentation, all rats were anesthetized with i.p. ketamine (160 mg/kg) and 
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xylazine (8 mg/kg).  Brain uptake index experimentation was conducted as 
described in (Hardebo and Nilsson, 1979).  Briefly, the right common carotid artery 
was exposed and injected (< 0.5 sec) with a 0.2-mL bolus of saline containing 1 µCi 
3H-VPA (50 µg/mL VPA) and 0.5 µCi 14C-inulin.  At 10 sec post-injection, brain 
tissue was collected by decapitation. 
 Quantitation of VPA.  VPA in serum and brain tissue samples was 
determined by gas chromatography with flame ionization detection (Shimadzu 
GC2014 series) with a method modified from Liu et al. (Liu et al., 1992).  Briefly, 
serum samples (50 µL), acidified 1:1 v/v with 2 N HCl, were extracted with 100 µL 
ethyl acetate containing CCA as an internal standard.  Brain samples were 
homogenized 1:1 w/v in saline, and 250 µL of the homogenate was acidified with 50 
µL of 12 N HCL prior to extraction with ethyl acetate containing CCA.  A 1-l aliquot 
of the organic layer of was injected onto a wide-bore fused silica capillary column 
(30 m x 0.53 mm id) with free fatty acid phase as the bonded stationary phase and 
helium as the carrier gas.  For serum samples, isothermal chromatography was 
used, with the column oven maintained at 180°C and the injector and detector at 
200°C.  For brain samples, these same column oven, injector and detector 
temperatures were maintained for 5 min post-injection. The column oven 
temperature then was increased to 230°C, and the injector and detector to 250°C.  
Analyte vs. internal standard peak area ratios were determined using GC Solution 
software (Shimadzu).  The assay detection limit was 0.5 µg/mL for brain and 0.1 
µg/mL for serum, and standard curves were linear through the relevant range of 
concentrations in these studies. 
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 Quantitation of 3H-VPA.  Upon collection, brain tissue was digested 
immediately with 3 mL of tissue solublizer (Solvable; PerkinElmer Life Sciences) 
overnight at 37°C.  Samples were mixed with 15 mL of scintillation cocktail (Ultima 
Gold; PerkinElmer Life Sciences) and stored at room temperature for 12 hr prior to 
simultaneous determination of total radioactivity (3H and 14C) via liquid scintillation 
analysis (PerkinElmer 1600TR liquid scintillation analyzer).  Brain tissue 
concentrations were corrected for residual blood contamination as described 
previously (Dagenais et al., 2000). 
 Data analysis.  Data are presented as mean ± SD.  For evaluation of VPA 
ER interruption methods, AUC0-8hr was calculated by the trapezoidal method.  The 
contribution of ER to AUC0-8hr was determined by subtracting from the total AUC0-8hr 
the AUC prior to ER, extrapolated through infinity using noncompartmental analysis 
(WinNonlin 5.0.1, Pharsight).  The degree of overshoot in the Cbrain / Cserum vs. time 
profile in treated and untreated rats was compared by calculating the AUC above the 
last measurable Cbrain / Cserum ratio for each treatment group.  In all cases, standard 
deviation on AUC measurements was calculated by the method of Bailer et al. 
(1988).  Statistical comparisons between groups were accomplished by t-test or 
ANOVA with post-hoc comparisons, as appropriate, using SigmaStat software.  
Numerical deconvolution of brain partitioning data was accomplished using 
PCDCON software.  
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RESULTS 
 
Interruption of enteroheptic recycling.  No interruption of VPA ER was 
observed in charcoal-treated rats vs. control Sprague-Dawley rats, based upon 
comparison of serum concentrations following a 75-mg/kg dose of VPA (Fig. 1).  
Concentration-time profiles for the two groups were nearly superimposable, with 
appearances of a secondary peak in VPA concentration beginning at 2 hr, and 
becoming maximal at 4-5 hr post-dose.  By subtracting the pre-ER AUC0-inf from the 
observed AUC0-8hr it was determined that the contribution of ER to the AUC0-8hr did 
not differ significantly between the charcoal-treated (39.9 µg/mL*hr) and control 
(43.5 µg/mL*hr) Sprague-Dawley  groups; 91.8% of the AUC contributed by ER in 
control animals remained following charcoal treatment (Table 1).   
A partial interruption of ER was achieved with antibiotic treatment.  In 
antibiotic-treated rats, the beginning of a secondary VPA concentration peak 
appeared, slightly later than in control Sprague-Dawley rats, at 4 hr post-dose (Fig 
2).  This secondary rise in serum concentrations did not peak within the time frame 
of the experiment, but appeared to rise slowly through 8 hr, with concentrations 
remaining consistently lower than those in the control group.  Antibiotic treatment 
significantly reduced ER-contributed AUC, relative to Sprague-Dawley control rats, 
with treated rats exhibiting approximately 44% of the ER-contributed AUC observed 
in controls.   
As illustrated in Fig. 3, a nearly complete attenuation of ER was observed in 
Mrp2 transporter-deficient TR- rats relative to normal control Wistar rats.  While no 
marked secondary VPA serum concentration peak was apparent in TR- rats, a minor 
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contribution of ER (or some other undefined distributional process) to the AUC0-8hr 
was calculated based on the functional definition underlying the area analysis, with 
ER accounting for 4.91 µg/mL*hr of the 94.4 µg/mL*hr AUC0-8hr.  TR- rats exhibited 
only 10.4% of the ER-contributed AUC0-8hr observed in Wistar control rats.   
Brain partitioning of VPA.  Brain VPA concentrations determined in 
antibiotic-treated and untreated control Sprague-Dawley rats, and in TR- and Wistar 
control rats, following administration of 100 mg/kg VPA are depicted in Fig. 4a and b, 
respectively.  Based upon pilot studies which indicated that brain concentrations 
dropped below the lower limit of detection (0.5 µg/mL) by approximately 2 hr post-
dose, sampling was limited to 4 and 2 hr for Sprague-Dawley and Wistar rats, 
respectively.  Serum VPA concentrations in antibiotic-treated and untreated control 
Sprague-Dawley rats, and in TR- and Wistar control rats, are illustrated in Fig. 5a 
and b, respectively.  The beginning of a secondary VPA concentration peak was 
evident in control animals by 2 hr post-dose.  A small secondary rise in the 
concentration-time profile in antibiotic-treated rats was observed at 2.5 hr post-dose. 
No apparent secondary increase in concentration was observed for the TR- animals.  
Brain-to-blood partitioning of VPA, represented as Cbrain / Cserum vs. time, is 
illustrated in Fig. 6.  As observed in the literature, in untreated Sprague-Dawley rats 
an early overshoot in Cbrain / Cserum was apparent (Fig. 6a).  The partition coefficient 
peaked at 10 min, and decreased thereafter, although the rate of decline grew 
smaller at approximately 1 hr post-dose.  In antibiotic-treated rats, an early 
overshoot also was observed, peaking within 10 min at a Cbrain / Cserum of 0.0810, 
slightly lower than that in untreated control rats (0.0953).  Notably, this early peak in 
the partition coefficient ratio decreased more rapidly in antibiotic-treated rats, and 
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remained lower through 45 min when the rate of change became low in both groups 
of animals.   
Untreated Wistar rats also exhibited an early overshoot in Cbrain / Cserum vs. 
time profile (Fig. 6b).  This overshoot peaked slightly later than that in Sprague-
Dawley rats, at 25 min, with a Cbrain / Cserum of 0.0733.  An overshoot was observed 
in the Cbrain / Cserum  profile for TR- rats, with a magnitude similar to that in the control 
animals (0.0726).   However, as with the ER-impaired Sprague-Dawley rats, this 
overshoot was truncated, with the partition ratio decreasing more quickly and 
remaining lower than that in untreated control animals.   
In both of the ER-interrupted groups, a brief (spanning 10-25 min post-dose in 
the Wistar group, and 5-15 min post-dose in the Sprague-Dawley group), early peak 
in the Cbrain / Cserum  vs. time profile was observed.  In order to evaluate the 
relationship between the appearance of this peak and the VPA ER process, a 
deconvolution analysis was conducted.  Ideally, the influence of ER on the time 
course of Cbrain / Cserum  vs. time profiles would be evaluated by comparing brain 
partitioning profiles in the presence and complete absence of ER.  As the VPA ER 
interruption experiment discussed above indicated near complete ablation of VPA 
ER in the TR- vs. Mrp2-competent control Wistar rats, data from these two groups of 
animals were utilized for this deconvolution analysis.  As illustrated in Fig. 7, this 
brief initial peak in the brain partitioning profile of the TR- animals was essentially 
identical to that in Wistar controls, leading to the absence of an early peak after 
deconvolution of the data.   
As a result of the rapid decrease of brain VPA concentrations below the 
assay limit of detection, it was not possible to evaluate the brain partitioning profile 
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through the attainment of distribution equilibrium.  Thus, the magnitude of overshoot 
in the Cbrain / Cserum vs. time profile was quantitated through the last time point at 
which brain concentrations remained detectable by calculating the AUC for Kp, brain 
vs. time above the last measureable value for each treatment group.  The resulting 
AUC values (±SD, as calculated by the method of Bailer for destructive sampling 
(Bailer, 1988)) are presented in Table 2.  Antibiotic-treated and TR- rats exhibited 
significantly reduced (p<0.01) overshoot areas, 32.7% and 21.3% of the size of the 
overshoot area calculated in each control group, respectively.     
 
 VPA brain partitioning under steady state conditions.  In order to rule out 
a generalized effect of ER-interrupting treatments on VPA brain partitioning, Kp, brain 
values were calculated for each treatment group under steady-state conditions.  As 
depicted in Fig. 8a-c, antibiotic-treated vs. control Sprague-Dawley rats evidenced 
similar serum and brain concentrations, and did not differ significantly in Kp, brain 
(0.0201 and 0.0136, respectively; p>0.05).  Although serum VPA concentrations 
were significantly higher in control Wistar vs. TR- rats, brain concentrations were 
also moderately higher.  Thus, Kp, brain did not differ significantly between the two 
groups (0.0262 and 0.0189, respectively; p>0.05).   
 VPA brain uptake index.  To determine whether ER-interrupting conditions 
affected brain permeability to VPA, the initial rates of VPA uptake, relative to uptake 
of the brain vascular space marker inulin, were compared between each set of ER-
interrupted vs. control rats (Fig. 9a-c).  In antibiotic-treated rats, 14C-inulin uptake 
was slightly lower than in control Sprague-Dawley rats, while 3H-VPA uptake was 
similar.  The treatment-related increase in the ratio of VPA to inulin uptake, however, 
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did reach statistical significance (12.1 ± 3.01 vs. 17.4 ± 2.68, respectively, in control 
vs. antibiotic-treated rats; p<0.05).  Although 14C-inulin uptake was significantly 
lower in TR- vs. Wistar control rats, 3H-VPA uptake was slightly lower (but not 
statistically different) in TR- rats.  Thus, the ratio of VPA to inulin uptake did not differ 
significantly between these groups (9.53 ± 2.41 and 10.6 ± 2.15, respectively, in 
Wistar control and TR- rats).    
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DISCUSSION  
 
 Interruption of VPA ER.  The present study examined the utility of three 
different experimental approaches to ablate VPA ER in rats.  The oral administration 
of charcoal, although reported to eliminate greater than half of the ER-related 
absorption of VPA administered to humans (Neuvonen et al., 1983), did not impact 
the ER of VPA in rats in this study.  The failure of this treatment to reduce VPA ER 
appeared to result from binding site saturation in the presence of relatively high 
concentrations of VPA.  A brief in vitro experiment demonstrated that the capacity of 
the activated charcoal used in this study to bind VPA was saturable within the 
relevant range of VPA concentrations (data not shown).   
 The 3-day regimen of oral penicillin G and streptomycin was selected based 
upon the reported loss of enzyme-mediated hydrolysis of a β-glucuronide metabolite 
after exposing rats to 1 or 2 mg/mL penicillin and streptomycin in drinking water 
(Takasuna et al., 1996).  In the current study, this treatment significantly reduced 
ER-associated VPA exposure in the serum concentration-time profile (by 56% 
relative to untreated controls).  Although other antibiotic regimens, including 
neomycin, bacitracin, and tetracycline, have been reported to be efficient inhibitors 
of ER (Gott and Griffiths, 1987; Takasuna et al., 2006), penicillin G and streptomycin 
were selected for the current study due to the fact that these compounds can be 
administered in drinking water and do not influence water consumption in rats.  This 
regimen provided a simple means of reducing ER, relative to other antibiotic 
administration protocols.  It also provided an intermediate level of VPA ER inhibition, 
less than the untreated controls but more than in TR- rats. 
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 The impact of the elimination of Mrp2 function on VPA ER was examined via 
an Mrp2-deficient TR- Wistar rat model.  Mrp2 deficiency has been demonstrated to 
almost completely eliminate active secretion of the acyl glucuronide metabolite of 
VPA across the canalicular membrane, based upon the nearly complete reduction of 
choleresis normally associated with movement of the VPA metabolite into bile 
(Wright and Dickinson, 2004).  The absence of Mrp2 in TR- rats in this study 
resulted in a 90% reduction in the VPA AUC attributable to ER, relative to Mrp2-
competent control rats, consistent with a central role of Mrp2 in the biliary excretion 
of VPA-glucuronide.   
 Although the interruption of VPA ER with antibiotics was incomplete, this 
treatment, as well as the efficient loss of Mrp2 strategy, was utilized in the 
subsequent brain partitioning studies, to investigate whether a continuum of degrees 
of ER interruption could elicit a continuum of ablation of overshoot behavior.   
 
Brain partitioning of VPA.  As predicted based upon the simulations 
reported in Chapter 7 and the abundance of examples in the literature, an overshoot 
in the brain-to-serum partition profile was observed in both Sprague-Dawley and 
Wistar control (untreated) rats as a rapid peak followed by a monotonic decline in 
the Cbrain / Cserum vs. time profile.  Although antibiotic treatment and Mrp2 deficiency 
elicited moderate and nearly complete ablation of VPA ER, notable, although brief, 
peaks in the Cbrain / Cserum vs. time profile were observed at early time points in both 
ER-reduced groups.   
Visual comparison of the brain partitioning profiles for each of the ER-
interrupted vs. control groups suggests some consistency with the simulation studies 
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described in Chapter 7.  These simulations demonstrated that increases in the size 
of the peripheral compartment were associated with a proportionate increase in the 
duration of the overshoot, but a ceiling value existed for the magnitude of the 
overshoot.  In the current study, the overshoot magnitude between treated and 
untreated rats appears nearly identical in absolute terms.  However, the Cbrain / 
Cserum  values decrease more rapidly in the ER-interrupted rats, approximating an 
earlier approach to DE than the untreated rats.  
While the brief, spike-like overshoot associated with the reduction of 
peripheral volume (as reduced ER) was consistent with prior simulations, an 
additional method of analyzing the relationship of this overshoot peak to ER was 
incorporated.  By deconvolving the brain partition vs. time profiles of the TR- rats 
from that of the control Wistar rats, the influence of ER was essentially isolated. 
Interestingly, deconvolution analysis abolished the initial early peak, indicating that 
this peak was a component of both profiles, independent of the influence of ER.  
Although ideally the deconvolution analysis would compare systems in the presence 
vs. the complete absence of the influence of interest (ER), the ablation of ER was 
approximately 90% in the TR- vs. control Wistar rats.  This analysis suggests that a 
factor unrelated to ER may be responsible for the brief overshoot observed in the 
ER-interrupted rats.  The mechanism leading to this non-ER related overshoot is 
unclear, and will require additional experimentation to explore.     
Although mathematical descriptors of the overshoot phenomenon were 
developed in Chapter 7, these metrics of the magnitude (peak Cbrain / Cserum value as 
a percentage of the Kp, brain value) and duration (time at which the system reaches a 
stable plateau value, Kp, brain) of the overshoot could not be utilized in the current 
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study.  Both metrics depend upon the observation of a plateau Cbrain / Cserum value, 
which remains stable with time.  Despite the good sensitivity of the gas 
chromatographic VPA assay, (0.1 - 0.5 µg/mL limit of detection), brain 
concentrations dropped below the assay limit of detection by 1.5 and 2 hr post-dose 
in Sprague-Dawley and Wistar rats, respectively.  A survey of reported VPA brain 
partitioning profiles failed to yield an example of attainment of DE after a bolus dose 
of VPA; assay times generally spanned a maximum of 180 min post-dose.   
An additional consequence of the inability to determine the plateau Kp, brain 
value for VPA in the current study is the inability to measure the total overshoot area 
in each treatment group.  Comparison of the upper (measurable) portions of the 
overshoot area between ER-inhibited and control groups necessarily overpredicts 
the ER-interruption associated difference between the two groups, although, 
depending on the true Kp, brain value, the magnitude of this overprediction could be 
large or small.  Although the Kp, brain for VPA was measured in all treatment groups 
under steady-state VPA administration conditions, this value, while relatively 
consistent across groups, was not used as the baseline Kp, brain value for comparison 
of overshoot area in the brain partitioning vs. time profiles.  First, this value 
(approximately 0.02) was substantially lower than the literature values for VPA Kp, 
brain (e.g., 0.11 in humans; (Shen et al., 1992)).  This lower value may reflect 
nonstationary kinetics of VPA, apparent under conditions of chronic administration 
over several days, as has been reported previously  (Arens and Pollack, 2001).   
 
 Influence of ER-interrupting conditions on VPA CNS kinetics.  The 
current study was intended to compare the effect of manipulation of peripheral 
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pharmacokinetic compartment volume (as degree of ER) on the brain partitioning vs. 
time profile.  In order to rule out any nonspecific effects of the ER-interrupting 
conditions on VPA CNS kinetics, two endpoints were evaluated.  One endpoint was 
the Kp, brain value under steady-state administration conditions.  Although no 
experimental evidence in the literature would suggest that steady-state Kp, brain 
values should differ in the presence vs. absence of ER, the simulation study 
described in Chapter 7 illustrated several situations under which small (typically 
<10% difference) changes in peripheral distribution volume on Kp, brain was observed.  
Although this effect was generally minor, one condition was identified under which a 
substantial effect of changes in peripheral distribution volume on Kp, brain was 
observed.  When systemic clearance was 10-fold higher than the brain and 
peripheral compartment clearances, (25 mL/min/kg, vs. 2.5 mL/min/kg), the 
simulated Kp, brain values varied up to a maximum of 8-fold with the manipulation of 
peripheral distribution volume.  In the current study, systemic VPA clearance values 
were in the range of approximately 1.3 mL/min/kg.  In the context of the simulation 
study, the maximum peripheral volume-related difference would be less than 
approximately 40%.  Although no statistical differences between Kp, brain in ER-
interrupted vs. control rats were observed in the present study, the differences in the 
average Kp, brain values in ER-interrupted vs. control Sprague-Dawley and Wistar rats 
were 38 and 47%, respectively, consistent with predictions from the preceding 
simulation study.   
 The other endpoint evaluated for a potential nonspecific influence of the ER-
interrupting manipulation was the initial uptake clearance into brain.  This endpoint 
was evaluated with the brain uptake index experimental paradigm.  Although 
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statistically significant differences were observed between antibiotic-treated and 
control Sprague-Dawley rats, the magnitude of this difference (43%) is unlikely to be 
biologically meaningful.  Currently, no mechanistic explanation for the observed 
difference is available.  
 
 Conclusions.  The current study demonstrated that overshoot in the VPA 
Cbrain / Cserum  vs. time profile occurs in the presence of active ER, and that 
attenuation of ER (and thus reduction of peripheral distribution volume) reduced the 
degree of overshoot.  The nearly complete ablation of VPA ER in TR- vs. Wistar 
control rats did not completely abolish the overshoot behavior.  Future simulation or 
experimental studies may be able to probe the origin of the brief, early overshoot 
peak in ER-interrupted animals.  Finally, although the present study constituted a 
reasonable validation of the simulated behavior predicted in Chapter 7, the 
identification of additional CNS-distributing compounds with significant ER would be 
desirable.   
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Figure 1. 
Serum VPA concentrations in Sprague-Dawley control rats and charcoal-treated rats 
following a 75 mg/kg bolus dose of VPA. Data are presented as mean ± SD. 
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Figure 2. 
Serum VPA concentrations in Sprague-Dawley control rats and antibiotic-treated 
rats following a 75 mg/kg bolus dose of VPA. Data are presented as mean ± SD. 
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Figure 3. 
Serum VPA concentrations in Wistar control rats and mrp2-deficient TR- rats 
following a 75 mg/kg bolus dose of VPA. Data are presented as mean ± SD. 
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Figure 4. 
Brain VPA concentrations in antibiotic-treated and control Sprague-Dawley rats (a) 
and in TR- and control Wistar rats (b) following a 100 mg/kg bolus dose of VPA. 
Data are presented as mean ± SD. 
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Figure 5. 
Serum VPA concentrations in antibiotic-treated and control Sprague-Dawley rats (a) 
and in TR- and control Wistar rats (b) following a 100 mg/kg bolus dose of VPA. 
Data are presented as mean ± SD. 
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Figure 6. 
Brain partitioning of VPA in Sprague-Dawley control (a) and antibiotic-treated (b) 
rats, and in Wistar control (c) and TR- (d) rats. Data are presented as means ± SD. 
Lines indicate linear least squares regression of Cbrain / Cserum vs. time over the 
relevant time domain. 
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Figure 7. 
Results of deconvolving Cbrain / Cserum vs. time data in TR- rats from Wistar control 
rats with intact enterohepatic recycling.  Points indicate cumulative additional brain 
partitioning in the presence of enterohepatic recycling.   
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Figure 8. 
Serum (a) and brain (b) VPA concentration, and calculated brain-to-blood partition 
ratios calculated following administration of VPA to steady-state.  Error bars indicate 
SD, asterisk indicates statistically significant difference (p<0.01). 
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Figure 9. 
Percent uptake of the injected dose of 14C inulin (a) and 3H VPA (b) and ratios of 
VPA vs. inulin uptake (c), determined by the brain uptake index method. Error bars 
indicate SD, asterisk indicates significant difference (p<0.05). 
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  S-D 
 Control 
S-D  
Charcoal- 
Treated 
S-D 
 Antibiotic-
Treated 
WI 
Control 
WI 
TR- 
AUC 0-8hr 124 (6.54) 133 (14.3) 145 (30.2) 102 (10.5) 94.4 (10.5) 
AUC pre-ER 80.1 (4.73) 92.8 (8.11) 126 (26.8) 54.9 (3.42) 89.4 (10.8) 
AUC ER 43.5 (4.44) 39.9 (11.5) 19.2 (3.54) 47.1 (13.6) 4.91 (0.862) 
% Control  91.8 44.1  10.4 
      
 
 
Table 1. 
Serum valproate exposure (as AUC; mg/L*hr) in ER-interrupted and control rats.  
Values represent means (± SD). 
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  S-D 
 Control 
S-D  
Antibiotic- 
Treated 
WI 
Control 
WI 
TR- 
AUC  (SD) 
 
 
0.0177  
(0.00436) 
0.00579*  
(0.00278) 
0.0237  
(0.00312) 
0.00505*  
(0.00266) 
% Ctrl  32.7  21.3 
 
 
 
Table 2. 
AUC (mg/L*hr) contributed to the Kp,brain vs. time profile in ER-interrupted and control 
rats. Values indicate means (± SD), asterisks indicate significant differences vs. 
control (p<0.05). 
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CONCLUSIONS 
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 Diseases of the brain and central nervous system (CNS) are particularly 
poorly-treated by extant pharmacotherapeutics (1).  The most significant limitation 
associated with the development of new therapeutics to treat these diseases is the 
ability to deliver drugs across the blood-brain barrier (BBB) to target sites within the 
CNS (2).  This requisite property of BBB penetrability complicates the difficulties 
associated with drug discovery and development in general: identification of new 
chemical entities that (1) can effectively modulate important therapeutic targets and 
(2) possess the appropriate ADME characteristics to ensure a balance between 
sufficient exposure levels and safety.   
The overall goal of this dissertation research was to evaluate the feasibility of 
a targeted P-gp inhibition strategy to augment the brain exposure of a systemically-
administered P-gp substrate, the model compound paclitaxel.  This research, in the 
aggregate, has probed both the efficacy of the strategy itself and the feasibility of the 
development of appropriate model systems and quantitative metrics to implement 
and evaluate this strategy.  
The three sub-goals of the dissertation project are discussed below in relation 
to their context within and contribution to the scientific literature.  The major findings 
of the experiments that comprised this project, together with limitations uncovered 
during pursuit of the stated research goals, are considered, and future avenues of 
investigation in each topic area are proposed.   
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 Establishment of the kinetic-dynamic linkage of cellular response to the 
model substrate paclitaxel.   
An important component of the ability to design effective therapeutic 
compounds is the ability to understand the linkage between exposure and response.  
While the overarching objective of this dissertation project was the evaluation of a 
targeted P-gp inhibition approach directed at enhancing brain exposure to a P-gp 
substrate, proof of concept of this idea was to be based upon the ability of the 
therapeutic intervention to elicit a therapeutically meaningful response in an in vivo 
brain tumor model.   
Several types of brain tumors are known to respond to paclitaxel in vitro; early 
demonstration of marked response to this drug generated significant interest in the 
potential utility of paclitaxel as a therapeutic agent for the treatment of brain 
neoplasms (3, 4).  Due to the limited ability of paclitaxel to penetrate the BBB, this 
agent, along with the majority of other antineoplastics, has not been effective in this 
capacity.  The incongruities between in vitro and in vivo observations clearly 
illustrate the critical importance of understanding the relationship between brain 
exposure and dose.   
The need to further relate the kinetics of brain exposure to the dynamics of 
cellular response has become apparent upon consideration of the numerous 
conflicting reports of paclitaxel activity against brain and other tumor cells.  Various 
studies report schedule-dependency, total exposure dependency, or concentration-
dependency of cellular response (5, 6).  In many cases, only a single exposure 
scenario was evaluated, and differences between the experimental conditions 
between studies render the results difficult to compare. The current study furnishes a 
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comparatively comprehensive evaluation of the influence of paclitaxel on brain tumor 
cells under conditions of varying exposure kinetics, and applies a mathematical 
modeling approach to provide insight into the associated kinetics of cellular 
response. 
The in vitro studies described in Chapter 2 evaluated the effect of a range of 
paclitaxel exposure kinetics, from prolonged, low-concentration exposures to various 
patterns of brief, high-concentration exposures, on the cytotoxic response of a 
human glioma cell line.  Mathematical modeling indicated that although a single 
initial high-concentration exposure was most effective, cellular response could best 
be predicted by expression of total exposure as AUC.   
 On several levels, the current studies are unlikely to determine cellular 
response precisely under clinical conditions, or even in a preclinical implanted tumor 
model.  Although the model system was designed to evaluate the fundamental 
behavior of cellular response to paclitaxel by considering the simplest possible 
conditions, many additional factors relevant to in vivo tumor physiology would 
impinge upon the relationships identified in this study.  These factors include, but are 
not limited to, intra-tumor blood flow rates and altered vascularity, chemical 
gradients, three-dimensional structure and development of multi-drug resistance.  
In addition, the intracellular kinetics of paclitaxel are complex, and would be 
expected to influence the relationship between the kinetics of exposure and cellular 
response (7, 8).  In order to characterize the behavior of this system fully, 
intracellular and extracellular concentrations of paclitaxel would be determined 
analytically and incorporated into the mathematical model.   
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 Finally, although reasonable predictions regarding anticipated cellular 
response may be achieved by mathematical modeling (9), it remains to be seen 
whether these exposure patterns may be achievable in vivo.  As demonstrated by 
the studies discussed in subsequent chapters, the achievement of a desired pattern, 
or indeed a desired overall magnitude of brain exposure, may not be straightforward. 
 A number of future directions are suggested by the results of these studies.  
As discussed above, evaluation of cellular and medium concentrations of paclitaxel 
would be an important next direction.  A corollary step would be to update the model 
with the concentration-adjusted relationships.  Although the model predictions 
generated by the work discussed in this chapter were not experimentally validated in 
vivo due to the demonstrated limitations of the proposed P-gp inhibition approach for 
achieving the requisite increase in relative brain concentrations of paclitaxel, two 
future paths of investigation might be interesting, in the context of evaluating model 
performance.  Additional data generated using (1) other tumor cell lines, or (2) other 
antineoplastics with similar or different mechanisms of antineoplastic effect, the 
generalizability of the model (within the same type of experimental system; i.e., 
monolayer culture) could be evaluated comprehensively.   
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 Evaluation of the potential utility of the targeted P-gp inhibition 
approach to augment delivery of the P-gp substrate paclitaxel.   
 The use of P-gp inhibitors as a means to increase brain delivery of 
compounds that are excluded from the CNS by this BBB efflux transporter is an 
intriguing possibility for several reasons.  First, this approach represents one of the 
least invasive means for increasing brain delivery of therapeutic agents.  In contrast 
to strategies such as using indwelling pumps to bypass the BBB or osmotic 
disruption of the BBB, this approach is reasonably selective, limiting enhanced influx 
to only those compounds that othwerwise would have been excluded by P-gp.  
Second, this approach is conservative; it capitalizes on the large number of extant 
compounds which possess P-gp inhibiting effects, mitigating the need for extensive 
drug development (10).  In addition, successful application of this approach could 
confer clinical utility upon compounds which may have good potency and 
physicochemical properties, but are excluded from the brain by P-gp.  Third, this 
approach is generalizable across the large number of potential CNS therapeutics 
which are excluded from the CNS by this barrier transporter (11).  As opposed to 
strategies involving structural modification to individual compounds toimprove BBB 
penetrability, this approach, in theory, could improve exposure to a large number of 
compounds, spanning many therapeutic areas.  Furthermore, if in the future other 
biologically significant barrier transporters are identified at the blood-brain interface, 
this approach would also generalize to substrates of other transporters, provided 
that appropriate inhibitors could be identified and developed.   
 The success of P-gp inhibition approaches has been minimal, due in part to 
the high systemic concentrations required to achieve sufficient unbound 
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concentrations at the BBB (12).   For this reason, a CNS-targeted delivery approach 
would potentially be useful.   
The current work evaluated several chemical inhibitors of P-gp in the context 
of both their ability to selectively penetrate into the brain following nasal delivery and 
their ability to elicit a meaningful P-gp inhibitory effect on the uptake of a model P-gp 
substrate into brain.  Although several reports describe the effective delivery of 
drugs to the brain using the nasal route of administration (13-15), there have been 
few side-by-side comparisons of the degree to which this route confers a selective 
brain delivery advantage.  To probe the selectivity of this approach, the nasal route 
was compared to systemic delivery.   
A significant effort was directed towards refining the use of modulators of P-
gp as potential therapeutic modalities, as well as research tools.  Due to its multiple 
properties in this regard,(as an inhibitor, inducer, and substrate of P-gp), rifampin 
was selected as a potential modulator of P-gp.  The lack of any preclinical 
pharmacokinetic information about rifampin represents a major void in the current 
scientific literature.  This information was required in this dissertation project to 
appropriately design studies to compare the efficacy of systemic vs. nasal delivery 
routes for conferring brain exposure to rifampin.  This information also would be of 
great import in the design of studies which aim to use rifampin as a tool for probing 
P-gp activity.  In addition, rifampin has other biologic effects (induction of CYP3A, for 
example). Enabling the use of a pharmacokinetically-directed approach for designing 
studies with rifampin was viewed as an important contribution to the literature. 
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 The studies described in Chapter 3 clearly demonstrated the ability of the 
nasal route, relative to systemic administration, to confer a substantial increase in 
the amount or the fraction of drug delivered to the brain vs. the systemic circulation.  
Equally importantly, this work also illustrated the compound-specific differences in 
these absolute and relative brain exposure advantages conferred by the nasal 
delivery route.  In particular, delivery via the nasal route resulted in a marked brain 
exposure advantage for rifampin, a compound that is substantially excluded from the 
brain upon systemic delivery, as confirmed by studies in Chapters 4 and 5.  Although 
a marked brain exposure advantage associated with the nasal route was also 
identified for GF120918, the advantage for quinidine was minimal.   
In light of the systemic toxicity and proclivity for drug-drug interactions which 
currently limit the clinical utility of P-gp inhibitors for modulating the transporter at the 
BBB (12), the major intent of this aspect of the dissertation research was to identify a 
means to increase brain exposure to these compounds selectively while minimizing 
systemic exposure.  Although this goal was realized, consideration of the brain 
concentrations of inhibitor achievable by this route, in light of their ability to elicit a 
pharmacologic effect in the brain, is warranted.  Clearly, mass delivery is an 
important limiting factor in utilizing this route of administration. Further potential 
challenges associated with this approach are centered on the eventual clinical utility 
of this administration strategy, which may also be limited, perhaps most significantly, 
by formulation and safety issues.   
 
 The work reported in Chapter 4 addresses a limitation encountered during 
the design of the studies comprising this dissertation, and other studies which 
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attempt to utilize rifampin as a tool to probe P-gp inhibition (16), cytochrome P450 
induction (17), or P-gp induction (18), namely, the dearth of preclinical 
pharmacokinetic data on this compound.  Considering the multiple functions of 
rifampin as a probe of drug metabolism and transport, characterization of the 
pharmacokinetics of rifampin in mice under single- and multiple-dose conditions is 
an important contribution to the scientific literature.   
The results of the pharmacokinetic experiments with rifampin will allow the 
rational design of studies for which attainment of pre-selected rifampin 
concentrations in specific organ sites are necessary.  In addition, the outcome of this 
study also sheds light on previous experiments in which unexpected results were 
obtained.  For example, upon rifampin-mediated intestinal induction of P-gp, a lower 
than predicted (based on increase in P-gp expression) increase in function was 
observed (19).  Based on the kinetics of rifampin described in Chapter 5, the 
substantial persistence of rifampin in intestine and other organs, leading to inhibition 
of transport in a concentration-dependent manner, may have offset to some extent 
increases in transport activity associated with P-gp induction.   
Of significance to the current studies, the extremely low brain partitioning of 
this compound suggests that negative reports of the ability of this P-gp inhibitor to 
increase brain delivery of P-gp substrates could likely be a consequence of low brain 
exposure rather than a lack of potency.  This limited brain exposure after systemic 
administration could be improved by nasal delivery, assuming that formulation 
issues could be adequately addressed. 
 The multiple studies described in Chapter 5 furnish a broad review of 
approaches to evaluate P-gp inhibition via nasal delivery of a chemical modulator of 
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the protein.  This chapter highlights several issues associated with nasal delivery 
that have not been previously appreciated.   
 Importantly, in the context of the clear brain exposure advantage 
demonstrated in Chapter 3, the studies reported in Chapter 5 illustrate a 
fundamental limitation of the nasal delivery approach as a means of eliciting a P-gp 
inhibitory effect at the BBB.  The studies described in Chapter 3 demonstrated that, 
for GF120918 and rifampin, equivalent or increased absolute brain exposure can be 
achieved with a very low mass of drug administered by nose as compared with a 
large mass administered systemically. Despite this augmented brain exposure in the 
case of rifampin, the ability of this P-gp inhibitor to increase brain exposure to 
paclitaxel was modest, and indicative of incomplete P-gp reversal. These data 
suggested that, even when delivery of rifampinlator to the brain was maximal, the 
resulting inhibition of P-gp would account for only about one-third of the total P-gp 
activity at the BBB (as identified by comparing mdr1a (-/-) mice with their transport-
competent counterparts). While these results provide proof-of-concept of selective 
delivery of rifampin to BBB P-gp after nasal administration, the magnitude of the P-
gp effect in mice was insufficient to suggest an important biological or 
pharmacological outcome.  
The work described in Chapter 5 also highlights the extensive time required 
for the attainment of paclitaxel brain-to-blood DE, which had not been reported in 
previously.  Unfortunately, the extensive time to DE, and the lack of availability of 
paclitaxel formulations that would facilitate steady-state administration, precluded 
the ability of this model system to allow efficient screening of nasal P-gp inhibition 
strategies.   
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Perhaps most importantly, the experiments comprising Chapter 5 illustrated 
the potential complications associated with the interpretation of brain partitioning 
measurements and, by analogy, measurement of the effects of P-gp modulation 
approaches on brain partitioning when assessed prior to the attainment of DE. The 
significance of this observation lies in the fact that efficacy of various P-gp inhibition 
approaches often is reported in the context of experimental paradigms which 
necessitate sampling prior to attainment of DE (20).   
 The collective goal of the studies reported in the chapters supporting the 
second sub-aim of this dissertation project was to evaluate the utility of chemical 
inhibitors of P-gp to increase brain exposure and partitioning when targeted to the 
brain by the nasal (as opposed to the systemic) delivery route.  In addition to the 
major observations and limitations discussed above, some future directions are 
apparent.   
 One interesting question concerns the inability of any of the evaluated nasal 
P-gp administration strategies to confer a biologically significant increase in 
paclitaxel brain exposure.  As the slow brain equilibration of paclitaxel renders this a 
difficult model compound to evaluate, these approaches might be better assessed 
with an alternative compound, or with a set of compounds.  This could allow 
determination of whether the low efficacy of these approaches is related to sampling 
time, or whether a substantial (e.g., 80-90%) reversal of P-gp function could be 
observed under optimized exposure conditions.   
As demonstrated in these studies, a murine model is likely not the most 
appropriate system for characterization of the utility of a nasal delivery approach.  
Aside from the potential overestimation of the degree of brain exposure which might 
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be achieved clinically, due to the significant physiological differences between 
mouse and human nasal epithelium (e.g., substantially larger surface area of 
olfactory epithelium, and larger relative size of the nasal cavity), major limitations 
associated with the technical feasibility of evaluating this approach in this species 
were noted.  These include the necessity for sedation, which potentially perturbs the 
kinetics of the compound under study, the difficulty in achieving precise delivery due 
to the small size of the nares and nasal cavity, and the complications associated 
with instilling a mass of drug into the nasal passage of an obligate nose-breathing 
animal.   
In light of the positive proof-of-concept, a logical next direction might be to 
evaluate this approach in an experimental model system with nasal physiology more 
representative of humans.  A more distant, but relevant, future direction might be the 
evaluation of this targeted P-gp inhibition strategy in humans.  These studies would 
require a model P-gp substrate that is compatible with either a sensitive brain 
imaging approach or an easily-observable pharmacodynamic endpoint, e.g. 
respiratory depression produced by loperamide under conditions of significant BBB 
P-gp inhibition, or an increase in the analgesic effects of methadone, another P-gp 
substrate, secondary to P-gp inhibition.  Additional requirements would include the 
development of an appropriate delivery device and a formulation optimized to 
provide absorption across the olfactory epithelium without unacceptable irritation or 
toxicity.   
 
 Characterization of the temporal behavior of the brain-to-blood 
partitioning metric (Kp, brain) in relation to kinetic conditions. 
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 Although the brain-to-blood partition coefficient is a commonly-used metric for 
quantitating brain exposure (21), few published studies have considered the time-
dependency of this metric (21). Discussion of the results of the experiments 
addressing this sub-goal of the dissertation is hampered by the stark lack of 
published data addressing this topic.  No guidances exist within the extant literature 
to standardize evaluation of brain partitioning in terms of either the calculation of the 
value (e.g., as AUC vs. discrete time point concentration ratios) or the temporal 
relationship of the metric to attainment of DE.  The result of this information void is a 
pervasive inconsistency in the calculation of brain partitioning metrics across 
experimental approaches and across laboratories, which precludes a robust 
comparison of the brain partitioning behavior of a given substrate, within a 
compound class, or in response to a variety of experimental manipulations.   
 The studies described in these final three experimental chapters highlight the 
importance of standardization of the Kp, brain metric in terms of the impact upon 
accurate calculation of a P-gp effect resulting from a given experimental 
manipulation.  In light of the frequency with which P-gp effects are calculated prior to 
attainment of DE, or without reference to the relationship to DE, this work addresses 
a potentially important source of variability in the reported P-gp inhibitory effects of 
chemical P-gp inhibitors.  
 Although the administration mode dependency of the partition coefficient 
metric has been addressed in a seminal paper by Gibaldi (22), references to this 
kinetic behavior, as well as consideration of this potential source of experimental 
variability resulting from administration mode selection, are not identified in the 
current literature. The results of this study reinforce and extend Professor Gibaldi’s 
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work, and emphasize the key temporal differences in partitioning produced by bolus-
dose administration and constant-rate infusion. Without adequate understanding of 
the experimental perturbations that can result from this apparently minor difference 
in drug administration, misleading or incongruent information can be generated even 
when the experimentation itself has been conducted appropriately.  Once again, the 
results obtained in pursuit of this dissertation project underscore the need to develop 
a solid framework for understanding the intricacies of tissue-to-blood partitioning 
from a pharmacokinetic perspective.  
 Studies reported in Chapter 6 illustrate the challenges associated with 
calculation of P-gp effect prior to DE, but also provide a potentially important means 
for reconciliation of brain partition coefficient, and thus the P-gp effect, when data 
are obtained prior to establishing an equilibrium condition in the system.  These 
studies identified the relationship between brain-to-plasma partitioning and time prior 
to distribution equilibrium, observable by expressing time on a fractional scale 
relative to the total time to attainment of DE. This recalibration of “clock time” in 
order to illuminate relationships of interest has precedent in the field of allometric 
scaling (23), in which time might be defined as a fraction of maximum lifespan 
potential. 
These studies also investigated the route-dependency of brain partitioning 
behavior, a concept which, as discussed above, has been largely lost from the 
current literature.  Administration route impacted several of the kinetic relationships 
evaluated in this study.  First, infusion slowed the attainment of DE.  Although 
administration route is not generally considered in the context of studies of P-gp 
effect, the implication of these results is that Kp, brain values, as well as the P-gp effect 
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calculated from these partition ratios, would not be in agreement unless systems 
under both administration conditions were sampled after the attainment of DE by the 
slowest-equilibrating approach.  A related observation was that the addition of 
unidirectional (e.g., P-gp-mediated) flux in the brain-to-blood direction decreased the 
time to attainment of DE.  Similar caveats about ensuring comparable sampling 
times, relative to DE, are proposed under the context of evaluating Kp, brain under 
conditions of variable BBB efflux.  
A major contribution of the studies outlined in this chapter was the 
identification of a set of circumstances under which an unusual brain partitioning 
phenomenon is observed.  A general assumption, borne out by extensive examples 
in the literature (21, 24) is that brain partitioning increases monotonically to a peak 
plateau value reflecting the attainment of blood-to-brain DE.  The simulations 
described in Chapter 6 identify kinetic behavior consisting of an overshoot of the 
plateau Kp, brain value, followed by a time-dependent decrease to the plateau value.  
Furthermore, these studies identified a relationship of this behavior to the volume of 
a peripheral, non-CNS pharmacokinetic compartment.  Consistent with the 
observations of Gibaldi (22) and the initial observations in the present studies, that 
brain partitioning (in the absence of protein binding) under infusion conditions cannot 
yield partition coefficients that exceed unity, infusion administration abolished 
overshoot behavior.   
The intriguing results of the simulation experiments described in Chapter 6 
led to a series of simulations in Chapter 7 to explore, in a comprehensive fashion, 
the overshoot phenomenon in the brain-to-plasma partition coefficient.  An obvious 
area of focus was on the volume (and by extension, the kinetics of equilibration with 
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the systemic circulation) of the peripheral pharmacokinetic (distributional) 
compartment. It is quite clear from the series of simulation experiments reported in 
Chapter 7 that the relationship between the magnitude or duration of overshoot and 
the volume of the peripheral compartment is robust.  Of course, the relationship 
between overshoot and peripheral volume can be modulated by all other kinetic 
parameters within the system, including systemic clearance, distributional 
clearances, and the apparent volumes of the central compartment and the brain (or 
CNS compartment).  The inter-relationships between these parameters are very 
complex, but form a rich area for continued evaluation. 
While the relationship of partitioning overshoot in brain to a peripheral 
distributional compartment, as elaborated through simulation experiments, was an 
interesting result, it was important to determine whether this was a mathematical 
anomaly or has some basis in the physiology of real kinetic systems.  This goal 
could be achieved in one of two ways: through prospective experimentation or 
through retrospective analysis of the literature (data mining).  Because there were 
available data on valproic acid partitioning to support the relationship between 
overshoot and peripheral distribution kinetics, that substrate quickly became an area 
of focus.  Data available from several literature reports of valproate disposition in 
serum and brain tissue or cerebrospinal fluid consistently supported the relationship 
identified in the simulation studies.  The correspondence between model predictions 
and existing data was so strong that a subsequent prospective experiment was 
conducted (Chapter 8). 
Valproate was an ideal compound for prospective analysis of this system 
because the peripheral distribution kinetics could be modulated with more than one 
308 
 
strategy.  Utilizing rats that do not express Mrp2 completely ablated the peripheral 
distribution (enterohepatic recycling); antibiotic pretreatment partially interrupted the 
recycling process in Mrp2-competent rats.  Consistent with model predictions, loss of 
recycling led to a decrease in the overshoot phenomenon; loss-of-overshoot was 
more significant in Mrp2-deficient rats than in animals pretreated with antibiotic.  
These results, although limited by the incomplete time course of partitioning due to 
analytical threshold, aligned completely with previous literature and with the 
mathematical simulations.  While such alignment does not prove a causal 
relationship between peripheral distribution and partitioning overshoot, the 
circumstantial evidence for this relationship is extraordinarily compelling, and worthy 
of continued study with alternative substrates or different pharmacokinetic systems. 
Multiple avenues of future experimentation are suggested by the results of 
studies comprising this sub-goal of the dissertation project.  The relationship 
between fractional attainment of DE and expression of either partitioning into brain 
or calculation of the P-gp effect is worthy of consideration.  This could be pursued 
through retrospective analysis of available data, but from the unique perspective of a 
time frame defined by approach to DE rather than by clock time post-administration.  
Although these data may be available in the literature, quantitation of time to DE is 
rarely reported and likely would require some limited (targeted) experimental 
determination.  
This strategy for evaluating the kinetics of brain partitioning may have utility 
not only for understanding differences between chemical compounds, but also for 
addressing differences in brain uptake among different animal species. This latter 
point is clearly a line of investigation that would be useful to follow.  
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It is important to emphasize that the partitioning overshoot phenomenon is not 
specific to brain.  In fact, the original simulation experiments did not postulate a 
specialized barrier between the “brain compartment” and the “systemic circulation”. 
Thus, this phenomenon may be relevant for drug partitioning into any organ or tissue 
space that does not equilibrate rapidly with blood, if there is a relatively large 
alternative peripheral compartment and if the relative kinetics of distribution are 
appropriate. It may be useful to identify other, non-CNS examples of partitioning 
overshoot that might allow further experimental corroboration of the current results. 
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